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During the past three decades there has been a 
remarkable acceleration in the rate of acquisition of 
new knowledge concerning the fundamental processes of 
the human body. The young science of biochemistry 
has gained new dignity year by year, and the benefits 
to mankind which have resulted and may yet result 
from its application to the problems underlying the 
aetiology and prevention of disease have become 
apparent to all. Few would deny that marked progress 
has been made in studies of the nature of the 
secretions of the endocrine glands and that the main 
impetus to that progress has resulted from an eluci- 
dation of the occurrence and nature of the steroid 
hormones. 
The development of techniques f or the isolation 
and characterisation of these substances made possible 
the identification of hormones secreted by the gonads 
and the adrenal cortices and of many of their 
metabolic products. The isolation, in 1929 and 1930, 
of the main urinary metabolites of the female sex 
hormones - pregnanediol and oestriol - by Marrian, and 
of oestrone by Doisy and his co- workers and by 
Butenandt, was soon followed by the isolation of 
androsterone, progesterone, oestradiol, testosterone, 
'oorticosterone and a large number of related steroids. 
Thus, / 
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Thus, for the first time, the biological actions of 
the pure steroid hormones could be studied, and 
attempts could be made to elucidate their intermediary 
metabolism in the body. The complexity of the subject 
was soon apparent. The rate of secretion of the 
hormone, the rate of its "inactivation ", the response 
of the target organs, the chemical changes occurring 
at the site of its action and in other tissues, 
antagonism and synergism between hormones, the possi- 
bility of anti- hormone formation - all these had to be 
considered in evolving a concept of hormone action. 
The plurality of actions attributable to one steroid 
hormone and the importance of the hormones as biolog- 
ical regulators gradually became apparent. Thus it 
came to be recognised that the sex hormones have many 
actions not directly related to reproductive function. 
They influence carbohydrate and protein metabolism, 
electrolyte and water balance and mitotic activity. 
It was not difficult to imagine how these substances, 
acting in abnormal relationship with other hormones 
or vitamins, influenced to undergo abnormal metabolic 
changes, or acting upon abnormally "conditioned" 
tissues might play a part in pathogenesis. Recent 
work - which will be discussed in this thesis - upon 
the participation of the steroid hormones of the 
adrenal cortex in the aetiology of disease has 
emphasised / 
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emphasised these possibilities. 
In so complex a field of study where so little is 
known and so much hoped for, attempts to elucidate new 
facts must be designed in such a way that, if possible, 
the result is unequivocal and the interpretation 
reasonably certain. It is here that biochemical 
research, employing rigid criteria for the purity of 
the substances studied, and carefully assessed methods 
for their quantitative determination, has so much to 
offer. 
This thesis is concerned with the intermediary 
metabolism of steroid hormones in the human body. 
The female sex hormone - progesterone, has been chosen 
as the main steroid to be studied for two reasons. 
First, it was certain that much remained to be learned 
concerning the chemical mechanism underlying the 
biological action of this important hormone and 
especially the part played by the tissues in its meta- 
bolic reduction to £ regnanediol and closely related 
steroids. Furthermore, little is known about the 
extent to which the urinary excretion of pregnanediol 
reflects endogenous secretion of the parent hormone - 
a problem with obstetrical and gynaecological 
implications. Secondly, since pregnanediol has been 
established as the main end -product of progesterone 
yetabolism / 
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metabolism (Yenning and Browne, 1938) and since a 
reasonably specific method has recently been described 
for the quantitative determination of small amounts of 
this steroid in human urine (Sommerville, Gough and 
Marrian, 1948) it seemed possible that a study of the 
proportion of administered progesterone excreted as 
urinary pregnanediol might constitute a new approach 
to the study of the possible participation of 
endogenous steroids in the aetiology of disease and, 
in particular, might contribute to an understanding of 
the mechanism whereby certain of the adreno- cortical 
steroid hormones exert their markedly beneficial 
action in the treatment of rheumatoid arthritis and 
related conditions. 
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PART I 
THE BIOCHtMICAL SIGNIFICANCE 
OF THE URINARY EXCRETION OF PREGNANEDIOL 
IN NORMAL HUMAN SUBJECTS WITH SPECIAL REFERENCE 
TO THE ROLE OF THE UTERUS 
IN THE METABOLISM OF PROGESTERONE 
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INTRODUCTION 
Prenant (1898) was probably the first to assign 
an endocrine function to the corpus luteum, in a 
monograph with the prophetic title - "Sur la valeur 
morphologique, sur l'action physiologique et théra- 
peutique possible du corps jaune ". In 1902, Fraenkel 
showed that destruction of the corpora lutea in the 
rabbit prevented nidation of the ova, and the experi- 
ments of Marshall and Jolly, in 1905, indicated that 
two active principles were produced by the ovary. 
Bouin (1906) noted the change which occurs in the 
uterine endometrium after corpus luteum formation and 
in 1913, Feltner produced this change by the injection 
of corpus luteum extracts. In 1928, Corner succeeded 
in maintaining pregnancy in an ovariectomised rabbit 
by the injection of corpus luteum extracts and in the 
following year, Corner and Allen described a method 
for the bioassay of the main active principle of these 
extracts. 
In 1929, pregnanediol, a saturated dihydroxy 
alcohol, was isolated from human pregnancy urine by 
Marrian. This substance was identified by Butenandt 
in 1931 and was later shown to have the steric con- 
figuration of pregnane- 3a,20a -diol. As progesterone 
had not yet been isolated, the biochemical 
significance / 
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significance of this steroid could not be appreciated 
at that time. In 1933, however, Allen and Meyer 
described a method for the separation of the oestrog- 
enic and progestogenio fractions in corpus luteum 
extracts, and in 1934, the isolation of progesterone 
(g pregnene- 3,20 -dione) in pure crystalline state was 
announced by four groups of workers (Butenandt, 
{estphal and Hohlweg; Slotta Ruschig and Fels; Allen 
and Wintersteiner; and Hartmann and Wettstein). 
Later in the same year Butenandt et al, and Fernholz 
prepared progesterone by partial synthesis from 
stigmasterol, It was now obvious that pregnanediol 
could be a metabolic product of progesterone formed by 
reduction of the C4 to C5 double bond (L4) and the C3 
and C20 ketone groups. The isolation by Hartmann and 
Locher in 1935 of the C5 stereoisomer of pregnane- 
3a,20a- diol,- allopregnane-3a,20a-diol, from pregnancy 
urine, supported this idea. Allopregnane- 3a,,20á -diol 
was isolated from human pregnancy urine by Marker and 
Rohrmann in 1939. 
Pregnanediol was isolated from pregnant mare's 
urine by Marker et al. in 1937, from bovine pregnancy 
urine by Marker in 1938, from the urine of the pregnant 
chimpanzee by Fish, Dorfman and Young in 1942 and from 
rabbit pregnancy urine by Verly, Sommerville and 
Marrian in 1950. 
Pregnanediol / 
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Pregnanediol was isolated in small amounts from 
the urine of ovariectomised women by Hirschman (1940) 
and of adult men (1944) . Marker et al. (1938) claim 
to have isolated large amounts of this steroid from 
bull's urine. 
In 1936, Odell and Marrian reported the presence 
of an acid -hydrolysable combined form of pregnanediol 
in human pregnancy urine and, later in the same year, 
Venning and Browne showed that this was a water - 
soluble complex - the sodium salt of pregnanediol 
gluouronide. In the following year, Venning success- 
fully developed a method for the rough quantitative 
determination of this complex in human pregnancy urine. 
This work opened up a new field of research and in a 
series of important experiments, Venning and Browne 
(1938, 1940) established beyond doubt that pregnane- 
diol is a metabolic product of progesterone. Thus 
they recovered pregnanediol gluouronide from the urine 
after the administration of progesterone to women in 
whom endogenous progesterone production could be 
assumed to be minimal and they studied for the first 
time the excretion of this steroid during the luteal 
phase of the menstrual cycle and during the course of 
normal pregnancy. 
In 1939, the recovery of pregnanediol glucuronide, 
after the administration of progesterone to men, was 
reported / 
-8- 
reported by Buxton and Westphal. In the following 
year, Hamblen, Cuyler and Hirst confirmed this 
observation and reported that the proportion of 
administered progesterone excreted in this way varied 
considerably from individual to individual - from 
0.0 per cent. to 42.5 per cent in their series, and 
also in the same individual when the procedure was 
repeated. In 1941 Seegar Jones and Telinde reported 
a recovery of 10.0 per cent.in the preovulatory phase 
of the menstrual cycle. 
Conflicting reports appeared in the literature 
concerning the effect of pretreatment with oestrogen 
upon the proportion of administered progesterone 
excreted as pregnanediol glucuronide. Yenning and 
Browne (1938) obtained results which suggested that 
pretreatment with oestradiol benzoate increased the 
recovery of pregnanediol glucuronide after proges- 
terone administration to women with secondary 
amenorrhoea and hypoplastic endometria. Cope (1941) 
did not confirm this observation nor was it confirmed 
in a series of post -menopausal women investigated more 
recently (Sommerville and Marrian, 1950a). Smith and 
Smith (1940), on the other hand, compared the effect of 
progesterone alone and progesterone plus oestradiol 
benzoate on the excretion of pregnanediol during 
pregnancy, and suggested - although with little 
experimental 
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experimental evidence - that oestrogen favoured the 
conversion of progesterone to pregnanediol. These 
workers also observed an increase in the urinary 
excretion of pregnanediol glucuronide of endogenous 
origin during the administration of diethylstilboestrol 
to pregnant diabetic women (Smith, Smith and Hurwitz, 
1946) . It appears, however, that this apparent 
increase may be due to the determination of the 
glucuronides of substances other than pregnanediol in 
the final product of the Venning method, since it has 
been shown that pregnanediol excretion actually falls 
during the administration of diethylstilboestrol to 
normal or diabetic pregnant women (Sommerville, 
Marrian and Clayton, 1948). 
An investigation of the effect of hysterectomy on 
the conversion of progesterone to pregnanediol 
glucuronide also led to contradictory results and 
differing interpretations. This problem has been re- 
investigated in the present work and relevant contri- 
butions to the subject will be discussed in section 2. 
The introduction of the Venning method (1937,1938) 
permitted a new approach to the problems of the 
placental origin of progesterone. Thus, in 1938, 
Jones and Weil reported removal of the corpus luteum 
at the eighth week of pregnancy followed by continuat- 
ion of the pregnancy which terminated in spontaneous 
delivery / 
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delivery of a healthy infant at tern. Pregnanediol 
glucuronide disappeared from the urine for several 
days after the excision (it was probably present in 
amounts too small to be detected by the Venning 
method) but soon reappeared in increasing amounts. 
This and other similar experiments indicate extra - 
ovarian sources of progesterone, and whereas it is 
reasonably certain that the placenta is the main site 
of progesterone production during pregnancy, the 
possibility that the adrenal cortices may play a 
subsidiary role cannot be overlooked. Progesterone 
and allopregnanolone were isolated from adrenal 
extracts by Beall and Reichstein in 1938 and pregnane- 
diol was isolated from the urine of women with adrenal 
virilism by Butler and Marrian (1937). Furthermore, 
Cuyler, Ashley and Hamblen (1940) and Horwitt, 
Dorfman, Shipley and Fish (1944) observed the excretion 
of urinary pregnanediol after the administration of 
desoxycorticosterone to human subjects. 
In 1940, Venning and Browne reported that when 
progesterone was injected during the luteal phase of 
the menstrual cycle, or during early pregnancy, a 
greater increase in pregnanediol excretion resulted 
than when the hormone was injected into women in whom 
endogenous progesterone secretion was minimal. This 
result, which is of considerable interest, was 
confirmed / 
confirmed by Davis and Fugo (1947) using a different 
method for the determination of the steroid. 
The method of Venning also led to preliminary 
observations on the rôle of the liver in the 
metabolism of progesterone. Thus Masson and Hoffman 
(1945) found that when progesterone was administered 
orally to rabbits the biological effect was eight 
times greater in partially hepatectomised than in 
intact animals, but the proportion of pregnanediol 
glucuronide excreted was similar in amount in both 
groups of animals. 
In 1937, two 3- hydroxy -20- ketosteroids - 
pregnan- 3a -o1 -20 -one and allopregnan- 3a -o1 -20 -one 
were isolated from human pregnancy urine by Marker 
and his co- workers, and a third stereoisomer - 
allopregnan- 316-o1 -20 -one was isolated from the same 
source by Pearlman, Pincus and Werthessen in 1942. 
In 1943, Strickler et al., applying the method of 
Venning to the urine of a girl with hirsutism, 
obtained evidence for the presence of the glucuronide 
of a 20- ketosteroid in the final product. In 1945, 
Mason and Kepler identified pregnane- 3a,17,20 -triol 
as a glucuronide in the "pregnanediol glucuronide" 
fraction of the urine of women with adrenal hyper - 
plasia. (This acid -labile 17- hydroxy steroid was 




In 1446, Marrian and Gough made the important ob- 
servation that the "sodium pregnanediol glucuronidate" 
obtained from human pregnancy urine by the Venning 
method is contaminated by ketonic glucuronides notably 
a water- soluble derivative of pregnan- 3a.ro1 -20 -one. 
This substance constituted about 20.0 pei cent. of the 
"sodium pregnanediol glucuronidate ". In the following 
year, Sutherland and Marrian separated the non -ketonic 
and ketonic sodium gluouronidate fractions by a modi- 
fication of the procedure of Girard and Sandulesco 
(1936), isolated pure sodium pregnane- 3cx,20a -diol 
glucuronidate and showed that the ketonic fraction 
consisted mainly of sodium pregnan- 3a -o1 -20 -one 
glucuronidate. (Heard, Hoffman and Mack had shown in 
1944 that the glucuronic acid in sodium pregnanediol 
glucuronidate was conjugated with the C3 hydroxyl 
group of the pregnanediol. The glucuronide isolated 
by Sutherland and Marrian must be conjugated in the 
same way but the form of conjugation of the allo- 
pregnanediols is not yet known) . 
These observations implied serious disadvantages 
in the use of the Venning method for the determination 
of pregnanediol, although that procedure still finds 
favour with those wishing to determine "progesterone 
metabolites" as one enigmatic complex composed of the 
glucuronides of several substances including 
pregnanediol / 
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pregnanediol and the pregnanolones. In this connect- 
ion it should be added that it cannot be assumed that 
all the glucuronides determined by the method of 
Venning are, in fact, metabolites of progesterone. 
Methods for the determination of pregnanediol as its 
glucuronide have the further disadvantage that 
fictitiously low results may be due to bacterial 
hydrolysis of the conjugate in inadequately preserved 
urine. 
Thus, although the method of Venning had con- 
tributed so much to our knowledge of the parallelism 
between the excretion of progesterone metabolites in 
the urine and the secretion of progesterone by the 
ovary or placenta, some other method was required for 
a more detailed investigation of the excretion of 
pregnanediol and of the metabolism of progesterone. 
In 1941, Astwood and Jones described a method 
for the determination of the free form of pregnanediol 
liberated by acid hydrolysis. The determination was 
gravimetric and it is certain that substances other 
than pregnanediol, e.g. certain 20- ketosteroids were 
present in the final product when this method was 
applied to human pregnancy urine. In the same year, 
however, Talbot et al. utilised the sulphuric acid 
reaction as a oolorimetric method of determination. 
Pregnanolone and allopregnanolone have almost no 
ohromogenic / 
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chromogenic power in this reaction and this modifica- 
tion, therefore, increased the specificity of the 
method. The combined Astwood- Talbot procedure was 
less time -consuming and technically more simple than 
the Venning method, but unsatisfactory results were 
obtained when it was applied to urines containing 
less than about 10 mg. per twenty- four -hour urine 
specimen and it was, therefore, unsuitable for 
studies of pregnanediol excretion during the menstrual 
cycle or early pregnancy, or for the determination of 
pregnanediol excretion after progesterone administrat- 
ion. 
An investigation of the procedure by Professor 
Marrian and Dr. Nancy Gough revealed deficiences in 
the technique of extraction and purification of the 
pregnanediol, many of which could be corrected and it 
was found that a serious source of error lay in the 
conditions of the repeated precipitation whereby the 
extracted steroid was purified (Sommerville, Gough 
and Marrian, 1947) . After various modifications had 
been tested in a series of recovery experiments in 
which pure sodium pregnane -3 a,20a -diol glucuronidate 
or pure pregnane- 3a,20a -diol were added to male urine, 
a method was finally evolved which permitted of the 
determination of more than about 0.4 mg. of 
pregnanediol in one -fifth of a twenty -hour urine 
specimen (Sommerville, Gough and Marrian, 1948). 
The / 
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The method was simpler and less time- consuming than 
the above -mentioned procedures and appeared to be more 
accurate than any which had hitherto been described. 
The procedure taies thirty -six hours (including over- 
night incubation of the first precipitation mixture) 
but six determinations (three in duplicate) can be 
carried through daily by one person. 
Many substances other than pregnanediol yield 
colours with concentrated sulphuric acid and it was 
necessary to test the specificity of the purification 
process by the addition of large amounts of other 
steroids prior to the first precipitation. 
Allopregnanediol, pregnanolone, allopregnanolone, 
pregnane- 3,17,2C- triol, androsterone, isoandrosterone, 
dehydroisoandrosterone, cholesterol, h orL 
androstene -17 -one and ¿5androstadiene -l7 -one were 
investigated. It was not surprising to find that 
allopregnane- 3a,20a -diol is determined along with 
pregnane -3a,20ä -diol, although, since the former 
steroid is about 20.0 per cent. less chromogenic in 
the sulphuric acid reaction than the latter, its 
recovery is not quantitative. The other steroids 
investigated would not interfere unless present in 
very large amounts as in the urine of certain cases of 
adreno -cortical tumour. 
Also based upon the combined Astwood- Talbot 
procedure, / 
-16- 
procedure, methods have been described for the quali- 
tative or semi -quantitative determination of pregnane- 
diol for clinical diagnostic or prognostic purposes. 
Such abreviations of the original procedure have been 
described by Guterman (194 6) and Mack and Parks (1946, 
1947). A method which is as rapid as these and more 
accurate was described in 1948 (Sommerville, Marrian 
and Kellar). This is a shortened version of the 
method of Sommerville, Gough and Marrian, permits of 
the reasonably accurate determination in three hours 
of more than about 0.4 mg. per 100 ml. of urine and is 
suitable for the determination of urinary pregnanedid. 
during pregnancy but is unsuitable for a study of 
progesterone metabolism. 
In order to investigate whether, as suggested by 
the results of Hamblen et al. and others using the 
method of Venning, there is considerable variation in 
the proportion of administered progesterone excreted 
as urinary pregnanediol, and in order to obtain a 
series of "control" figures as a preliminary to work 
such as that described in this thesis, a reinvesti- 
gation of this problem was undertaken under the super- 
vision of Professor Marrian in 1947, When progester- 
one was administered to different groups of human 
subjects, and the pregnanediol excretion determined by 
the method of Sommerville, Gough and Marrian, the 
range of proportion of the hormone so excreted was as 
follows: / 
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follows: normal post -menopausal women : - 12.1 per cent, 
to 16.0 per cent., hysterectomised post -menopausal 
women : - 13.3 per cent. to 14.9 per cent., oestrogen 
pre -treated post -menopausal women:- 15.1 per cent. to 
16.1 per cent., men:- 9.3 per cent. to 14.7 per cent. 
Furthermore, it was found that when the administration 
was repeated in the same individual, the results were 
remarkably constant. Thus, when 120 mg. of pro- 
gesterone was administered to a normal man on four 
occasions:- 10.4 per cent., 10.0 per cent., 10.8 per 
cent. and 10.0 per cent. of the hormone was excreted 
as urinary pregnanediol. In a comparison of the 
proportion of pregnanediol excreted after oral and 
intra- muscular administration, it was found that 
excretion was more rapid after oral administration, 
and that a slightly higher proportion of the metabolite 
appeared in the urine. This proportion was also 
remarkably constant in a given individual - e.g. when 
120 mg. of progesterone was administered orally to a 
normal man on three occasions, 18.6 per cent, 
17.4 per cent, and 19.6 per cent. was excreted as 
urinary pregnanediol, (Sommerville and Marrian, 1950a1 
The observation of Venning and Browne (1938) and 
Davis and Fugo (1947) that a much higher proportion 
of the progesterone administered to a pregnant woman 
is excreted as urinary pregnanediol than after 
administration / 
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administration to a subject with minimal progesterone 
secretion, was confirmed, and the steady excretion of 
the steroid during the control periods enabled a 
fairly accurate estimate to be made of the amount of 
pregnanediol of exogenous origin. Thus, after the 
administration of 120 mg. of progesterone on two 
occasions to a woman at the twenty -seventh and twenty - 
ninth weeris of a normal pregnancy, 35.0 per cent. and 
45.0 per cent. of the administered hormone was 
excreted as pregnanediol. 
In the course of this work, the urinary excretion 
of pregnanediol following the administration of pure 
pregnane- 3a,20a -diol was studied for the first time. 
Venning and Browne (1938) had shown that when "sodium 
pregnanediol glucuronidate" was administered by intra- 
muscular injection, a large proportion was excreted as 
pregnanediol glucuronide in the urine (58.0 per cent. 
and 43.0 per cent. in their experiments) but they were 
unable to recover pregnanediol after injection of the 
steroid into two hysterectomised post -menopausal 
women. When pregnane-3a, 2Qa -diol was administered to 
normal men in gelatin capsules by mouth (Sommerville 
and Marrian, 1950a) it was found that the recovery of 
pregnanediol from the urine was very similar to that 
obtained after the oral administration of progesterone 
to the same subjects. This result suggests the 
interesting possibility that administered progesterone 
may / 
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may be largely reduced to pregnanediol in the body and 
that the low recoveries of urinary pregnanediol follow- 
ing administration of either the hormone or its meta- 
bolite may be due to excretion of the reduction 
product by other routes and /or further metabolism into 
as yet unidentified products. 
The experiments leadiné; to the evolution of 
methods for the determination of urinary pregnanediol 
(Sommerville, Gough and Earrian, 1948; and Sommerville, 
Z:arrian and Kellar, 1948); the experiments in which 
pregnanediol excretion was studied after the adminis- 
tration of progesterone to men, post -menopausal women, 
hysterectomised women, oestrogen pre-treated post- 
menopausal women and during normal pregnancy; the 
excretion of pregnanediol after the excision of the 
corpus luteum of pregnancy; and the investigation of 
the effect of diethylstilboestrol upon the excretion 
of pregnanediol during normal and diabetic pregnancy 
were described in a thesis submitted for the degree 
of Doctor of Philosophy in 1948. 
Part I of the present thesis is divided into five 
sections. In the first section, a series of experi- 
ments is described in which an attempt is made to 
elucidate some aspects of the biochemical significance 
of pregnanediol excretion during pregnancy, by a study 
of the urinary excretion of the steroid during pro- 
longed administration of progesterone to human subjects. 
The 
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The second section constitutes an investigation of the 
possibility that the administration of vitamin E 
( d,l- alpha -tocopherol acetate) influences the metabol- 
ism of progesterone. In the third section, prelimin- 
ary observations on the urinary excretion of pregnane- 
diol during normal pregnancy are described and the 
results discussed in relationship to the urinary ex- 
cretion of the glucuronides determined by the method 
of Venning (1937, 1938). In the fourth section a 
substance with progesterone -like activity (ethinyl- 
testosterone) is investigated in relation to urinary 
pregnanediol excretion. In the fifth section, an 
investigation is made of the possibility that the more 
sensitive method employed in the present work could be 
applied to the determination of urinary pregnanediol 
























URINARY EXCRETION OF PREGNANEDIOL AFTER PRDLONGED 
AND OF PREGNANIDIOL TC HUL:AN SUBJECTS 
Since the recognition of pregnanediol as an im- 
portant metabolite of progesterone, the possibility 
has been considered, and on occasion the assumption 
made, that a simple quantitative relationship exists 
between the amount of progesterone secreted by the 
ovary or placenta and the amount of pregnanediol ex- 
creted in the urine. The importance of this relation- 
ship lies in the possibility that the level of endog- 
enous progesterone secretion could thus be assessed by 
determination of the urinary pregnanediol excretion, 
and its elucidation would not only contribute to our 
knowledge of the intermediary metabolism of the 
hormone, but would be relevant to the current use of 
urinary pregnanediol assay as a prognostic criterion 
in the complications of pregnancy and as a guide to 
rational progesterone therapy. 
The experimental approach to the problem is 
fraught with difficulty. A direct comparison cannot 
be made between the blood level of progesterone and 
the urinary level of the metabolite since it is not 
yet possible to determine the amount of chemically 
identifiable progesterone in the serum of pregnant 
women. / 
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women. Furtherr.:ore, even if such a method were 
available, it would by no means follow that the blood 
level of the hormone so determined would be a reliable 
index to the amount secreted. The results of the 
bioassay of the progestational activity of pregnancy 
serum indicate that the hormone is present in very 
small amounts (Hoffmann and von Lam, 1942; Hooker and 
Forbes, 1948) and this finding, and the relatively 
high excretion of pregnanediol in the urine of pregnant 
women suggest veri; rapid utilisation and metabolism of 
the hormone. It is even possible that the blood is a 
site for the metabolic reduction of progesterone to 
pregnanediol. On the other hand, the possibility may 
be considered that progesterone is present in the 
blood - not only protein -bound (Hooker and Forbes,1948) 
but in a chemically conjugated form, and that the low 
results obtained by bioassay are due to the low biolo- 
gical activity of this hypothetical conjugate. 
Observation of the biological effects of the 
endogenous hormone may throw some light on the level 
of endogenous secretion. Thus the endometrium 
reflects the action of progesterone on one tissue, but 
this action is modified by other hormones and a 
correlation of endometrial histology and urinary 
pregnanediol excretion gives no reliable indication of 




As it is not pos.- ;ible, therefore, to estimate the 
level of secretion of endogenous progesterone, attent- 
ion has been turned to experiments in which this 
variable is replaced by the administration of weighed 
amounts of the pure hormone, in the hope that the fate 
of administered progesterone closely resembles that of 
the endogenous hormone. 
When it was found that the administration of 
progesterone to subjects in whom endogenous progester- 
one secretion was thought to be negligible, resulted 
in the excretion of about 10.0 per cent. of the ad- 
ministered hormone as urinary pregnanediol, some ob- 
servers were tempted to calculate that a daily urinary 
excretion of 100 mg. of pregnanediol during pregnancy 
must represent a daily endogenous secretion of 1,000 mg. 
of progesterone. On the other hand, as has been 
mentioned in the introduction, when progesterone is 
administered during pregnancy, about 50.0 per cent. of 
the hormone is excreted as urinary pregnanediol 
additional to that of endogenous origin. This ex- 
periment suggests that when the body is already under 
the influence of progesterone the metabolism of the 
hormone is in some way altered. Discussing this 
problem, Davis and Fugo (1947) state the activity of 
the corpus luteum must exert some effect on the 
metabolism of progesterone so that a much greater 
per- 
centage can be accounted for as the inert metabolite 
pregnanediol ". 
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pregnanediol". This is not, however, the only 
possible interpretation which can be derived from this 
observation, since it may be related to any of the 
factors known and unknown which are associated with 
the presence of an active corpus luteum or placenta - 
for example, gonadotrophic, oestrogenic or adreno- 
cortical activity. Furthermore, it may be doubted 
whether it is entirely justifiable to calculate the 
proportion of the administered hormone which is ex- 
creted as pregnanediol over and above that of endog- 
enous origin. In this calculation it is assumed that 
the excretion level of endogenous origin is not affec- 
ted by the administered hormone and although this 
assumption gains support from the levels of the 
adjacent control periods of excretion of endogenous 
pregnanediol it is not open to direct investigation. 
In order to investigate whether this apparent 
change in the metabolism of progesterone is, in fact, 
due to the secretion and physiological activity of 
that hormone, it was felt that some light might be 
thrown on the problem by studying the urinary pregnane- 
diol excretion of human subjects with minimal endogen- 
ous progesterone secretion during periods of prolonged 
administration of progesterone. 
The only earlier workers who appear to have 
studied urinary pregnanediol excretion during periods 
of / 
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of progesterone administration longer than three days 
are Yenning and Browne (1940) and Cope (1941). The 
former workers administered doses of progesterone of 
about 10 mg. per day for four to eight days but the 
pregnanediol recoveries were irregular and showed no 
definite daily trend. Cope injected a case of 
secondary amenorrhoea with 10, 5, 5, 5 and 5 mg. of 
progesterone on five consecutive days. It is doubt- 
ful whether much quantitative significance can be 
attached to the results in view of the small doses 
injected but it is interesting to note that whereas 
only doubtful traces of pregnanediol were recovered 
from the urine during the first five days, 2.5 mg. was 
found on the sixth day. b similar effect was obser- 
ved in a second experiment on a case of anovular 
menstruation. Cope suggested that these findings 
might be explained on the basis of a saturation 
phenomenon comparable to that associated with the 
excretion of orally administered ascorbic acid, and 
his results provided a suggestion that prolonged ad- 
ministration of progesterone might, in some way, cause 
an enhancement of the power of the body to convert 
progesterone into urinary pregnanediol. 
In the course of previous experiments in which 
an 
attempt was made to study the effect of oestrogen 
ad- 
ministration on the proportion of administered 
progesterone 
progesterone excreted as urinary pregnanediol, the 
present worker had obtained two interesting results 
which appeared to substantiate some of these specu- 
lations. During the daily administration of 60 mg. 
of progesterone by intramuscular injection to a post- 
menopausal woman for ten days and by mouth to a similar 
subject for fifteen da;;s, the pregnanediol excretion 
showed the following trends. In the first case, the 
daily pregnanediol excretion was maintained between the 
third and eighth days at an almost constant plateau 
level corresponding to about 10.0 per cent, of the 
daily dose of progesterone. The pregnanediol excret- 
ion then rose sharply on the eighth, ninth and tenth 
days and by the tenth day, Then the experiment was dis- 
continued, it had reached a value corresponding to 
17.0 per cent of the daily dose of progesterone. In 
the second case, after reaching a preliminary plateau 
level corresponding to from 16.0 per cent. to 18.0 per 
cent, of the daily dose of progesterone, the pregnane- 
diol excretion rose to 27.0 per cent. of the daily dose 
of progesterone by the fifteenth day. In a third 
experiment in which 40 mg. of progesterone was ad- 
ministered daily by mouth to a young man for sixteen 
days, a plateau corresponding to about 10.0 per cent. 
of the daily dose was maintained throughout the exper- 
ment. No definite conclusion could be drawn from 
these / 
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these experiments in view of the number of variables 
involved - dose, route of administration, age and sex 
of subjects nut in view of the theoretical consider- 
ations outlined above, it seemed probable that a more 
extensive investigation along these lines would yield 
interesting results. 
Subjects for these experiments were selected with 
great care, particular attention being paid to their 
willingness to co- operate in the collection of accurate 
twenty -four hour specimens. The results bear witness 
to their felicity in that respect. The normal post- 
menopausal women were on the waiting lists of the 
gynaecological units of the Royal Infirmary, .iestern 
General Hospital and Deaconess Hospital. They were 
all suffering from a mild degree of prolapse of the 
uterus (without disturbance of bladder function) and 
the investigations were made possible through the 
courtesy of Professor H.J. Kellar, Dr. Morris 
and Dr. I.N. L.acCregor. The twenty -four hour 
specimens were collected from all the subjects in 
their own homes during a control period of several 
days prior to the administration of the steroid and 
throughout the experiments. As in the other 
experi- 
ments described in this thesis specimens of urine 
of 
volumes less than 2,500 ml. were made up to that 




samples for the determination in duplicate of the 
pregnanediol content by the method of Sommerville, 
Gough and Marrian (1948) . In the few instances where 
the twenty -four hour volumes were greater than 2,500m1. 
determinations were carried out on two 500 ml. samples 
and the appropriate volume correction subsequently 
applied. 
Progesterone, dissolved in arachis cil (10 mg. 
per ml.) was administered either by intra- muscular in- 
jection or in gelatin capsules by mouth. As mentioned 
in the introduction, it has been shown that when pro- 
gesterone is administered by mouth to human subjects, 
the proportion excreted as urinary pregnanediol is 
approximately 3.0 per cent. higher than when the hor- 
mone is injected, (Sommerville and Marrian, 1950a). 
(a) Urinary pregnanediol excretion during continued 
dail administration of ro esterone to normal ost- 
menopausal women 
Four experiments were carried out in an attempt 
to elucidate the following points suggested by the two 
preliminary experiments. 
(i) to determine the height to which the pregnane- 
diol excretion will rise in such experiment 
(since the level was still rising when the 
preliminary experiments were terminated). 
-29- 
(ii ) to determine whether a second plateau of preg- -- 
aanediol excretion is attained and whether 
it is maintained. 
(iii) to determine whether the phenomenon is re- 
lated to the physiological activity of the 
administered hormone. 
1. Subject 'H': 
Post -menopausal woman, aged 70 years. 
Progesterone, 50 mg. administered daily for 
22 days by intra -muscular injection. 
The results are shown in Fig. 2 and Table 1. 
After attaining a short plateau corresponding to 
abcut 10.0 per cent. of the administered progesterone, 
the excretion of pregnanediol rose rapidly and a secoi 
plateau corresponding to about 22.0 per cent. of the 
administered hormone was reached at about the seven- 
teenth day. 
2. Subject 'H': 
Progesterone, 60 mg. administered to the same 
subject daily for 22 days in gelatin 
capsules by mouth. 
The results are shown in Fig. 2 and Table 2. 
The urinary excretion of pregnanediol rose from a 
level corresponding to about 14.0 per cent. of the 
administered progesterone at the fourth day to about 
24.0 per cent. at the eighteenth day. The rise was 
more / 
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more gradual than in the previous experiment and the 
second plateau had just been established at the end of 
the experiment. 
3. Subject 'D': 
Post -menopausal woman, aged 60 years. 
Progesterone, 40 mg. administered daily for 
22 days in gelatin capsules by mouth. 
The results are shown in Fig. 3 and Table 3. 
The first plateau of pregnanediol excretion was 
unusually high in this case - about 25.0 per cent, of 
the administered hormone. It was maintained until 
about the ninth day when the level began to rise and 
attained about 36.0 per cent. on the nineteenth day. 
The excretion had returned to the control period 
"blank" value forty -eight hours after the last dose of 
progesterone. 
4. Subject 'G': 
Post -menopausal woman aged 58 years. 
Progesterone, 40 mg. administered daily for 
27 days in gelatin capsules by mouth. 
The results are shown in Fig. 3 and Table 4. 
The first plateau of urinary pregnanediol excret- 
ion corresponded to about 15.0 per cent. of the admin- 
istered hormone. bbout the eighth day of the 
experiment the level began to rise and attained about 




steady plateau of excretion was maintained until the 
conclusion of the experiment on the twenty -seventh day. 
Two interesting observations concerning the bio- 
logical activity of progesterone were made in this 
series. 
(a) Endometrial biopsy was performed by 
Dr. T._. MacGregor two days after the last in- 
jection of progesterone to subject 'H'. 
(The experiments in this series are not in 
chronological order and this was the last 
experiment in which pregnanediol excretion 
was studied in subject 'H') 
Despite the administration of relatively large 
amounts of the hormone - 1.1 gm. in three 
weeks - there had been no withdrawal bleeding 
and although too little material was obtained 
for histological examination the scrapings 
were such as are obtained from an atrophic 
post-menopausal endometrium. 
(b) During the experiments in which progesterone 
was administered by mouth in 60 mg. doses 'H' 
and 'N', the patients complained of progress- 
ive drowsiness. after ten days of proges- 
terone therapy both subjects tended to fall 
asleep during the day and their relatives 
noted that they were less alert than usual. 
Subject 'H' who was accustomed to play cards 
in / 
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in the evenings became an unwelcome partner. 
These findings are discussed at the end of this 
section. 
Conclusion 
In all four experiments the daily urinary preg- 
nanediol excretion, after reaching a temporary initial 
plateau level, rose considerably despite the adminis- 
tration of a constant dosage of the hormone. The 
extent of this increase, which shall be referred to as 
a progesterone "priming" effect, expressed as the 
percentage increase of the final plateau level above 
the initial plateau level is sur-marised in the follow- 
ing table. 
(The two preliminary experiments previous referred 
to (subjects 'F' and 'n') are included, but the 
percentage increase is only an interim figure 
since the experiments were interrupted before the 
second plateau levels were attained). 
NORMAL POST -MENOPAUSAL WOMEN 
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NORMAL POST -MENOPAUSAL WOLITIN 
Continued Daily Administration 
of Progesterone 
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5.0 11.2 125 
'A' 
(Preline.) 
Oral 60 mg. 
x 15 
10.5 (16.0) (53) 
'H' Oral 60 mg. 
x 22 
8.5 14.0 65 
'G' Oral 40 mg. 
x 27 
6.0 8.5 42 
'D' Oral 40 mg. 
x 22 
11.0 14.5 32 
It will be seen that the percentage increase was 
greatest in the experiment in which progesterone was 
administered by intra- muscular injection. Further- 
more, in the experiments in which oral administration 
was employed, a dose of 60 mg. per day produced a 
greater "priming" than was obtained with 40 mg. per 
day. These results suggested the following answers 




(i) In suxh experiments, the pr egnanedi of level 
can rise as high as 125 per cent. above the 
initial plateau level. 
(ii) A second plateau is attained. The time taken 
depends on the route of administration, the 
rise being more rapid with intra- muscular 
administration. In one experiment 
(subject 'G') the plateau was maintained 
for sixteen days. 
(iii) The progesterone "priming" effect appears to 
be related in some way to the physiological 
activity of the progesterone. The effect 
is still apparent, however, when the pro- 
gesterone is administered by mouth and it 
is known that the hormone has a very much 
reduced biological activity when adminis- 
tered by that route. Furthermore, no 
structural change in the endometrium was 
observed in a subject receiving large 








































































































































CONTINUED DAILY ADMINISTRATION OF PROGESTERONE 










- 1900 0.11 Prog. 940 10.25 
0.12 50 mg. 10.38 
Prog. 910 0.13 " 1010 10.63 
50 mg. 0.16 10.50 
" 1600 3.20 " 600 10.43 
3.05 (Comp.) 10.34 
n 1460 5.20 If 1240 10.75 
5.08 10.78 
It 1210 4.98 " 1300 10.65 
4.95 10.58 
" 1450 5.28 " 1080 11.10 
5.38 11.02 
" 1480 5.45 " 1100 11.05 
5.53 11.18 
" 880 6.10 t' 950 11.08 
5.98 11.12 
" 1380 6.88 " 1140 11.25 
7.08 11.39 
" 1250 7.43 " 880 11.00 
7.58 10.85 
If 1050 9.28 " 1200 11.10 
9.30 11.16 
" 1030 9.38 - 1120 10.80 
9,58 10.75 
TABLE 2 
CONTINUED DAILY ADMINISTRATION OF PROGESTERONE 
N P - 
SUBJETT ' A' 











- 1600 0.19 Prog. 1240 13.20 
0.15 60 mg. 13.10 
Frog. 1320 0.13 " 1320 13.70 
60 mg. 0.13 13.65 
" 1210 7.85 " 1380 13.60 
7.73 13.45 
" 1290 8.80 " 1340 13.30 
8.65 13.40 
" i 1500 8.40 " 1040 13.75 
8.35 13.65 
" 1230 8.50 " 1600 14.10 
8.30 14.30 
" 1180 8.70 " 1220 13.15 
8.90 13.20 
" 860 10.05 " 870 14.05 
9.90 (cm.) 14.20 
" 1660 10.70 " 1375 14.45 
10.80 14.53 
n 10.50 - 1200 14.40 
, 10.60 14.25 
, 
" 1530 11.40 - 1680 3.68 
11.50 3.80 
" 960 11.83 - 980 1.75 
11.70 1.73 
" 1300 12.83 - 1700 0.20 
12.63 0.18 
" 1550 11.60 
11.75 
TABLE 3 
CONTINUED DAILY ADE1NISTRATION OF PROGESTERONE 











mg. 24 hr. 
- 1480 0.18 Prog. 1145 12.75 
0.16 40 mg. 12.80 
Prog. 1260 0.15 " 1300 13.02 
40 mg. 0.16 13.20 
" 1100 5.13 " 1470 13.65 
5.20 13.62 
" 1260 10.65 " 1220 14.12 
10.78 14.20 
" 1080 9.90 " 900 14.00 
9.95 13.92 
If 920 10.70 If 980 14.62 
10.75 14.77 
IT 1010 11.40 " 1005 13.65 
11.20 14.00 
u 1280 11.25 " 1240 14.20 
11.15 - 
" 1070 10.38 " 1580 13.45 
10.58 13.55 
T' 1140 10.05 - 1395 14.42 
10.23 14.50 
" 1270 10.88 - 1100 7.70 
10.75 7.67 
" 1520 11.18 - 1120 0.99 
11.30 0.92 
IT 1060 11.50 - 1230 0.13 
11.65 0.11 
" 980 11.98 
12.15 
TABLE 4 
CONTINUED DAILY ADIúIINISTRATION OF PROGESTERONE 












- 1630 0.27 Prog. 1800 7.55 
0.24 40 mg. 7.50 
Prog. 1590 0.18 " 1880 7.75 
40 mg. 0.21 7.90 
'T 2170 5.23 it 1820 7.65 
5.12 7.65 
" 1990 5.80 TT 2355 7.85 
5.68 7.95 
" 1780 6.30 11 1840 8.20 
6.10 8.33 
T' 1735 6.05 1' 2200 8.33 
6.07 8.50 
1' 1780 5.90 T' 1490 7.70 
- 7.55 
Ti 1540 6.45 11 2300 8.20 
6.53 8.25 
1' 2040 6.75 IT 1950 8.10 
6.85 - 
IT 1900 6.20 " 1980 8.45 
6.33 8.44 
TI 2075 - 11 1850 8.33 
7.23 8.23 
TT 2450 7.55 TT 1810 8.58 
7.65 8.55 
" 2425 7.95 T' 2010 8.00 
8.00 7.90 
T' 2300 8.15 - 1900 8.20 
8.33 8.28 
1' 1850 7.80 - 2100 4.68 4.63 





(b) Urinary preEnanediol excretion during continued 
daily administration of proEesterone to normal men 
As indicated in the introduction, when progester- 
one is administered for one or two days to normal men, 
a proportion similar to that obtained in post- 
menopausal women is excreted as urinary pregnanediol. 
It might have been anticipated, therefore, that the 
prolonged administration of progesterone to men would 
esult in a "priming" effect similar to that observed 
lin post -menopausal women. This would also follow if 
the "priming" effect is a saturation phenomenon. On 
the other hand, in the preliminary experiment in which 
40 mg. of progesterone was administered by mouth to a 
young man no "priming" effect was observed. Two 
further experiments were carried out, therefore, to 
determine whether this failure to observe the phenom- 
enon was due to lack of response to the lower dose of 
the hormone administered by mouth or to an age differ- 
ence. 
. Subject 'P': 
Normal man aged 23 years. 
Progesterone, 60 mg. daily for 18 days, in 
gelatin capsules by mouth. 
The results are shown in Fig. 4 and Table 5. 
The determination of urinary pregnanediol was not 
carried out on five days of the experiment but it is 
clear / 
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olear that a plateau level corresponding to about 18.0 
per cent. of the administered hormone was maintained 
!throughout the experiment. 
2. Subject 'R': 
Normal man aged 62 years. 
The experiment was repeated (60 mg. x 18) in 
a subject of the same age group as the 
post -menopausal women. 
The results are shown in Fig. 4 and Table 6. 
A plateau corresponding to about 18.0 per cent. 
of the daily dose of progesterone was maintained 
throughout the experiment. 
Conclusion 
The results show clearly that there is a sex 
difference in the occurrence of the progesterone 
"priming" effect. It by no means followed that the 
absence of this phenomenon in men was attributable to 
the difference in reproductive anatomy, since the 
metabolism of tissues common to male and female - for 
example the liver - may differ in the sexes under 
hormonal influences. None the less the possibility 
had to be investigated that the post -menopausal uterus 
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CONTINU D DAILY ADMINISTRATION OF PROGESTERONE 












- 1200 0.11 Prog. - - 
0.12 60 mg. 
Prog. 1100 0.10 n - - 
60 mg. 0.12 
" 1700 9.60 n - - 
9.73 
u 1820 10.50 " 1780 11.33 
10.35 11.50 
" 1825 11.10 " 1310 11.05 
11.00 11.35 
u 1200 10.00 " 1680 10.00 
9.70 9.90 
n 1600 10.90 " 1940 11.50 
10.85 11.35 
n 1500 11.40 - 1740 11.10 
11.55 10.85 
« - - - 1840 4.73 
4.63 
" 2750 11.40 - 1800 0.63 
11.66 0.66 
" 1280 11.05 - 1420 0.12 
11.10 0.15 
IT _ - 
TABLE 6 
CONTINUED DAILY ADMINISTRATION OF PROGESTERONE 












- 1800 0.16 Prog. 1360 11.90 
0.17 60 mg. 11.75 
Prog. 1770 0.19 " 1760 9.65 
60 mg. 0.18 9.75 
" 2000 8.50 " 1290 11.10 
8.20 11.25 
" 2315 11.60 1' 1325 10.50 
11.75 10.70 
" 1680 11.20 " 1700 10.80 
11.25 11.00 
" 1460 9.45 " 2435 11.75 
9.75 11.90 
" 1750 12.25 " 1680 11.45 
12.10 11.50 
" 1400 11.30 " 1800 11.25 
11.40 11.40 
TT 1700 12.15 - 2450 11.10 
12.00 11.00 
" 1430 10.40 - 1780 7.75 
10.45 7.60 
" 1310 9.10 - 1880 1.60 
9.35 1.52 
" 1620 12.10 - 1900 0.28 
11.95 0.39 
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(c) Urinary pregnanediol excretion during continued 
daily administration of progesterone to hysterectomised 
(ovariectomised or post -menopausal) women 
As indicated in the introduction, conflicting 
results have been reported concerning the possible im- 
portance of the uterus in the metabolism of progester- 
one and their discussion was postponed until this 
section. Venning and Browne (1938) were unable to 
recover "pregnanediol glucuronide" from the urine of 
two hysterectomised women after the administration of 
progesterone. In 1940 however, the same workers re- 
ported that following the administration of the hormone 
after supravaginal hysterectomy, 9.6 per cent. was re- 
covered as "pregnanediol glucuronide" expressed as 
pregnanediol. Buxton (1940) recovered pregnanediol 
glucuronide from the urine of only two of four hyster- 
ectomised women similarly investigated. Seegar Jones 
and TeLinde (1941) reported the recovery of 15.6 per 
cent. of the administered hormone as pregnanediol from 
the urine of a woman after panhysterectomy and 12.9 per 
cent. and 10.9 per cent. after supravaginal hysterec- 
tomy. Hamblen (1939) had reported the absence of 
detectable pregnanediol excretion in a woman during 
the luteal phase of the menstrual cycle after 
curettage of the uterus. On the other hand, Seegar 
Jones and TeLinde recovered 6.1 mg. of "pregnanediol 
glucuronide" / 
-38- 
glucuronide" (expressed as pregnanediol) from the 
urine on the sixteenth day of a menstrual cycle in a 
woman in whom total hysterectomy had been performed on 
the first day- of the cycle. After the administration 
of progesterone (60 mg.) on two successive days to 
three post- menopausal women after total hysterectomy, 
the present worker recovered 13.3 per cent., 14.1 per 
cent. and 14.9 per cent. as urinary pregnanediol 
(Sommerville, 1948; Sommerville and Marrian, 1950a). 
These results, and the results obtained after the ad- 
ministration of progesterone to men, prove beyond 
doubt that the uterus is not essential for the con- 
version of a proportion of administered progesterone 
to urinary pregnanediol. 
In all these experiments, however, progesterone 
was administered for only one or two days and, there- 
fore, it could not be assumed that such experiments 
gave a fair indication of the biochemical mechanism of 
progesterone disposal in action since, under physiológ1 
ical conditions - daring the luteal phase of the 
menstrual cycle and during pregnancy - the human body 
is subjected to the influence of the hormone for con- 
siderably longer periods of time. Thus in view of 
the results obtained in the present work it seemed 
possible that a different state of affairs might 
exist when a comparison was made between normal and 
ysterectomised post -menopausal women after the 
prolonged 
-39- 
prolonged administration of progesterone. 
Since it had been found that a higher proportion 
of administered progesterone may appear in the urine 
as pregnanediol when the hormone is injected in the 
immediate post- operative period than when the 
experiment is repeated in the same subject several 
weeks later (Sommerville, 1948) , the cases in the 
present series were investigated not less than two 
months after total hysterectomy. 
1. Subject 'H': 
Hysterectomised post -menopausal woman aged 
50 years (eight years after the menopause). 
Progesterone, 60 mg. was administered daily 
for 22 days in gelatin capsules by mouth. 
The results are shown in Fig. 5 and Table 7. 
After an initial control period, the determin- 
ation of urinary pregnanediol was carried out daily. 
A plateau of excretion corresponding to about 17.0 per 
went. of the dose of administered progesterone was 
maintained throughout the experiment. 
2. Subject 
Hysterectomised- ovariectomised woman aged 45 
years. 
Progesterone, 60 mg. was administered daily 
for 18 days in gelatin capsules by mouth. 
The results are shown in Fig. 5 and Table 8. 
A plateau corresponding to about 16.0 per cent. 
of the dose of administered progesterone was maintain- 
ed throughout the experiment. 
3. / 
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3. Subject 'R': 
Hysterectomised -ovariectomised woman aged 42 
years. 
Progesterone, 40 mg. was administered daily 
for 18 days in gelatin capsules by mouth. 
The results are shown in Fig. 5 and Table 9. 
It will be seen that a plateau of pregnanediol 
excretion corresponding to 19.0 per cent. of the ad- 
ministered hormone was maintained throughout the 
experiment. 
Conclusion 
In all three cases under investigation the ex- 
cretion of urinary pregnanediol was maintained at a 
level corresponding to the temporary initial plateau 
observed in the series of normal post -menopausal 
women. There was no indication whatsoever of a pro- 
gesterone "priming" effect. Under these experimental 
conditions, therefore, it is certain that the post- 
menopausal uterus is essential for the occurrence of 







































































































CONTINUED DAILY ADMINISTRATION OF PROGESTERONE 
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- 850 0.19 Prog. 910 9.65 
0.18 60 mg. 9.75 
Prog. 740 0.15 " 1260 10.20 
60 mg. 0.16 10.05 
" 520 7.50 " 1120 10.55 
7.55 10.50 
IT 980 10.50 if 600 10.75 
10.70 10.95 
It 740 10.15 " 1540 11.10 
10.05 11,25 
" 1280 9.65 " 950 10.40 
9.75 10.15 
" 470 10.75 " 780 10.70 
(Comp.) 10.80 10.70 
" 1180 10.05 " 960 9.80 
10.10 9.75 
" 820 11.10 " 980 11.00 
11.25 10.80 
" 600 9.70 - 850 9.85 
9.55 10.10 
" 1380 11.20 - 920 5.75 
11.05 5.90 
" 1080 10.40 - 1000 1.76 
10.50 1.74 
" 920 11.00 - 880 0.54 
11.10 0.46 
" 1195 10.70 - 750 0.20 
10.65 0.21 
TABLE 8 
CONTINUED DAILY ADMINISTRATION OF PROGESTERONE 












mg./ 24 hr. 
- 2750 0.09 Prog. 3150 8.88 
0:07 60 mg. 9.01 
Prog. 2725 0.10 IT 3500 9.87 
60 mg. 0.11 10.01 -.r 
IT 2775 8.60 " 3010 8.85 
8.71 9.21 
IT 2500 8.50 " 3200 10.05 
8.75 10.05 
1f 3780 10.58 " 2750 10.12 
10.36 10.23 
" 3400 9.93 " 3100 9.98 
9.86 9.61 
TT 3200 9.60 " 3250 9.63 
9.79 9.75 
" 4420 10.43 - 3580 9.13 
10.17 9.19 
" 3200 9.92 - 3400 4.25 
9.66 4.18 
" 3100 9.73 - 2950 1.24 
1.24 
Ti 3200 9.34 - 2550 0.42 
9.54 0.39 
" 2800 9.35 
9.07 
TABLE 9 
CONTINUED DAILY ADMINISTRATION OF PROGESTERONE 













- 750 0.10 Prog. 880 7.50 
0.11 40 mg. 7.50 
Prog. 1300 0.12 " 1005 7.00 
40 mg. 0.12 7.15 
TT 1240 7.75 " 1140 7.75 
7.60 7.90 
" 1080 7.8C " 950 7.75 
7.85 7.85 
IT 1100 7.40 " 1310 7.80 
7.10 7.50 
" 1310 7.50 " 1050 8.00 
7.25 8.10 
" 1130 8.00 " 885 7.95 
7.75 7.80 
" 720 7.05 - 1100 7.65 
7.15 7.50 
" 760 7.25 - 1020 3.45 
7.20 3.38 
" 1500 7.85 - 990 1.09 
7.75 1.06 
IT 1600 7.80 - 1005 0.31 
7.60 0.28 
n 1200 8.05 
8.15 
-41- 
(d) Urinary pregnanediol excretion during continued 
daily administration of pregnane -3á,20a -diol to normal 
lost- menopausal women 
In view of the possibility, which will be dis- 
cussed, that the "priming" phenomenon in post -meno- 
pausal women may be associated with the action of pro- 
gesterone in causing structural changes in the uterus, 
it seemed of is ::portance to test for "priming" activity 
related steroids which are known or suspected to be 
progesterone metabolites but which lack the physiolog- 
ical activity of the hormone. Unfortunately, owing 
to the lack of sufficient quantities of other possible 
progesterone metabolites, pregnane- 3a,20 -diol is the 
only one of these steroids which could be tested. It 
was especially interesting to investigate this steroid 
in view of the possibility discussed in the introduct- 
ion that all or most progesterone is largely reduced 
to this metabolite in the body and that the relatively 
small proportion appearing in the urine is due to 
further metabolism of the pregnanediol so formed or to 
excretion of pregnanediol by other routes. Further- 
more, the result might throw some light on whether the 
progesterone "priming" effect is associated with the 
metabolic reduction of progesterone to pregnanediol or 
with the glucuronidic conjugation of the metabolite. 
Because of the low solubility of pregnane- 3a,20m-diol 
in/ 
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in oil it was not practicable to administer sufficient 
by injection to give an accurately measurable urinary 
excretion. Accordingly, administration in arachis 
oil in gelatin capsules by mouth was adopted. 
400 mg. of pure pregnane -3a, 20a -diol was dis- 
solved in a minimal volume (about 10 ml.) of warm 
ethanol, 60 ml. of arachis oil (Organon) added, and 
the excess of ethanol boiled off by heating in a water - 
bath. After cooling the volume was made up to 100 ml. 
with more arachis oil. This solution contained 4.04 
per ml. and 40 mg. was administered daily in gelatin 
capsules by mouth. 
1. Subject 'H': 
Normal post- menopausal woman aged 70 years. 
The experiment was carried out on the same 
subject who had shown marked "priming" after the 
administration of progesterone either by intra- 
muscular or oral administration. A period of 
four months was allowed to elapse between this and . 
the previous experiments. 
Pregnane- 3a,201 -diol, 40 mg. was administered 
daily for 17 days. 
The results are shown in Fig. 6 and Table 10. 
An irregular plateau corresponding to about 12.0 
per cent. of the administered metabolite was maintain- 
ed throughout the experiment. 
2. 
-43- 
2. Subject 'S': 
Normal post -menopausal woman aged 58 years. 
Pregnane- 3a,20a -diol, 40 mg. was administered 
daily for 18 days. 
The results are shown in Fig. 6 and Table 11. 
As in the previous experiment a rather irregular 
plateau - in this case corresponding to about 10.0 per 
cent. of the administered metabolite was maintained 
throughout the experiment. 
It was interesting to note that in subject 'H', 
who had previously complained of drowsiness after the 
administration of progesterone by mouth, but not after 
intra- muscular injection, observed the same effect in 
the present experiment. 
Conclusion 
There was no evidence of a "priming" effect after 
the prolonged administration of pregnane- 3a,20ä -diol 
to two post -menopausal women, one of whom had previous- 
ly exhibited the effect during prolonged administrat- 
ion of progesterone. 
DISCUSSION 
Figure 5e 
Urinary pregnanediol (mg./24 hr.) 









Urinary pregnanediol (mg./24 hr.) 
N o% CO 
Determinations discontinued 
TABLE 10 
CONTINUED DAILY ADMINISTRATION OF PREGNANE- 3m ,20a -DIOL 












- 970 0.11 Preg. 1360 4.62 
0.13 40 mg. 
- 1200 0.15 " 1220 4.75 
0.14 - 4.75 
Preg. 1210 0.10 " 1280 4.90 
40 mg. 0.11 5.05 
" 940 4.43 " 1400 5.45 
4.50 5.40 
" 1580 5.22 " 1350 5.10 
5.12 5.03 
It 1500 4.62 n 1410 4.65 
4.68 4.55 
" 1440 5.12 " 1480 4.32 
5.10 4.43 
IT 1340 4.28 - 1500 5.30 
4.38 5.20 
" 1140 4.78 - 1250 2.88 
4.72 2.97 
u 1700 5.38 - 1290 0.97 
5.30 0.99 
" 1120 4.38 - 1420 0.28 
4.50 0.29 
It 1390 4.90 
4.82 
TABLE 11 
CONTINUED DAILY ADMINISTRATION OF PREGNANE- 3a,20a -DIOL 












Preg. 1Z0 0.17 Preg. 1360 4.00 
40 mg. 0.19 40 mg. 4.05 
" 1400 2.52 " 1400 3.92 
2.58 3.87 
" 1420 4.17 " 1280 3.55 
4.25 3.40 
" 1280 4.00 " 1350 2.70 
4.10 2.85 
" 1500 3.42 n 1425 4.55 
3.50 4.40 
" 1240 4.37 n 1460 4.25 
4.30 4.35 
it 1520 3.90 " 1320 3.58 
3.87 - 3.50 
IT 1560 4,33 " 1540 4.73 
4.43 _ 4.65 
" 1500 4.50 " 1310 4.23 
4.55 - 4.10 




(a) The role of the uterus in the metabolism of 
progesterone 
The results of the experiments in which proges- 
terone was administered to men and hysterectomised 
women prove that the uterus is not essential for the 
conversion of the administered hormone to its urinary 
metabolite. On the other hand, it is clear from the 
present work that the enhanced power of the normal 
post -menopausal woman to excrete urinary pregnanediol 
after prolonged daily administration of progesterone 
is dependent upon the presence of the uterus. Accord- 
ingly, it may be concluded that the post -menopausal 
uterus, after prolonged exposure to the action of pro- 
gesterone or of one of its metabolic products, is able 
to effect the conversion of an additional proportion 
of administered progesterone into urinary pregnanediol. 
The fact that in men and hysterectomised women, a 
steady plateau of pregnanediol excretion is establish- 
ed in two to three days after the commencement of pro- 
gesterone administration and is maintained for periods 
of up to twenty days indicates that the effect is not 
due to the saturation of tissues other than the uterus. 
The possibility that the progesterone "priming" effect 
is due to saturation of the uterine tissue with pro- 
gesterone or its metabolites seems unlikely for two 
reasons. Firstly, if such saturation was to occur, 
then / 
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then in experiments of short duration, the pregnanediol 
excretion would be relatively lower in normal post- 
menopausal women than in hysterectomised women. This 
is not so. Secondly, if the "priming" effect was due 
tic) saturation of the uterine tissue with progesterone 
and/or its metabolites, one would expect that the 
clearance of pregnanediol, as judged by its rate of 
disappearance from the urine after stopping the 
administration of progesterone, would be delayed in the 
experiments of long duration in comparison with those 
of short duration. No such delay was, in fact, 
observed. 
The fundamental problem revealed by the present 
work is to determine in what way the progesterone 
"priming" phenomenon is related to histological or 
biochemical changes in the uterus. 
At the present time there is no definite evidence 
to show whether the effect is associated with the 
physiological action of progesterone in inducing 
structural changes in the uterine endometrium or 
myometrium. The observation that the "priming" was 
greater with intra- muscularly than with orally ad- 
ministered progesterone, and the observation that in 
the three oral administration experiments the higher 
dose gave the greater "priming ", suggest that this 
may be the case. It is unfortunate that more exten- 
sive studies of endometrial histology and vaginal 
oytology / 
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cytology were not carried out in the subjects under 
study, but when the experiments were in progress it 
seemed unlikely that such doses of orally administered 
progesterone would induce detectable changes in the 
endometrium or vaginal epithelium. Furthermore, in 
previous studies in which progesterone was adminis- 
tered to three post -menopausal women pre- treated with 
oestrogen, a similar proportion of the hormone appear- 
ed as pregnanediol in the urine despite the varied 
responses of the endometria - in one case, atrophic, 
in another, proliferative; and in a third, secretory. 
These results suggested that differences in endometrial 
histology are not associated with alterations in the 
quantative relationship between progesterone and preg- 
nanediol. There remain the possibilities, however, 
that biochemical changes are occurring in the endo- 
metrium or that histological and biochemical changes 
are occurring in the myometrium. 
Little is known about the effect of progesterone 
on a uterus unprimed by oestrogen. The most detailed 
report is that of Crandall (1938), who administered 
progesterone daily by subcutaneous injection to 
ovariectomised rabbits and studied the uterine histol- 
ogy. The most interesting observation was the effect 
upon mitotic activity of the muscle cells. In un- 
treated ovariectomised rabbits there were about 1.5 
mitoses per sq. mm. of muscle tissue whereas after 
three / 
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three days of progesterone administration (0.2 to 0.5 
mg. daily) mitoses among these cells numbered about 25 
to 30 per sq. mm. This effect was evanescent and the 
mitotic activity had returned to the control level 
after six dare of progesterone administration. 
It would be of considerable interest to correlate 
such structural changes in the uterus with the propor- 
tion of the hormone excreted as urinary pregnanediol. 
This could be carried out most satisfactorily in an 
experimental animal and preliminary work directed 
towards this end is described in section 5. Tako- 
metric studies might also contribute to the elucidat- 
ion of this problem. 
The observation that the oral administration of 
pregnane- 3¢,20a -diol gave no "priming" in post- 
menopausal women is compatible with the theory that 
the effect is due to the action of progesterone per se. 
The possibility must be borne in mind, however, that 
"priming" might result from other progesterone 
metabolites which cannot be tested. In this connect- 
ion it may be pointed out that pregnanediol is by no 
means an "inert metabolite" of progesterone. In the 
present work, reference has been made to the soporific 
effect of 60 mg. of progesterone administered by mouth, 
and the lack of this effect when a similar dose was 
administered to the same woman ('H') by intra- muscular 
injection. / 
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injection. The effect was also noted when 
pregnane -3a, 20a -diol was administered by mouth. 
These observations suggest that rapid absorption of 
the hormone or the metabolite from the intestine re- 
sults in a higher serum concentration of either stero 
than results from the gradual absorption of intra- 
muscularly injected hormone. Selye (1941) was the 
first to investigate the anaesthetic property of 
steroids administered to rats and found that anaes- 
thesia was produced by intra- peritoneal injection of 
progesterone, pregnanediol, desoxy corticosterone 
acetate, androsterone, testosterone and other steroids. 
Hartman, Burge and Doctor (1947) showed that the 
term steroid anaesthesia is justifiable by studying 
the effect of progesterone on the brain potentials of 
rats. As might be expected from the present work, 
the anaesthetic potency of steroids administered to 
animals depends largely upon the route of administrat1 
ion. Injection of the steroid into the intestine 
below the pylorus gives rapid anaesthesia deep enough 
to allow prolonged abdominal operations whereas sub- 
cutaneous administration is much less effective. A 
second biological action attributable to pregnanediol 
is mucification of the vagina in ovariectomised mice 
(Freud, 1937). 
Although it follows from the above remarks that 
histological studies of endometrium and myometrium 
ought / 
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ought to be carried out in animals receiving proges- 
terone, it seems more likely to the present worker 
that the mechanism underlying the progesterone 
"priming" effect will be elucidated a fuller under- 
standing of the metabolism of uterine tiss,,e. The 
part played by the uterus in the metabolism of pro - 
igesterone may be concerned either with the metabolic 
reduction of progesterone to pregnanediol, with the 
further metabolism of pregnanediol or with its con- 
jugation with glucuronic acid. In the absence of 
evidence to the contrary it seems not unreasonable to 
speculate that progesterone is largely reduced to 
pregnanediol in the body, that a considerable proport- 
ion of the metabolite is either further metabolised or 
excreted in the bile and that the proportion appearing 
in the urine is that fraction of the pregnanediol 
which is conjugated as a glucuronide. The role of 
the enzyme g- glucuronidase in glucuronide synthesis 
and hydrolysis is far from certain, but it would be 
surprising if it does not play a significant part in 
this process (Marrian, 1946) . If then, progesterone 
were to inhibit the hydrolytic activity of the 
glucuronidase in uterine tissue then elevation of the 
urinary level of excretion of pregnanediol glucuronide 
might result. It has been shown that there is a 
correlation between 3- glucuronidase activity and cell 




the high mitotic activity of the myometrium and a high 
glucuronidase activity are responsible for the priming 
then on the basis of the working hypothesis suggested 
above, the enzyme would require to be exerting a pre- 
dominantly synthetic role. 
Similarly, if the progesterone "priming" effect 
is associated with factors influencing the reduction 
and oxidation of progesterone and its metabolites a 
correlation might be found between the proportion of 
administered progesterone excreted as urinary pregnane- 
diol and the activity of appropriate enzymes and co- 
enzymes in the uterus. In this connection it is 
interesting to note that in ovarian tissues, correlat- 
ions can be made between the functional state of the 
tissues and fluctuations in the activity of such 
enzymes as succinic dehydrogenase (Meyer et al., 1947), 
malie dehydrogenase and cytocrrome oxidase (McShan et 
al., 1948). It is of the greatest interest to find 
that the uterus is a rich source of such vitamins as 
alpha- tocopherol and ascorbic acid since, as will be 
discussed, these substances might be expected to 
participate in such a reaction as the metabolic re- 
duction of progesterone to pregnanediol. Experiments 
to investigate the possibility that alpha- tocopherol 
participates in the metabolism of progesterone are 
described in the section which follows. If the bio- 
chemical mechanism whereby the uterus exerts its 
effect / 
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effect on the metabolism of progesterone is concerned 
with reduction- oxidation reactions or with glucuronide 
synthesis or hydrolysis, it would be anticipated that 
the uterus plays a similar role in the intermediary 
metabolism of other steroid hormones. 
(b) Speculation as to possible clinical implications 
The present results suggest the possibility that 
during pregnancy and, to a less extent, during the 
luteal phase of the menstrual cycle, the relationship 
of endogenous progesterone secretion to urinary preg- 
nanediol excretion may be similar to that observed 
when the post -menopausal uterus is subjected to the 
influence of the hormone for prolonged periods of tima 
Thus, it may be that the rise in pregnanediol excretion 
which occurs after about the twelfth week of pregnancy 
is a manifestation of this changing relationship and 
is not an indication of a rising placental output of 
the hormone. It would be reasonable to expect that 
the effect observed in the atrophic post -menopausal 
uterus would be present to a greater degree in the 
physiologically active uterus. It may be, therefore, 
that during pregnancy the conversion of 50.0 per cent. 
of administered progesterone to pregnanediol, over and 
above that of endogenous origin, represents the 'second 
plateau" observed after prolonged administration of 
the / 
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the hormone to normal post -menopausal women. Before 
any final conclusion can be reached as to the possi- 
bility of calculating the level of endogenous proges- 
terone secretion from that of urinary pregnanediol 
excretion the effect of oestrogenic and gonadotrophic 
hormones upon the progesterone "priming" effect would 
require investigation. 
The participation of the uterus in the metabolism 
of progesterone has the further implications that 
abnormalities of that metabolism may result from 
uterine dysfunction. The excretion of urinary preg- 
nanediol is abnormally low in pre -eclamptic toxaemia 
(Browne et al., 1938; Smith and Smith, 1938, 1940, 
1946) . This may be due to an abnormally low level of 
progesterone secretion, to an abnormality of proges- 
terone metabolism, or to impaired renal function. 
The first possibility is incalculable and the third is 
improbable. The possibility may be entertained, how- 
ever, that there is an abnormality of progesterone 
metabolism in the toxaemias of pregnancy and that this 
reflects a fundamental and possibly pathogenetic 




TOCOPHE, .UL AND THE METABOLISM OF PROGESTERONE 
"Despite more than two decades of research, 
vitamin E still remains the mysterious 
intruder in the vitamin family, accepted 
at first with much reluctance and later 
reared somewhat as an outcast largely 
because of failure to satisfactorily estab- 
lish its practical it portance for man and 
beast. Its chemical nature is known, its 
laboratory synthesis accomplished, its wide 
distribution in the plant and animal world 
recognised, and the effect of its absence 
extensively studied in a large series of 
laboratory animals. Its physiological role 
in the animal body is still a matter of 
conjecture ". (Mason, 1944). 
The observation of structural and functional 
derangements characteristic of experimental vitamin E 
deficiency, and in particular the observation that 
intra- uterine death with resorption of the autolysed 
products of conception terminates pregnancy in vitamin 
E deficient rats (Evans and Burr, 1927) have long 
suggested the possibility that the vitamin may be of 
importance in human reproductive physiology. This 
contention has, however, lacked clear -cut confirmation 
from clinical and experimental studies and one is 
tempted to conclude that, either the vitamin does not 
play such a rôle or that it plays a rôle of such a 
fundamental nature as to remain untouched by the 




the latter connection, and in view of the speculations 
discussed in the previous section, it is of consider- 
able interest to find in the literature references to 
the possibility that the tocopherols may participate 
as anti -oxidants in reversible oxidation -reduction 
systems in the body. Thus Houchin (1942) suggests 
that tocopherols, probably in phosphorylated form, 
may inhibit or regulate oxidative processes in muscle, 
and this worker may have provided a clue to the type 
of enzyme system involved, by the observation that the 
dystrophic muscle of vitamin E deficient animals ex- 
hibits a high succinoxidase activity and that this 
activity is inhibited by a- tocopheryl phosphate. 
Since the observations of Zondek (1934) on the 
inactivation of oestrogens by the liver, there have 
been many reports indicating the importance of that 
organ in determining the biological activity of the 
steroid hormones, and in particular the dependence 
of this liver function on the presence of certain 
essential food factors (Biskind, 1942; Unna et al., 
1944; Kochakian et al., 1944) . The ró1 e of the 
liver in steroid metabolism, however, is still obscure 
although reference has already been made to the work 
of Masson and Hoffman (1945) on the metabolism of 
progesterone and to experiments in which the proport- 
ion of administered progesterone excreted as urinary 




administration (Marrian, 1949; Sommerville and Marrian, 
1949). Clark and Koehakian (1944) have studied the 
metabolites arising from the incubation of testosterctif 
with rabbit liver slices in serum; Glass et al. (1940) 
found evidence for abnormal oestrogen metabolism in 
human subjects with impaired liver function, and 
Samuels and McCaulay (1948) have reported recently 
that human cirrhotic livers do not destroy testos- 
terone as rapidly as normal livers. It is interest- 
ing, therefore, to consider whether certain aspects of 
experimental dietary necrosis of the liver may not be 
relevant to the present problem. It has been shown 
that this lesion is attributable to a deficiency of 
cystine (Glynn and Himsworth, 1945) and Schwarz 
(1944) found that its occurrence could be prevented by 
supplementing the diet with vitamin E. This effect 
has been confirmed and extended by György (1947) and 
it appears that tocopherol deficiency may sensitize 
the animal to the deficiency of the amino -acid. 
In view of these indications of the rôle of 
vitamin E as an "antioxidant" in cell metabolism and 
as a factor in liver function attention was turned to 
previous studies in which the possible interaction of 
progesterone and vitamin E had been considered. No 
clear -cut evidence of an interdependence of hormone 
and vitamin had been adduced - whereas, in the case 
of I 
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of androgen there is some ground for the belief that a 
synergism exists between vitamin E deficiency and 
androgenic potency (Caridroit, 1942). The develop- 
ment of methods for the determination of urinary 
pregnanediol provided a new method of approach to this 
problem and one which has not yet been fully exploited. 
In 1942, Winkler determined the excretion of 
"pregnanediol glucuronide" by the method of Venning, 
in the urine of women who were receiving synthetic 
d,l- a- tocopherol acetate throughout the menstrual 
cycle. The results indicated that an increase in the 
excretion of "pregnanediol glucuronide" accompanied 
the administration of tocopherol but the results were 
not convincing in view of the known variability in the 
amount of "pregnanediol glucuronide" excreted during 
the menstrual cycle and in view of the insensitivity 
of the method of determination employed. Winkler 
concluded that the apparent increase in pregnanediol 
excretion reflected a stimulation of endogenous pro- 
gesterone secretion. 
In 1948, de Watteville, Borth and Gsell 
questioned the validity of this assumption and sugges- 
ted that the effect - if it existed - might equally 
well result from a "shift in the intermediary metab- 
olism of progesterone ". To investigate this possi- 
bility these workers administered progesterone to 
post -menopausal / 
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post -menopausal women and determined the proportion 
excreted as urinary pregnanediol by a modification of 
the method of Huber (1947) . The vitamin, d, l -a -toco- 
pherol acetate ("Ephynal ", Roche) was then administer& 
for seven days after the disappearance of pregnanediol 
from the urine, and the progesterone administration 
and pregnanediol determination were then repeated. 
The experiment was carried out in twelve post- 
menopausal women, and in two of these the administrat- 
ion of the vitamin was omitted. The results showed 
that the proportion of administered progesterone ex- 
creted as urinary pregnanediol was increased by the 
previous administration of synthetic a- tocopherol. 
Thus, before treatment the proportion of progesterone 
excreted as urinary pregnanediol ranged from 7.3 per 
cent. to 13.8 per cent. (mean 9.66 per cent.) whereas 
after treatment the results represented 10.4 per cent. 
to 19.9 per cent. (mean 14.17 per cent.) of the ad- 
ministered hormone. There is no suggestion in the 
description of these experiments that the women in- 
vestigated were receiving diets deficient in vitamin E; 
and the authers cautiously refrain from relating their 
results to the possible therapeutic value of 
tocopherol therapy in pregnancy but suggest that the 
effect might be due to "diminished oxidative destruct- 





The results obtained by de datteville et al.(1948) 
gained a new significance in view of our speculation 
that the mechanism of the progesterone "priming effect" 
might depend upon the activity in uterine tissue of 
vitamin E or of some similar substance. Accordingly, 
tentatively assuming that the results obtained by these 
workers were valid, it seemed important to repeat 
their experiments but to investigate men and, if 
necessary, hysterectomised women, instead of post- 
menopausal women. 
In the present work, the selection of normal 
human subjects, the collection of twenty -four -hour 
urine specimens and the determination of urinary 
excretion of pregnanediol by the method of Sommerville, 
Gough and Marrian (1948) were as in the previous 
section. Apart from the choice of subjects and the 
choice of method of pregnanediol assay, the experi- 
mental conditions were identical with those of 
de 'rdatteville et al. 
(i) Progesterone, 100 mg., was administered by 
intra- muscular injection and urinary preg- 
nanediol determined on the day preceding 
the injection and until the excretion had 
returned to the control "blank" value. 
(ii) "Ephynal" (Roche), 60 mg., was administered 
by mouth for seven days. 
(iii) On the seventh day, pregnanediol determinat- 




second intra- muscular injection of 100 mg. 
of progesterone was administered. 
The proportion of the administered hormone excret- 
ed as urinary pregnanediol was calculated after 
correction of the apparent pregnanediol excretion for 
the control period "blank" value. This "blank" value 
which may be due to pregnanediol of adreno- cortical 
origin or to traces of other substances which are 
chromogenic in the sulphuric acid reaction does not 
amount to more than about 0.2 rra. per twenty- four -hour 
specimen in normal men or normal post -menopausal women. 
The pattern of excretion in such experiments is shown 
in Fig. 6 which illustrates the urinary excretion of 
pregnanediol after the administration of progesterone 
to subject 'R'. The arrow indicates the intra- 
muscular injection of 100 mg. of progesterone and the 
values obtained in the duplicate determinations are 
indicated by the double lines at the tops of the 
columns. 
(a) Proportion of administered progesterone excreted 
as urinar e«nanediol b normal men after the 
administration of d,l -a- tocopherol acetate 
The experiment was carried out as above in three 
normal men, and to a third man ('S') the progesterone 
was administered in gelatin capsules by mouth. The 
results / 
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results are shown in the following table, and in 
Tables 12 and 13. 
Subject 
Recovery o Pregnanediol from Adminis Bred 
Progesterone Per Cent. 
Before Tocopherol After Tocopherol 
8.48 1 ,.? 8.29 
'P' 15.83 15.74 






These experiments show very clearly that pre- 
treatment with synthetic vitamin E has no effect upon 
th e proportion of administered progesterone excreted a 
úrinary pregnanediol. Before concluding, however, 
that there is a sex difference in the occurrence of 
effect observed by de Watteville et al., it was obvious- 
necessary to confirm the occurrence of the effect in 
normal post- menopausal women. 
(b ) / 
6 
Figure 6. 
UR1NMay EaccRE.ToH of IktC/4044.910. Fo1.1-0W44 
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ADMINISTRATION OF PROGESTERONE (100 mg. INTRA -LUSC. ) 
TO NORI:AL YEN BEFORE (A) AND AFTER --(B) 





mpg. /24 hr. 
Profi. 
100 mg 1500 0.19 
(A) 0.16 
- 3200 7.04 
6.94 
- 2520 1.63 
1.64 
- 3250 0.18 
0.27 
- 1660 0.15 
0.15 
Prog. 
100 mg 1020 0.16 
(B) 0.18 
- 1740 5.25 
5.30 
- 1340 3.05 
2.99 
- 940 0.56 
0.59 
- 1820 0.28 
0.21 
- 1520 0.14 
0.15 






100 mg 2315 0.15 
(A) 0.13 
- 2600 6.29 
6.36 
- 2265 2.17 
2.18 
- 1980 0.28 
0.26 
- 1900 0.18 
- 1800 0.16 
0.18 
Prog. 
100m,g 1400 0.13 
(B) 0.14 
- 1600 7.25 
7.30 
- 1820 1.44 
1.42 
- 1250 0.20 
0.21 
- 1400 0.15 
TABLE 13 
AD1INISTRATION OF PROGESTERONE 
(INTRA-LUSC. TO SUBJECT 'P' AND ORAI, TO SUBJECT 'S') 
TO NORLAT, LEN BEFORE (A)- 







100 mg 1310 0.10 
(A) 0.11 
- 1500 8.98 
9.08 
- 1420 6.60 
6.75 
- 1500 0.41 
0.49 
- 1480 0.09 
0.14 
Prog. 
100 1620 0.16 
(B) 0.13 
- 1800 10.35 
10.23 
- 1520 5.35 
5.43 
- 1680 0.52 
0.49 






riig . /24 hr. 
Prog. 
100 mg 1440 0.13 
(A) 0.13 
- 1640 9.58 
9.63 
- 1350 0.99 
0.96 
- 1290 0.52 
0.46 
- 1920 0.17 
0.15 
- 1530 0.10 
0.12 
Prog. 
100 mg 1720 0.12 
(B) 0.11 
- 1920 8.83 
8.85 
- 1220 1.02 
1.03 
- 1640 0.43 
0.40 
- 1400 0.11 
0.09 
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(b) Repetition of the experiment in normal post- 
menopausal women 
Up to the present time, two cases have been in- 
vestigated. 
1. Subject 'C': aged 60 years:- The proportion of 
injected progesterone excreted as urinary 
pregnanediol before administration of 
d,l- a- tocopherol acetate was 10.22 per cent. and 
after administration was 9.71 per cent. 
2. Subject 'H': aged 70 years:- In this case 12.23 
per cent. was recovered before and 12.79 per 
cent. after pre -treatment with d,l-a-tocopherol- 
acetate. 
Conclusion 
The results in these two cases are sufficiently 
clear -cut to justify the conclusion that, under these 
experimental conditions, pre- treatment with synthetic 
vitamin E has no effect upon the proportion of admin- 
istered progesterone excreted as urinary pregnanediol 
by normal post -menopausal women. 
The results of the twelve metabolic experiments 
described above are illustrated in Fig. 7, in which 
the total excretion of urinary pregnanediol (corrected 
for the "blank" value) is represented as a percentage 
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TABLE 14 
ADMINISTRATICN OF PROGESTERONE (100 mg. INTRA -MUSC.) 
TO NORMAL POST-MENOPAUSAL WOMEN 







100 mg 1320 0.15 
(A) 0.11 
- 1830 4.83 
4.95 
- 1320 2.45 
2.46 
- 1420 1.98 
1.99 
- 960 1.33 
1.34 
- 770 0.18 
0.19 
Frog. 
100 mg 800 0.18 
(B) 0.18 
- 1400 5.60 
5.75 
- 1050 4.17 
4.19 
- 1200 0.35 
0.36 








100 mg 1010 0.23 
(A) 0.20 
- 1040 7.78 
7.70 
- 1640 2.70 
2.73 
- 1360 1.52 
1.54 
- 800 1.08 
1.04 
- 1150 0.26 
0.30 
Prog. 
100 mg 1420 0.29 
(B) 0.28 
- 1350 9.93 
9.98 
- 1200 2.80 
2.68 
- 1600 0.94 
0.92 




The schedule of dosage and timing of the experi- 
ments in the present work and in the investigation by 
de ,jatteville et al. were identical, and it is reason- 
able to suppose that the factors responsible for the 
contradictory results were associated either with the 
choice of subjects or with the choice of method for 
the determination of urinary pregnanediol. 
It is a criticism of the investigation of 
de _tteville et al. that all of their cases were 
suffering from either carcinoma of the cervix (nine 
cases) or carcinoma of the breast (three cases). The 
former had received radiation therapy and in many of 
the cases the disease was well established with, in at 
least two cases, cachexia and general metastases. 
Whereas it is unlikely that the cases studied in 
either set of experiments were receiving a diet 
deficient in vitamin E, it does seem possible that a 
relative deficiency of the vitamin might be associated 
with the clinical condition of the cases of 
de ;iatteville et al. Alternatively, the neoplastic 
tissue may have an increased affinity for the adminis- 
tered vitamin and, since the neoplasms were confined 
to secondary sex organs, it is not impossible (in 
view of the results in section 1) to visualise 
a 
consequent / 
consequent effect on steroid metabolism. In this 
connection it would seem more logical to investigate 
the hypothesis that a- tocopherol is acting as an anti- 
oxidant in progesterone metabolism by the simultaneous 
rather than by the previous administration of the 
vitamin. It is a considerable assumption to relate 
the anti - oxidant activity of the vitamin - a function 
which has been studied in other fields of biochemistry, 
to the intermediary metabolism of the steroids but a 
recent discovery has greatly strengthened the status 
of a- tocopherol as a participant in oxidation-reduct - 
ion systems. 
Until recently it was difficult to reconcile such 
a role for a- tocopherol with the nature of its 
oxidation product, a-tocopheryl quinone (Fig. 8). 
The reversibility of this reaction has not been demon- 
strated and the quinone is biologically inactive when 
administered to rats (Wright and Drummond, 1940) and 
guinea pigs (Golumbic, 1940). Since the tocopherol 
molecule has only one unsubstituted phenolic hydroxyl 
group, the bivalent oxidation to the quinone involves 
an opening of the side -ring and presumably explains 
the irreversibility of the oxidation. In 1949, how- 
ever, Lichaelis and 'Wollman obtained evidence for a 
reversible univalent oxidation of the vitamin by the 
demonstration of a semiquinone arising by the removal 
of only one electron from a- tocopherol. Although 
this 
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this process would undoubtedly involve a large amount 
of free energy, these workers suggest that the vitamin 
may be present as a prosthetic group of an enzyme and 
that the process may take place intramolecularly with- 
in the enzyme- substrate complex. This finding 
suggests new possibilities in relation to cell metab- 
olism in general and dehydrogenation in particular. 
None the less even if the vitamin does participate 
in the metabolism of progesterone, there are many more 
ways in which it might act than by diminishing the 
"metabolic oxidation" of the hormone as suggested by 
de -datteville et al. It is less difficult to imagine 
how the univalent oxidation of the vitamin might enable 
it to participate as a co- enzyme in the metabolic re- 
duction of progesterone to pregnanediol and the possi- 
bility that the activity of the vitamin might favour 
the formation of pregnanolone is especially relevant 
to the present problem. 
The modified method of Huber (1947) - used by 
de ,Jatteville et al. - and based upon that of Astwood 
and Jones (1941), has the disadvantage that the esti- 
mation of the steroid depends upon a gravimetrie 
determination. This diminishes the specificity of 
the procedure and it is possible that pregnanolone and 
allopregnanolone would be determined as pregnanediol 
by this method. A shift in the metabolism of 
progesterone 
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progesterone favouring the formation of such ketonic 
glucuronides to the detriment of non -ketonic glucuron- 
ides such as sodium pregnanediol glucuronidate would 
account for the discrepancy between the results ob- 
tained in the two sets of experiments. 
In view of these considerations, two lines of 
action are indicated. 
(i) Normal subjects should be investigated by the 
modified method of Huber and /or patients 
with carcinoma should be investigated by 
the method of Sommerville, Gough and Líarriam 
(ii) Normal subjects should be investigated in ex- 
periments in which both methods for the 
determination of urinary pregnanediol are 
applied to aliquots of each twenty -four hour 
specimen. 
Whatever the outcome of such studies, it may be 
concluded from the present work, and the work of 
de Watteville et al. does not constitute evidence to 
the contrary, that, under these experimental condit- 
ions, the proportion of administered progesterone 
excreted as urinary pregnanediol by normal men or 
normal post -menopausal women is not influenced by 
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SECTION III 
THE ADLiINISTRATION OF 17a- ETHINYLTESTOSTERONE 
AND ITS IMPLICATIONS TO 
URINARY PREGNANEDIOL DETERMINATION 
Although a very large number of steroids closely 
related to progesterone have been isolated from 
natural sources, or synthesised, relatively few of 
these exhibit progestational activity. 
In 1938, Inhoffen and Hohlweg, and Ruzicka et al. 
prepared a new synthetic progestogenic substance by 
the oxidation (Oppenauer, 1937) of an ethinylandros- 
4 
tenediol. This substance, 17a- ethinyl- 0- androsten- 
17 -o1 -3 -one (Fig. 8) which has received many names, 
notably anhydro- hydroxyprogesterone, pregneninolone, 
pregneninonol and ethisterone, will be referred to in 
the present work as ethinyltestosterone. A comparison¡ 
of the progestational activity of progesterone and of 
ethinyltestosterone showed that a 4 mg. dose of the 
latter administered orally produced an endometrial 
response in the rabbit comparable with that produced 
by the injection of about 0.6 mg. of progesterone. 
In 1939, Courrier and Jost maintained pregnancy in an 
ovariectomised rabbit by the administration of 
ethinyltestosterone, and in the same year, Zondek and 
Rozin induced intracyclic bleeding by the administrat 
ion of the steroid to women with normal menstrual 
habit 
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habit and observed that the effective dose was about 
six times greater than that of intra- muscularly injec- 
ted progesterone. The progestational activity of 
orally administered ethinyltestosterone has received 
ample confirmation (Emmens and Parkes, 1939; Salmon 
and Salmon, 1940; Weisbader, 1941; Zondek, 1942) and 
in addition, it has been shown to possess weak andro- 
genic and oestrogenic activity (Ernmens and Parkes, 
1939). 
Other steroids such as desoxycorticosterone and 
testosterone are much less active progestationally 
than ethinyltestosterone but a synthetic unsaturated 
derivative of progesterone prepared by Wettstein 
(1940) (Fig. 8) is more active, having approximately 
one -half of the biological activity of progesterone 
while 10- norprogesterone (Fie. 8) prepared by 
Ehr enstein in 1944 is claimed to be as active or even 
more active than the natural hormone. These 
substances differ from ethinyltestosterone, however, 
in that they do not possess its remarkable activity on 
oral administration and, therefore, lack its clinical 
possibilities. 
A study of the literature on intermediary steroid 
metabolism reveals the surprising fact that almost 
nothing is known about the fate of ethinyltestosterone 
in the body. Hamblen, Cuyler and Hirst (1940) 
ad- 




woman with "uterine bleeding of an oestrogenic nature" 
and were unable to demonstrate the presence of preg- 
nanediol glucuronide in the urine. Goldberg and 
Hardegger (1941) were also unable to detect pregnane- 
diol glucuronide in such urine. In 1944, however, 
Allen, Viergiver and Soule administered 200 mg. of 
ethinyltestosterone daily for six days to patients 
with primary and secondary amenorrhoea and recovered 
about 10.0 per cent of the administered steroid as 
"pregnanediol_ ". The method of determination (Allan 
and Viergiver, 1941) depends upon the estimation of 
the amount of glucuronic acid liberated by acid 
hydrolysis of urinary glucuronides and these workers 
admit that the final product determined as "pregnane- 
diol glucuronide" might be the glucuronide of a 
related steroid. 
In 1948, Dorfman, Ross and Shipley administered 
¿CO mg. of ethinyltestosterone orally for two to four 
days to three human subjects - two men, one with 
Addison's disease, the other with diabetes and hypo - 
pituitarism, and one woman with secondary amenorrhoea. 
Neither "pregnanediol glucuronide" as determined 
by 
the method of Venning nor any other steroid 
conjugate 
was demonstrated in the urine. 
Ethinyltestosterone is frequently employed 
in 




progesterone. It is important, therefore, to estab- 
lish whether administered ethinyltestosterone is 
metabolised to urinary pregnanediol in view of the 
implications to the clinical use of pregnanediol 
determination, since, if this conversion does not occur 
the pregnanediol excreted by cases receiving ethinyl- 
testosterone must be entirely of endogenous origin. 
in view of the contradictory results obtained by 
previous workers and in order to establish whether the 
method employed in the present work determines an ex- 
cretion of urinary pregnanediol after ethinyltestoster - 
one administration, the synthetic steroid was adminis- 
tered to three normal men. The shorter method des- 
cribed by Sommerville, Larrian and Kellar (1948) is 
commonly employed for clinical studies in pregnancy, 
and since this method is less specific than the method 
of Sommerville, Gough and Marrian (1948) it was im- 
portant to compare the results obtained when both 
methods were applied to the same urine specimens. 
1. Subject 'B': 
Ethinyltestosterone, 150 nag. was administered 
by mouth on two consecutive days and the 
twenty -four hour urine specimens examined 
by the method of Somerville, Gough and 
Marrian (1948) on the day before the ad- 
ministration and until the level had retur- 
ned to the control "blank" value 
The results are shown in Table 15. 
Apparent 
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The results show that using method (i) from 0.1 to 
0.6 per cent of administered ethinyltestosterone was 
determined as urinary pregnanediol and using method 
(ii) less than 1.0 per cent was so determined. The 
nature of the colour obtained with concentrated 
sulphuric acid indicates that the chromogenic substance 
is not pr egnane -3a, 20a -di ol, and it was very int erest- 
ling to observe that numerous large crystals appeared 
during the incubation of the precipitation mixture 
formed by the addition of N /10 sodium hydroxide to an 
ethanolic solution of the neutral toluene -soluble 
fraction. It was not possible to examine these 
crystals as the total final product was necessary for 
the determination, but they were seen to become less 
numerous after the second and third precipitations of 
the longer method. The large amount of crystals and 
the low chromogenicity of the final product after one 
precipitation (shorter method) indicate that this sub- 
stance is weakly chromogenic with sulphuric acid. The 
administration of large amounts of ethinyltestosterone 
o subjects with negligible endogenous progesterone 
Secretion should permit of the isolation and identifi- 
cation of this interesting substance which is presum- 
ably steroid in nature and may be a metabolite of 
ethinyltestosterone. If it is excreted as a glucur- 
onide this would afford a reasonable explanation for 
the 
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the results obtained by kllen, Viergiver and Soule 
(1944). 
Conclusion 
Assuming that the metabolism of ethinyltestoster - 
one is qualitatively similar in pregnant and non- 
pregnant subjects these experiments indicate that when 
urinary pregnanediol excretion is studied in cases 
receiving ethinyltestosterone during pregnancy, using 
either the method of Sommerville, Gough and Marrian or 
that of Sommerville, Marrian and Kellar, the values ob- 
tained will not be confused by the presence of signifi- 
cant amounts of pregnanediol of exogenous origin. 
In addition, the fact that this progestogen is 
not excreted as urinary pregnanediol could be applied 
to the further investigation of at least two problems 
discussed in the present work. 
(a) The assumption that progesterone administration 
does not affect the level of excretion of 
urinary pregnanediol of endogenous origin 
could be investigated as far as progestational 
activity is concerned by determining the 
level of pregnanediol excretion during 




(b) The dependence of the progesterone "priming" 
effect upon the physiological activity of the 
hormone might be clarified by experiments in 
which ethinyltestosterone was administered to 
human subjects. 
TABLE 15 
ADMINISTRATION OF ETHINYI,TESTOSThRONE 





mg. /24 hr. 
150 mg 1580 0.20 
Oral 0.25 
150 mg 2360 0.41 
Oral 0.44 
- 1360 0.49 
0.46 
- 1060 0.32 
0.36 






mg. /24 hr. 
150 mg 1350 0.18 
Oral 0.14 
150 mg 1660 0.21 
Oral 0.18 
- 1580 0.27 
0.30 
- 970 0.11 
0.11 
TABLE 16 
ADMINISTRATION OF ETHINYLTESTOSTERONíE 
( 200 m. T TO NORMAL MAN 
SUBJECT 'P' 
Administration Volume 
200 mg. Oral 940 
Pre nanediol mmgg.f24 hr. 















Method (i) :- Sommerville, Gough and Marrian (1948) 
Method (ii) :- - - - -, Marrian and Kellar (1948) 
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SECTION IV 
URINARY EXCRETION OF PREGNANEDIOL 
DURING NORII.AL PREGNANCY 
Following the pioneer work of Venning and Browne 
(Venning, 1937, 1938; Browne et al., 1937) on the 
quantitative determination of the urinary excretion of 
"pregnanediol glucuronide" during pregnancy, other 
workers, using the method of Venning confirmed and ex- 
tended their observations (Bachman et al., 1940; 
Smith and Smith, 1940; Hain, 1942; De1fs and Jones, 
1948) . 
These workers are in general agreement that there 
is a progressive increase in the excretion of the 
"pregnanediol glucuronide" (expressed as pregnanediol) 
from the eighth week of gestation when the level is 
about 8 to 10 mg. per twenty -four hours to the thirty - 
sixth week when it attains from about 70 mg. to 110 mg. 
per twenty -four hours. In many cases there then 
follows a gradual or swinging fall in the excretion of 
the steroid until immediately, before labour it reaches 
a level 10 mg. to 20 mg. lower than its maximum. 
This pre -labour fall in pregnanediol excretion requires 
confirmation especially in view of the significance 
attached to it by Smith and Smith (1948) in connection 
with their theory of the interdependence of progester- 




a sudden fall in the level of excretion which reaches 
a non -pregnant level by about the third day of the 
puerperium. 
Bachman et al. (1940) obtained a mean excretion 
curve which showed monthly cyclic fluctuations, but 
this has not been a general finding. Davis and Fugo 
(1947) studied the excretion of pregnanediol during 
normal pregnancy using a semi- quantitative modification 
of the method of Guterman (1946). When this method 
and the method of Venning were applied to the same 
urine specimen, similar results were obtained, and it 
was not surprising £herefore that the curve of excret- 
ion of "pregnanediol" during normal pregnancy obtained 
by Davis and Fugo (1947) resembled that obtained for 
"pregnanediol glucuronide" by Venning ( 1938). 
In view of the evidence, discussed in the intro- 
duction, that the Venning procedure determines as 
pregnanediol the glucuronides of substances other than 
pregnanediol, it seemed of interest to investigate 
whether the excretion of pregnanediol during pregnancy 
differed markedly from the excretion of the "pregnane- 
diol glucuronide" determined by the method of Venning. 
In the method employed in the present work (Sommerville, 
Gough and Marrian, 1948) pregnanediol is isolated 
in 
relatively pure form before the application of 
the 
sulphuric acid reaction and, as has been discussed 
in 




specific for pregnanediol than any hitherto described 
does not determine pregnanolone or allopregnanolone in 
human pregnancy urine. 
As a preliminary investigation, one hundred and 
fifty determinations were carried out throughout the 
course of three normal pregnancies and, in addition, 
thirty -two determinations were carried out during the 
first and second trimesters of a farther sixteen 
normal pregnancies. 
Twenty -four hour specimens of urine were collected 
from the patients in their homes until a few days be- 
fore term when the patients were transferred to hospit- 
al. The urine was diluted snd its pregnanediol 
content determined in duplicate. The results are 
shown in Fig. 9. 
RESULTS 
It will be seen that in two of the cases studied- 
'M' and 'L' - the patterns of excretion were very 
similar throughout pregnancy and that the levels in 
all cases during the first two trimesters were closely 
related. Until the fifteenth week of pregnancy, the 
(levels ranged from 7 mg. to 14 mg. of pregnanediol 
per 
twenty -four hours and showed a rather flat but 
grad- 
ually ascending curve. The excretion then 
began to 
rise more rapidly until at mid -term a level 
of about 
20 mg. / 
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20 mg. per twenty -four hours was attained. At the 
twenty -third week, the levels ranged from 22 mg. to 
28 mg. per twenty -four hours but at this stage the 
excretion by case TF' rose rapidly so that by the 
thirty -fourth week it had reached a plateau of about 
90 mg. per twenty -four hours, whereas at that stage 
the other two cases had attained only 50 mg. per 
twenty -four hours. In cases 'I,' and 'F' there was a 
fluctuating plateau from the thirty -third week until 
term but in case 'i::' there was a steadily climbing 
excretion which did not reach a maximum until the 
thirty- eighth week. There was a swinging pre- labour 
fall in the former cases but not in the latter. In 
all three cases the excretion feel rapidly during 
labour and had reached a non -pregnant level of 0.2 to 
0.5 mg. per twenty -four hours by the fourth day of the 
puerperium. Frequent determinations were carried out 
in case " :' from the sixth week of pregnancy and the 
results which show some interesting features are 
illustrated in Fig. 10. There are few detailed 
reports of the level of pregnanediol excretion during 
the first trimester, and these have been characterised 
by the irregularity of the excretion from day to day. 
It is probable that such apparent irregularities of 
excretion at levels below about 15 mg. per twenty -fourt 
hour specimen were due to technical difficulties in 
the quantitative determination of the steroid. In 
this / 
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this case the level of pregnanediol excretion remained 
'relatively constant from the sixth to the tenth week 
of pregnancy, from the tenth to the twelfth weeks 
there was a slight but definite depression and it was 
not until the succeeding weeks that the excretion 
level showed a definite rise. 
DISCUSSION 
Apart from the more regular pattern of excretion 
during early pregnancy, the trend of excretion of 
urinary pregnanediol is similar to that based upon the 
excretion of the glucuronides determined by the method 
of Venning. 
There is, however, in the present work a suggest- 
ion that there is a quantitative difference between 
the results obtained by the two methods of determinat- 
ion. When the mean curves of excretion obtained by 
Venning (1938), Bachman et al., (1940) and Delfs and 
Jones (1948) were compared with a tentative mean for 
the excretion in the present work it was found that 
throughout pregnancy the latter was about 20 to 30 per 
cent. lower than the former. This finding would re- 
quire confirmation by the study of a much larger 
series, but it is in excellent agreement with 
the ob- 
servations of Liarrian and Gough (1946). As 
discussed 
in the introduction, these workers found that 
samples 




method of Venning contain about 20.0 per cent of 
ketonic glucuronides notably sodium pregnanolone 
glucuronidate (Sutherland and Marrian, 1947). It is 
also compatible with the finding of Dobriner et al. 
(1948) that the urinary excretion of pregnanolone 
during pregnancy follows a similar trend to that of 
"pregnanediol glucuronide". The level of excretion 
of pregnanolone determined by Dobriner et al. is 
higher than would be expected even if the difference 
between the curves of excretion of "pregnanediol 
gluouronide "(expressed as "pregnanediol ") and of preg- 
nanediol is mainly due to the determination of sodium 
pregnanolone glucuronidate by the method of Venning. 
On the other hand it is most unlikely that pregnanolone 
glucuronide is recovered quantitatively by the method 
of Venning and the results of Dobriner et al. may re- 
flect the physiological relationship. If pregnanolone 
is present in pregnancy urine in more than one con- 
jugated form this would afford an alternative explanat- 
ion for the apparent anomaly. 
It is interesting to speculate that the absence of 
a significant rise in pregnanediol excretion in case 
'M' (Fig. 10) from between the sixth and twelfth 
weeks of pregnancy, and the gradual rise in the excret- 
ion level which followed, reflect the smooth transfer 
of the main site of progesterone production from the 
corpus 
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corpus luteum of pregnancy to the maturing placenta. 
The quantitative determination of urinary preg- 
nanediol excretion is receiving increasing attention 
as a potential prognostic criterion in pregnancies 
complicated by pre- eclamptic toxaemia or by threatened 
or habitual abortion. In assessing the significance 
of a pregnanediol determination in such cases, there 
is little doubt that previous determinations at an 
earlier stage of the same pregnancy constitute a 
better standard for comparison than does a mean curve 
of excretion for a series of normal pregnancies. 
This is frequently impossible, however, and precious 
time is lost in determining whether the level is 
rising or not. It is essential, therefore, that the 
scatter of normal values should be established, and it 
is clear from the preliminary results reported here 
and from the theoretical considerations previously 
discussed that, when a method reasonably specific for 
the determination of pregnanediol is employed, curves 
of excretion based upon the method of Venning are un- 
suitable for this purpose. It follows, that a large 
number of determinations should be carried out during 
normal pregnancy by a routine laboratory using the 
same method which is to be employed in the study of 
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THE ,UANTITATIVE DETERMINATION OF SMALL AMOUNTS 
OF PREGNANEDIOL IN RABBIT URINE 
In section I, reference was made to the desirab- 
ility of finding an experimental animal suitable for 
the further investigation of the metabolism of prog- 
esterone. For the present purpose, it was necessary 
that the intermediary metabolism of the hormone in 
this animal should resemble as closely as possible 
that of the human subject. A study of the literature 
was not entirely encouraging in this respect. 
It will be recalled that pregnane- 3a,2Oa -diol had 
been isolated from the pregnancy urine of cows, mares 
and chimpanzees and from the urine of bulls (Intro- 
duction), but it was also claimed that the pregnancy 
urine of chimpanzees (Elder, 1940), rabbits, cats and 
monkeys (Westphal and Buxton, 1939; Westphal, 1942) 
does not contain detectable amounts of the glucuron- 
ides determined by the method of Venning. Marker and 
Hartman (1940) were unable to isolate "pregnanediol 
glucuronide" or any end -product of progesterone 
metabolism from the urine following the injection of 
1 gm. of progesterone to a pregnant monkey, and Fish, 
Dorfman and Young (1942) did not detect urinary "preg - 
nanediol glucuronide" after the administration of 
progesterone 
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progesterone to guinea pigs. On the other hand, it 
has been clearly shown that "pregnanediol glucuronide" 
can be determined by the method of Venning in the 
urine of male and female rabbits after the adminis- 
tration of very large doses of the hormone (Heard, 
Bauld and Hoffman, 1941; Hoffman and Browne, 1942; 
Hoffman, 1942 and ',Vestphal, 1942) . It seemed possible 
that the apparent anomaly afforded by these results 
and by repeated failure to detect pregnanediol of 
endogenous origin in the urine of pregnant rabbits 
might be due to the low level of urinary excretion 
attained in these animals and to the relatively in- 
sensitive methods of determination employed. 
1,ccordingly, an attempt was made to discover 
whether the more sensitive method of pregnanediol 
determination used in the present work was applicable 
to the determination of the steroid in rabbit urine. 
Experimental Conditions 
The rabbits were housed in metabolic cages, re- 
ceived 200 to 300 ml. of water daily and were fed on a 
'pellet diet advocated by Dr. A.S. Parkes (Diet "43 ", 
Lssociation of London Flour liners). The urine was 
collected over twenty -four periods in vessels contain- 
ing 0.5 ml. toluene as a preservative. The volume of 
each specimen was measured and the specimen was then 
diluted 
-83- 
diluted by cage washings. Each specimen was made 
faintly acid to litmus with HC1 in order that the pH. 
should be similar to that of human urine. Each 
specimen was then filtered through glass wool, made up 
to 500 ml. with water, and divided into two 250 ml. 
samples for the duplicate determinations. Since this 
volume was half that employed in the original method 
(Sommerville, Gough and Marrian, 1948) all volumes of 
reagents and solvents used in the determinations were 
halved. The only other modifications of the original 
method were the following: - 
(i) In the precipitation procedure for the puri- 
fication of the pr egnanedi of the times of 
incubation at 37 °C were increased to twenty - 
four hours in each case. 
(ii) The charcoal treatment for the elimination of 
interfering pigment was thought to be un- 
necessary with rabbit urine and was replaced 
by a simple filtration in ethanolic solution 
through a 'Nhatman No. 1 paper. 
Although it was anticipated that gums and resins 
foreign to human urine might interfere in the quanti- 
tative precipitation of the steroid, the following 
preliminary experiments were carried out with the 
method as above. 
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(a) Hydrolysis of the conjugated pregnanediol in 
rabbit urine 
On the basis of the observation that a similar 
result is obtained when the pregnanediol excreted 
after progesterone administration to a rabbit is 
determined by the method of Venning, as when it is 
determined in the free form from acid -hydrolysed 
urine, Hoffman (194) concluded that the steroid is 
present "for the most part if not entirely" as the 
gluouronide. It seemed probable that conditions of 
acid hydrolysis giving the maximum yield of free preg- 
nanediol from human urine would also be optimal for 
rabbit urine containing conjugated pregnanediol. How- 
ever as it could not be assumed that this was the case 
experimental verification was sought. 
Progesterone (30 mg. intra- muscularly) was ad- 
ministered to two male rabbits on two consecutive 
days. Twenty -four hour specimens were collected on 
the second and third days after the first injection, 
the four specimens were pooled and diluted to 2 litres, 
and 8 samples each of 250 ml. were taken. Two 
samples of the pooled urine were each boiled for 5, 
10, 15 and 20 minutes after the addition of 10 per 
cent. (v/v) HC1 and the pregnanediol determined in 
the usual manner. The results shown in the follow- 
ing table indicate that, as in the case of human 
urine 
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urine (Listwood and Jones, 1941), 1C minutes boiling 
gives optimal hydrolysis of the conjugated pregnane- 
diol. 












(b) Lccuracy of procedures for the extraction and 
purification of the pregnanediol 
The sensitivity of the method was investigated 
in a series of recovery experiments in which pure 
pregnane -3 a,20a -diol was added to acid -hydrolysed 
urine from male rabbits. Three twenty -four hour 
urine specimens were collected from three male rabbits, 
pooled, made up to 1,500 ml. with water and divided 
into six samples of 250 ml. Each sample was boiled 
under reflux for ten minutes after the addition of 
25 ml. concentrated HC1 and then cooled. Two of the 
acid -treated 
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acid -treated samples were retained as male urine 
"blanks ", while to the remaining four, pure pregnane- 
3a,20a -diol in ethanolic solution was added in two 
different known amounts in duplicate. This procedure 
was repeated on five occasions and the amounts of 
added pregnanediol were varied between 0.13 and 2.51mg. 
The results of these experiments are shown in Table 17. 
It will be seen that whereas the recovery was unsatis- 
factory when 0.13 mg. was added to half a twenty -four 
hour specimen, good recoveries resulted when 0.23 mg. 
or more were added. supply of highly purified 
sodium pregnane- 3a,20¢-diol glucuronidate was not 
available, but it has been shown (Sommerville, Gough 
and Marrian, 1948) that the loss incurred in the acid - 
hydrolysis of the glucuronide is negligible in the 
original method and it may be concluded that as little 
as 0.25 mg. of pregnanediol will be determined with a 
satisfactory degree of accuracy in one half of a 
twenty -four hour specimen of rabbit urine. 
The urinary pregnanediol excretion following the 
intra- muscular injection of progesterone to a male 
rabbit is illustrated in Fig. 11. It will be seen 
that the pattern of excretion is very similar to that 
obtained after administration of progesterone to human 
subjects with minimal endogenous progesterone product- 
ion. The proportion of administered progesterone ex- 
óreted as urinary pregnanediol is also of the same 
order 
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order as in such human subjects - in this case 6.9 per 
cent. The most striking feature of this experiment, 
however, is the agreement of the duplicate determin- 
ations and the knowledge that they accurately 
represent the excretion of the steroid at levels far 
below the range of excretion which could be determined 
by previous methods. 
The importance of the availability of a method of 
determination of urinary pregnanediol of such sensitiv- 
ity became apparent when consequent upon the present 
work, the urine of pregnant rabbits was investigated 
(Verly, Sommerville and Marrian, 1950). Not only was 
it now possible to detect pregnanediol in such urine - 
and to identify it as consisting almost entirely of 
pregnane- 3a,20a -diol - but it was possible to follow 
the daily excretion of the steroid by duplicate 
determinations even although the plateau of pregnane- 
diol excretion which was maintained throughout the 
greater part of each gestation did not rise above a 
level of about 0.8 mg. per twenty -four hour specimen. 
New possibilities are, therefore, offered for the 
investigation of the relationship between the inter- 
mediary metabolism and the physiological activity 
of the hormone. 
Figuré 11. 
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0.00 0.045) ay. - - 
0.00 0.030) 0.037 - - 
2.51 2.50 2.46 98.4 
2.51 2.47 2.43 97.1 
1.26 1.28 1.24 99.0 
1.26 1.24 1.20 96.2 
0.00 0.018) ay. - - 
0.00 0.023) 0.020 - - 
1.00 0.99 0.98 97.5 
1.00 1.05 1.03 102.5 
0.50 0.491 0.471 94.2 
0.50 0.484 0.464 92.8 
0.00 0.033) ay. - - 
0.00 0.037) 0.035 - - 
0.05 0.540 0.505 101.0 
0.50 0.523 0.488 97.6 
0.25 0.285 0.250 100.0 
0.25 0.272 0.237 94.8 
0.00 0.030 - - 
0.00 - - - 
0.04 0.448 0.418 92.1 
0.45 0.447 0.417 92.1 
0.23 0.236 0.206 90.0 
0.23 0.235 0.205 90.0 
0.00 0.060) ay. - - 
0.00 0.037) 0.048 - - 
0.25 0.266 0.218 87.2 
0.25 0.275 0.222 88.8 
0.13 0.120 0.072 57.6 
0.13 0.118 0.070 56.0 
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Chronic polyarthritis is as old as history, or 
indeed may be older, since arthritic changes are found 
in the skeletal remains of palaeolithic and neolithic 
man (Osgood, 1940; Murphy, 1943) and in the early 
fossil vertebrates (Moodie, 1923). The disease was 
common in ancient Persia and Egypt and would undoubted- 
ly be studied (circa 2950 B.C.) by the Egyptian 
physician, Imhotep (Buffer, 1921). Its clinical 
features were clearly described by Hippocrates, 
Asclepiades, Celsus, Galen and Aretaeus, and Galen - 
differentiating certain types of polyarthritis from 
gouty arthritis - introduced the term "rheumatism" re- 
flecting the Hippocratic concept of a "humoral" 
aetiology. 
In the first century of the Christian era, 
Aretaeus stated that "the medicines for the disease are 
innumerable; for the calamity renders the patients 
themselves expert druggists" and that if the disease 
"has acquired strength from time, all treatment is use- 
less". An accurate account of the attempts which 
have been made to influence the onset or modify the 
course of arthritic diseases, especially of the 
rheumatic group, would form a fascinating record of 
human 
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human endeavour over a period of some six thousand 
years. 
That these attempts have, until very recently, 
been largely unsuccessful is shown by the fact that, at 
the present time, the rheumatic diseases and their 
sequelae are responsible for more disability, higher 
economic loss and greater human suffering than any 
other group of medical disorders (Comroe, 1949) . 
Countless theories concerning the aetiology of th4 
diseases of this group have been formulated in the 
millennia during which they have been prevalent, and 
it is natural that , in more recent times, dysfunction 
of the endocrine glands should be considered as a 
possible aetiological factor. In fact, almost two 
thousand years ago, Celsus had suggested a correlation 
between reproductive function and the incidence of 
chronic polyarthritis. 
"Ea (vitia articulorum) raro vel castratos, vel 
pueros ante feminae coitum, vel mulieres, nisi 
quibus menstrua suppressa sunt, tentant". 
De Medicina; Book IV. 
The observation of the rarity of articular disease in 
gonadectomised men is of especial interest since 
Celsus was able to study a larger series than is ever 
likely to be available in modern times. 
The occurrence of menopausal arthralgia, the 
rarity of rheumatoid arthritis in hyperthyroidism, the 
arthralgia 
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arthralgia of myxoedema, the spondylitis of acromegaly 
(Marie, 1886) and the recognition of endocrine factors 
in osteoporosis, all suggested possible inter- relationi 
ships between arthritis and dysfunction of the ovarie4 
the thyroid, the parathyroid and pituitary glands. 
The results of thyroid medication and parathyroidec- 
tomy were discouraging, however (Oppel, 1929; Shkurov, 
1935), and although beneficial effects have been ob- 
served following oestrogen administration these have 
been mainly confined to menopausal arthralgia 
(Kuipers, 1935; Siemelink, 1945; Laroche & Hochfeld, 
1948) . None the less it is doubtful if adequate 
doses of oestrogen have ever been administered in 
clinical trials of oestrogen therapy in rheumatoid 
arthritis. 
In 1890, Garrod noted that a remission in the 
progress of rheumatoid arthritis might occur during 
pregnancy. On the other hand, pregnancy has sometimes 
been regarded as a misfortune for such cases since the 
disease may have its onset or appear to be severely 
aggravated during pregnancy or the puerperium (Hench 
et al., 1940; Gil, 1944). The only large series of 
pregnancies studied in rheumatoid arthritics is that 
described by Hench (1938) from which it was concluded 
that pregnancy is more commonly beneficial than 
detrimental / 
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detrimental to the course of the disease. 
In 1933, Hench had reported that hepatitis and 
jaundice had an ameliorating effect upon the course of 
chronic arthritis, and in 1938, was able to summarise 
studies on forty -five cases. He concluded that this 
effect of jaundice was invariably observed in cases 
with marked hyperbilirubinaemia. In the cases ob- 
served by Hench, the jaundice was of the obstructive 
type or due to infective or cincophen hepatitis. 
From these studies made over a period of twenty 
years (1929 - 1949), Hench concluded that the 
"inherent reversibility of rheumatoid arthritis is 
activated more effectively by the intercurrence of 
jaundice and pregnancy than by any other condition or 
agent thus far known. Regardless of the superficial 
validity of the microbic theory, rheumatoid arthritis 
can be profoundly influenced by phenomena which are 
primarily biochemical" and that the lesion is "some 
basic biochemical disturbance which is transiently 
corrected by some incidental biologic change common 
to a number of apparently unrelated events ". 
For many years, attempts to derive therapeutic 
benefit from this concept met with repeated failure. 
Thus attempts to reproduce the ameliorating effects of 
pregnancy by the administration of female sex hormones 
( Hench, 1938) or the serum of pregnant women (Barsi, 
1947) or to reproduce the effects of jaundice by 
experimental / 
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experimental hyperbilirubinaemia (Hench, 1938; Thomson 
and Wyatt, 1947; Hanssen, 1942) were largely unsuccess- 
ful. Attention was then turned by Hench and his 
colleagues to the possibility of a clinical trial of 
the steroid hormones of the adrenal cortex since it 
i:ad been clearly shown that the activity of the adrenal 
cortex is markedly increased during pregnancy (Vennin& 
1946; 1948). 
Such an investigation could not have been encour- 
aged by the knowledge that the incidence of rheumatoid 
arthritis is not significantly different in subjects 
with Addison's disease or Cushing's syndrome from that 
in previously normal individuals, nor by the obser- 
vations of Selye (1944) on the induction of experi- 
mental "arthritis" by the administration of 
11- desoxycorticosterone to rats sensitised by unilat- 
eral nephrectomy and a high salt diet. It is inter- 
esting to note that de- Genres et al. (1947) have ob- 
served 4subacute arthritis" which they attribute to 
implantation of 11- desoxycorticosterone acetate in two 
cases of Addison's disease. There would appear, 
therefore, to have been some evidence against the 
possibility that administration of the most readily 




At least twenty -eight crystalline steroids have 
been isolated from the adrenal cortex and of these six 
have been found to possess adreno -cortical activity. 
The residual amorphous fraction retains about 14 to 
30 per cent. of the activity (based on life mainten- 
ance) of the total cortical extract (Heard, 1948). 
Four of these steroids have marked effects on carbo- 
hydrate metabolism (gluconeogenesis) but are relative- 
ly ineffective in life maintenance or in causing reten- 
tion of sodium or chloride ions, whereas the remaining 
two steroids have a powerful action on electrolyte and 
water balance, but little effect on carbohydrate 
metabolise.. The former group, possessing high glucon- 
eogenic activity may be designated the gluco- corticoids 
and since they all possess a carbonyl or hydroxyl groi 
in the C11 position may be termed the 11- oxygenated 
series. These steroids which are illustrated in 
Fig. 12 have the following structural characteristics. 
(i) Corticosterone: ( Reichstein, 1937). 
4- pregnene- 11p,21-dio1- 3,20- dione. 
(ii) 11- dehydrocorticosterone: (Kendall, 1937) 
04 -pr egnene -21 -o1- 3,11, 20- trione. (Kendall "s 
compound 'k'). 
(iii) 17- hydroxycorticosterone: (Reichstein, 1937) 
p4- pregnene- 11p,17a,21- triol- 3,20 -dione 
(Kendall's compound 'F'). 
(iv) 17- hydroxy- 11- dehydrocorticosterone: 
(Reichstein, 193-6) 
A4- pregnene -17x,21 -dio1- 3,11,20- trione 
(Kendall's compound 'E'). 
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The steroids of the latter group which may be re- 
ferred to as the mineralo- corticoids and which consti- 
tute the 11- desoxy series are illustrated in Fig. 13 
and have the following structural characteristics. 
(i) 11- desoxycorticosterone: (Reichstein and 
von Euw, 1938) 
p-pregnene-2l-o1-3,20-dione. 
(ii) 17- hydroxy- 11- desoxycorticosterone: (Reichstein 
and von Euw, 1938) 
Q4- pregnene -17a,21 -dio1- 3,20 -dione: 
(Reichstein's compound 'S') 
Thus if Selye's results in experimental 
"arthritis" were valid and applicable to the problem 
in man, and if none the less, the adrenal cortex was 
implicated in the "basic biochemical disturbance" 
postulated by Hench, it was reasonable that in the 
clinical trial one of the gluco- corticoids should be 
administered. 
Whatever the reason for their choice in 1948, 
Hench in collaboration with Kendall began a clinical 
trial of 17- hydroxy- ll- dehydrocorticosterone. This 
substance had been isolated from cortical extracts 
almost simultaneously by Reichstein; Mason, Myers and 
Kendall; and '+'dintersteiner and Pf_iffner, in 1936. 
It was renamed "cortisone" for clinical purposes by 
Kendall in 1949. 
In the series studied by Hench et al. (1949) 
cortisone and later cortisone acetate were administers. 
to / 
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to fourteen cases of rheumatoid arthritis in doses of 
100 mg. daily. The dramatic clinical response, which 
occurred within a few days of the first injection, in- 
cluded diminution in muscular and articular stiffness, 
disappearance of pain, swelling and deformity, increase 
in weight and appetite, correction of anaemia, fall in 
erythrocyte sedimentation rate and reversion of ab- 
normal albumin /globulin ratios. Also included in 
this now famous series were two cases to whom the 
adreno -corticotrophic hormone of the anterior pituitary 
gland (A.C.T.H.) was administered. The clinical res- 
ponse was essentially similar to that obtained follow- 
ing the administration of cortisone. Certain impli- 
cations of the administration of the adreno- cortico- 
trophic hormone are considered in section 1I. 
The report of Hench et al. aroused world -wide 
interest and, in the year which has elapsed, their ob- 
servations on rheumatoid arthritis have been generally 
confirmed and attempts have been made to extend the 
use of this new form of therapy to related diseases. 
These clinical studies with their wide implications lie 
outwith the scope of this thesis but two related facts 
have emerged which colour the background of the 
present work. In the first place, it is clear that a 
relatively large dose of cortisone or A.C.T.H. is re- 
quired to elicit the clinical response and that if 
this / 
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this therapy is not maintained a relapse to the pre- 
treatment clinical status occurs. Secondly, it is 
certain that in many if not the majority of cases pro- 
longed administration of cortisone or A.C.T.H. is com- 
plicated by the advent of serious toxic effects. It 
would be unwise at the present time to attempt to 
assess the severity of these effects which include 
disturbances of electrolyte and water balance, of 
carbohydrate metabolism and of pituitary function, but 
they appear to be of such a nature as to preclude the 
prolonged replacement therapy necessary for permanent 
cure. This appears to constitute an even more serious 
bar to the application of the therapy than does the 
acute shortage of supply which will undoubtedly con- 
tinue until methods for the synthesis of one or other 
hormone have been devised. 
A search is being made for a suitable substitute 
for cortisone or A.C.T.H. but so far no non -toxic 
substance with comparable activity to cortisone has 
been described. The use of 11- desoxycorticosterone 
in combination with ascorbic acid is discussed in 
section IV. 
It is reasonable to suppose that the probability 
of resolving these difficulties would be greatly in- 
creased by an elucidation of the mechanism of 
cortisone action. Furthermore, an understanding of 
this 
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this mechanism should throw light upon the fundamental 
biochemical disorder which determines the occurrence 
and course of rheumatoid arthritis and of other 
responding diseases. The present work has been direc- 
ted towards this end. 
From a study of the papers of Hench et al. (1949) 
and of subsequent writings on cortisone and A.C.T.H. 
therapy, it appears that it is tacitly assumed that 
the success of this therapy indicates the existence of 
a deficiency of endogenous adreno -cortical hormones in 
rheumatoid arthritis. On the other hand, rheumatoid 
arthritic patients do not exhibit any of the generally 
recognised symptoms of adrenal insufficiency such as 
occur in Addison's disease, and conversely patients 
with Addison's disease are not especially prone to 
rheumatoid arthritis. Furthermore, much larger doses 
of cortisone are required to elicit the clinical 
response in rheumatoid arthritis than had been previous- 
ly found to effect replacement therapy in Addison's 
disease (Sprague et al., 1947, 1948; Perara, 1941). 
These facts suggested to Professor Marrian and the 
author the possibility that the biochemical error in 
rheumatoid arthritis might consist of an abnormality 
in the intermediary metabolism of the adreno -cortical 




Apart from the aetiological implications of such 
a theory its therapeutic implication must be obvious 
since, if this hypothetical abnormal metabolism could 
be corrected minimal amounts of cortisone would be re- 
quired and these requirements might even be met by 
endogenous secretion. It is not possible to study 
quantitatively the metabolism of cortisone in rheuma- 
toid- arthritic subjects since not only are insufficient 
quantities of the steroid available but its metabolites 
have not yet been established nor is it certain that 
methods for their quantitative determination could be 
devised. 
The related steroid, progesterone, (L pregnene- 
3,20 -dione) has also been isolated from the adrenal 
cortex (Beall, 1938) and, as has been described in 
Part I, not only has the status of its metabolic re- 
duction product - pregnanediol - been securely estab- 
lished and a method devised for its quantitative 
determination in human urine, but a considerable 
amount of information has been accumulated concerning 
the conversion of administered progesterone into 
urinary pregnanediol in normal people. It was of the 
greatest interest, therefore, to consider the possi- 
bility that the metabolic pathways followed by 
cortisone might be similar to those followed by 
pro- 




progesterone in rheumatoid arthritic subjects might 
contribute to the present problem. 
As illustrated in Fig. 14, the conversion of 
11- desoxycorticosterone (as its acetate) to urinary 
pregnanediol can be accomplished by the human subject 
(Cuyler et al., 1940; Horwitt, et al. 1944) . Thus 
the ring A of 11- desoxycorticosterone can be reduced 
in the same way as the ring A of progesterone. 
Similarly the side -chain of 11- desoxycorticosterone 









CH / \ 
Similar metabolic reductions may, therefore,occur 
in other adreno -cortical hormones and thus, by analogy, 
17- hydroxy- ll- dehydrocorticosterone (cortisone) might 
yield a compound with the structure of the hypothet- 








In addition, 20- ketosteroids analogous to pregnanolone 
or 11- ketosteroids such as the hypothetical pregnane 
áa,17,20- triol -ll -one might be formed (Fig. 15). 
ÇH3 
CHOH 
O. / \I) -OH 
HO' 
These speculations on the metabolic reduction of 
adreno -cortical hormones assume a certain probability 
in view of the isolation and characterisation of 
steroids from the urine of cases of adrenal hyperplasia. 
There is no doubt that these compounds could arise by 
the metabolic reduction of adreno -cortical hormones in 
a manner analogous to the metabolic reduction of pro- 
gesterone to pregnanediol. These relevant steroids 
are:- 
(i) pregnane- 3,l7,20- triol: Isolated from the 
urine of women with adreno -cortical hyper - 
plasia by Butler and Marrian (1937, 1938) 






(ii) sre nane- 3eí,17- dio1 -20 -one: Isolated from 
the urine of patients with adrenal hyper - 
plasia, adrenal tumour and cryptorchidism, 





(iii) ,pregnane- 3(1,20a- diol -ll -one: Isolated from 
the urine of two cases of Addison's disease 
after the administration of large doses of 




(iv) ,pregnane- 3ä:,l7 -2l- trio1- 11,20 -dione: 
Isolated from the urine of a man receiving 






The possible relationships of these steroids to 
the adreno -cortical hormones are shown in Fig. 15. 
It 
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It would not be surprising that if such hypo- 
thetical metabolites such as pregnane-3a,11,17,20- 
tetrol and pregnane -3 a,17,20- triol -11 -one had escaped 
isolation in the urine of cases with adreno- cortical 
hyperfunction since chance isolation would be rendered 
difficult by the acid- lability and high degree of 
water solubility of steroids with a tertiary hydroxyl 
group in the C 17 position. 
All this evidence supports the contention that 
cortisone may to some extent be metabolised to 
analogues of pregnanediol or of pregnanolone. If 
this is so, then it would be reasonable to suppose 
that the enzymatic reducing system involved in the 
reduction of progesterone to pregnanediol would also 
participate in the metabolic reduction of cortisone. 
Accordingly it might reasonably be expected that an 
abnormality of the metabolism of cortisone would be 
associated with an abnormality of the metabolism of 
progesterone. The following experiments were carried 
out to investigate this hypothesis. 
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Figure 1.4. 
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KEY TO FIGURE 15. 
I : 11-desoxycorticosterone 
Ia : pregnane-3a,20a-diol 
Ib : pregnan-3a-o1-20-one 
II : 17-hydroxy-l1-desoxycorticosterone 
IIa : pregnane-3a,17,20-triol 
IIb : pregnane-3a,17-dio1-20-one 
III : corticosterone 
IIIa : ( pregnane- 3,11,20 -triol ) 
IV : 11-dehydrocorticosterone 
IVa : pregnane-3a,20a-diol-11-one 
V : 17-hydroxycorticosterone 
Va : ( pregnane-3,11,17,20-tetrol ) 
VI : 17-hydroxy-11-dehydrocorticosterone 
VIa : ( pregnane- 3,17,20- triol -11 -one ) 
VIat: pregnane- 3a,17a,21- triol -11,20- dione. 
(As indicated in Figure 15, the metabolic status of 
these urinár;y steroids has not heen established 
in the majority of cases. Thus although Ib has been 
isolated from the urine during adreno- cortical hyperactivity 
its derivation from I has not been proved. 20- ketosteroids 























PROPORTION OF kDLíINISTERAl) PROGESTERONE ELCRETED 
EL NAR' 'Ri rT o I, BY 
RHEW kTOID ARTHRITIC SUBJECTS 
The conversion of administered progesterone to 
urinary pregnanediol was investigated in a series of 
twenty -three rheumatoid arthritic subjects. Post- 
menopausal women (thirteen cases) and men (ten cases) 
were selected in order to ensure that the urine would 
not contain significant amounts of pregnanediol 
derived from progesterone of endogenous origin. The 
patients who were under the care of Dr. J.J.R. Duthie 
at the Rheumatic Unit of the Northern General Hospital, 
Edinburgh, were all suffering from rheumatoid arthritis 
and in no case was the diagnosis in doubt. The 
clinical status of these patients will be discussed 
later in this section. 
The cases were divided into two series. In 
series (a), which comprised nine post -menopausal 
women and four men, 120 mg. of progesterone (60 mg. 
on two successive days) were administered by intra- 
muscular injection. This was a procedure identical 
to that previously employed by the author in a study 
of six normal post -menopausal women and four normal 
men. / 
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men. In series (b), which comprised three post- 
menopausal women and six men, 60 mg. of progesterone 
was administered by intra- muscular injection. Apart 
from this difference in progesterone dosage the experi- 
mental procedure was identical in all cases and was as 
follows. 
Experimental Procedure 
Progesterone dissolved in arachis oil was admin- 
istered to the subjects in daily doses of 60 mg. 
Twenty -four hour urine specimens (preserved with 
toluene) were collected from each subject during a pre- 
liminary control period of one or two days, during the 
day or days on which the hormone was administered and 
for the following three to four days until the excret- 
ion of urinary pregnanediol had returned to the 
control period "blank" value. Each specimen was made 
up to a volume of 2,500 ml. with distilled water, and 
pregnanediol determinations in duplicate were carried 
out on 500 ml. samples by the method of Sommerville, 
Gough and Marrian (1948). The total pregnanediol 
excreted as a result of the administration of the 
hormone was calculated after correction of the daily 
apparent pregnanediol excretion for the average 
control -period "blank ". 
(a) Administration / 
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(a) Administration of progesterone (intra -muscular) 
to rheumatoid arthritic ost- menopausal women and 
rheumatoid arthritic men 
The results of thirty -three such metabolic ex- 
periments, comprising 210 pregnanediol determinations 
(in duplicate) , are shown in Table 18, in which a 
comparison is made between the rheumatoid arthritic 
subjects in series (a) and the series of normal post- 
menopausal women and normal men. This comparison is 
illustrated in Fig. 16. The pattern of pregnanediol 
excretion following the administration of progesterone 
to a typical normal subject is compared with that in a 
typical rheumatoid arthritic patient in Fig. 17. 
Satisfactory agreement was obtained between the 
duplicate determinations in all cases, and the values 
given are calculated from the mean of the duplicates. 
Table 18 / 
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TLB LE 18 
PERCENT1tGE OF ADMINISTERED PROGESTERONE RECOVERED 
AS URINARY PREGNANEDIOL 
Type of Subject Normal Rheumatoid Arthritic 
Post -Menopausal Women 19.0 (C) 
12.1 20.7 (L) 
(a) 13.7 22.0 (M) 
15.2 25.1 (Y) 
120 Mg. Intra -Must. 15.6 25.7 (A) 
15.6 26.8 (D) 




(b) 20.5 (W) 
24.7 (Bo) 
60 M8. Intra -Lust. 36.5 (B) 
Men 9.3 21.7 (F) 
10.0 23.8 (C) 
(a) 12.2 26.1 (L) 
120 Mg. Intra -must. 14.7 27.4 (R) 
19.9 (Mu) 
(b) 20.9 (M) 
22.4 (K) 




Each of these experiments is detailed below, and 
an attempt is made to assess the activity of the 
disease at the time of each progesterone metabolism 
experiment. This impression of "activity" (expressed 
as "quiescent ", "active ") is based mainly upon the 
acuteness of the articular lesions (pain, swelling, 
mobility), course of the disease (deteriorating, 
static, improving) and upon such features as elevation 
of erythrocyte sedimentation rate (E.S.R. Westergren), 
malaise, loss of weight, lack of appetite and degree 
of anaemia. This impression is open to the criti- 
cisms discussed in sub -section (c) but is to some ex- 
tent supported by the independent assessment of the 
expert rheumatologists in charge. 
Rheumatoid Arthritic Post -menopausal Women 
Series (a) 
Subject 'C': Age 46; duration of disease - 4 years. 
Admitted with active disease but now 
quiescent, E.S.R. has fallen from 
87 mm./ hr. to 56 mm. /hr. 
Anaemia persisting (lib. 72 per cent.) 
Progesterone: 120 mg. intra- musoular. 
Apparent pr egnanedi of recovery: 23.95 mg, 
Corrected for control "blank ": 22.75 mg. 
Recovery from administered progesterone- 
19.0 per cent. 
Subject 'L': 
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Subject 'L': Aged 65; duration of disease - 10 years. 
Old quiescent case with acute exacerbation 
one year ago. Admitted to ward six 
weeks ago with active disease. 
General condition improving but L.S.R. 
is stationary at 70 mm. /hr. 
Rb. 85 per cent. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 25.98 mg. 
Corrected for control "blank ": 24.78 mg. 
Recovery from administered progesterone - 
20.7 per cent. 
Subject 'L': Aged 60; duration of disease - 9 years. 
Quiescent case of long standing with 
steady level of E.S.R. which was 
35 mm./hr. on admission and is now 
28 mm. /hr. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 27.46 mg. 
Corrected for control "blank ": 26.38 mg. 
Recovery from administered progesterone - 
22.0 per cent. 
Subject 'Y': Aged 53; duration of disease - 5 years. 
Admitted eight weeks previously with 
acute arthritis of both knee joints 
and with L.S.R. 71 mm. /hr. Improving 
steadily. L.S.R. now 25 mm. /hr. but 
still active. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 31.42 mg. 
Corrected for control "blank ": 30.12 mg. 
Recovery from administered progesterone - 
25.1 per cent. 
Subject 'A': Aged 57; duration of disease - 10 weeks. 
Admitted one month previously with very 
active disease. Condition improved 
but still active with acute involvement 
of one joint after another. E.S.R. - 
120 mm. /hr. Appetite poor. Patient 
looks toxic. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 31.73 mg. 
Corrected for control "blank ": 30.89 mg. 
Recovery from administered progesterone - 
25.7 per cent. 
Subject 'D':/ 
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Subject 'D': Aged 61; duration of disease - 7 years. 
Moderatefyactive disease for several 
years with prolonged immobilisation. 
E.S.R. 30 mm. /hr. Complains of 
almost continuous pain even at rest. 
Obesity (14 st. 2 lb.) 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 33.82 mg. 
Corrected for control "blank ": 32.20 mg. 
Recovery from administered progesterone - 
26.8 per cent. 
Subject 'H': Aged 68; duration of disease - 15 years. 
Active disease with fluctuating course. 
Condition steadily improving. L.S.R. 
rising slightly from 25 mm. /hr. on 
admission to 40 mm. /hr. at time of 
metabolic experiment. No anaemia. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 38.68 mg. 
Corrected for control "blank ": 37.18 mg. 
Recovery from administered progesterone - 
31.0 per cent. 
Subject 'MeG': Aged 58; duration of disease - 1 year. 
Subacute onset following delayed healing 
of fracture of right wrist. Left 
knee swollen, ua.driceps atrophic. 
Complains of sacral pain. E.S.R. 
falling, now 50 mm. /hr., and otherwise 
disease moderately quiescent. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 40.49 mg. 
Corrected for control "blank ": 39.59 mg. 
Recovery from administered progesterone - 
33.0 per cent. 
Subject 'Ca': Aged 49; duration of disease - 4 years. 
Very active disease especially affecting 
knee joints with E.S.R. fluctuating 
between 24 mm. /hr. and 52 mm./hr. 
Anaemia responding to ferrous sulphate 
with Hb. rising from 66 per cent. to 
80 per cent. As with subject 'D' the 
patient complains of severe pain at 
rest which has been increased by the 
withdrawal of salicylates. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 44.86 mg, 
Corrected for control "blank ": 43.72 mg. 
Recovery from administered progesterone - 
36.4 per cent. 
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Series (h) 
Subject 'S': Aged 50; duration of disease - 9 months. 
Subacute onset with generalised stiff- 
ness and joint pain. Disease 
quiescent and patient "much improved" 
with few complaints. None the less 
E.S.R. is 62 mm. /hr. A resistant 
anaemia has responded to intra -venous 
iron therapy but is still present. 
(lib. 84 per cent.) May be s ignif i c aíß 
that the patient has had three severe 
attacks of acute rheumatic fever since 
childhood. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 9.93 mg. 
Corrected for control "blank ": 9.42 mg. 
Recovery from administered progesterone- 
18.8 per cent. 
Subject '.v' : Aged 69; duration of disease - 6 months 
A recent case with minimal articular 
damage but very high E.S.R. (117 mm. 
and anaemia (Kb. 58 per cent.) 
Improving. Joints relatively pain - 
free but splinted. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 13.05 mg. 
Corrected for control "blank": 12.29 mg. 
Recovery from administered progesterone - 
20.0 per cent. 
Subject 'Bo': Aged 50; duration of disease - 29 years. 
L:ultiple arthritis with gross articular 
damage. Disease quiescent with ex- 
ception of hip joints.. E.S.R.22mm /hr. 
and Kb . 68 per cent. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 15.63 mg. 
Corrected for control "blank ": 14.79 mg. 
Recovery from administered progesterone- 
24.7 per cent. 
Subject 'B' :/ 
Subject 'B': Aged 58; duration of disease - 2 years. 
ILultiple arthritis, active, but with 
minimal articular damage. Condition 
improving with E.S.R. falling from 
47 mm. /hr. on admission to 23 mm. /hr. 
Ho. 80 per cent. Patient found to be 
suffering from hitherto undiagnosed 
diabetes mellitus. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 22.69 mgt 
Corrected for control "blank ": 21.89 mg. 
Recovery from administered progesterone - 
66.5 per cent. 
Rheumatoid Arthritic Yen 
Series (a) 
Subject '7': Aged 58; duration of disease - 14 years. 
Steady clinical improvement since admiss- 
ion with correction of anaemia - 
(Hb. 87 per cent.) and falling B.S.R. 
(48 mm. /hr.) Disease still moderately 
active. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 27.45 mg. 
Corrected for control "blank ": 26.05 mg. 
Recovery from administered progesterone - 
21.7 per cent. 
Subject 'C': Aged 60; duration of diseas.e - 8 years. 
Gross changes in knee joints with 
effusion and marked wasting of quadri- 
ceps. inees very painful even at 
rest. active disease but condition 
static. E.S.R. 63 mm. /hr. 
Hb. 56 per cent. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery:29.88 mg. 
Corrected for control "blank ": 28.50 mg. 
Recovery from administered _progesterone - 
23.8 per cent. 
Subject 
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Subject 'L': Aged 45; duration of disease - 1 year. 
Subacute onset with pain and stiffness 
in neck and shoulders. Fluctuating 
course with ankles and knees mainly 
affected. Left knee swollen and 
painful even at rest. E.S.R. 40 my/hr. 
Active disease. No anaemia. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 32.49 mg. 
Corrected for control "blank ": 31.34 mg. 
Recovery from administered progesterone - 
26.1 per cent. 
Subject TR': Aged 40; duration of disease - 4 years. 
Moderately active disease with pain 
mainly extra -articular. 
E.S.R. 39 mm. /hr. but rising. 
Anaemia has responded to ferrous sul- 
phate. 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 34.45 mg. 
Corrected for control "blank ": 32.89 mg. 
Recovery from administered progesterone - 
27.4 per cent. 
Series (b) 
Subject '1i': Aged 62; duration of disease - 14 years. 
4,uiescent case of very long standing. 
E.S.R. 15 mm. /hr. Arteriosclerosis. 
History of trauma to the right shoulder - 
the most severely affected joint. 
Progesterone: 60 mg. int ra- muscular . 
Apparent pregnanediol recovery: 13.16 mg. 
Corrected for control "blank ": 11.92 mg. 
Recovery from administered progesterone - 
19.8T per cent. 
Subject 
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Subject 'IL': Aged 46; duration of disease - 7 years. 
E.S.R. has remained elevated (45 mm. /hr.) 
despite excellent improvement in 
clinical condition following a recent 
attack of scarlatina. No anaemia and 
minimal damage to joints. Residual 
disability in the wrist joints which 
were the most severely affected. 
Interesting to note occupation - baker. 
Quiescent. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 11.10 mg. 
Corrected for control "blank ": 10.47 mg. 
Recovery from administered progesterone 
20.94 per cent. 
Subject 'K': Aged 24; duration of disease - 6 months. 
Moderately active case with rising L.S.R. 
which was only 12 mm. /hr. at the time 
of the metabolic experiment but rose 
to 54 mm. /hr. within a month. 
Improving slowly. General condition 
excellent. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 14.22 mg. 
Corrected for control "blank ": 13.46 mg. 
Recovery from administered progesterone- 
22.43 per cent. 
Subject 'Mo': Aged 57; duration of disease - 1 yr. 3mth 
Very acute exacerbation occurred four 
months ago. There is now multiple 
arthritis but articular changes are 
not severe. Patient appears toxic 
and complains of continuous pain at 
rest after withdrawal of salicylates. 
E.S.R. 83 mm. /hr. Anaemia (Hb. 70 per 
cent.) - i.e. active case: Very active. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 14.42 mg. 
Corrected for control "blank ": 13.70 mg. 
Recovery from administered progesterone - 
22.93 per cent. 
,Subject 'Be':/ 
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Subject se': Aged 46; duration of disease - 2 years. 
Acute onset affecting left tarsal joints 
and left knee. Responded well to 
gold therapy one year ago but left 
knee now very painful with effusion. 
Anaemia following gold therapy has 
been corrected. E.S.R. 30 mm. /hr. 
Active disease. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 20.36 mg. 
Corrected for control "blank ": 19.68 mg. 
Recovery from administered progesterone - 
32.8 per cent. 
Subject 
Mc; 
Aged 59 - duration of disease - 3 years. 
Multiple arthritis with marked limitat- 
ion of movement especially of hips and 
much pain on walking especially after 
withdrawal of salicylates. Condition 
static but disease still very active. 
E.S.R. 90 mm. /hr. Anaemia (Eb. 74 per 
cent.) 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 23.66 mg. 
Corrected for control "blank ": 22.38 mg. 
Recovery from administered progesterone - 
37.3 per cent. 
Conclusion 
The results indicate clearly that rheumatoid 
arthritic subjects of both sexes excrete in the urine 
as pregnanediol an abnormally high proportion of intra- 
muscularly injected progesterone. The percentage con- 
version by normal subjects ranged from 9.3 per cent. to 
16.0 per cent whereas that of rheumatoid arthritic 
subjects ranged from 18.8 per cent. to 37.3 per cent. 
Although only ten identical metabolic experiments 
have so far been carried out in normal human subjects, 
the normal range indicated by these experiments is 




previously carried out by the author. Furthermore, 
in previous experiments the proportion of administered 
progesterone excreted as urinary pregnanediol did not 
appear to be influenced by the dosage employed, since 
similar values were obtained following the adminis- 
tration of doses varying from 40 mg. to 240 mg. 
(Sommerville and P::arr ian, 1950a, b) . Thus, in the 
experiments in which 100 mg. of progesterone were ad- 
ministered prior to a- tocopherol therapy (Part I, 
Section II) and in the preliminary plateaux of preg- 
nanediol excretion obtained during prolonged adminis- 
tration of the hormone (Part I, Section I) it may be 
deduced that the proportion of administered hormone 
excreted as urinary pregnanediol fell within this 
range. The total amount so excreted could not be 
accurately assessed, however in the experiments of 
prolonged duration and in experiments in which the 
progesterone was administered by mouth the proportion 
which would have been excreted following intra- muscular 
administration could only be tentatively deduced by 
the substraction of 2 to 3 per cent., assuming that 
the proportion excreted after oral administration is 
about 2 to 3 per cent. higher than after intra- 
muscular administration (Part I, Introduction) 
(Sommerville and Larrian, ian 1950a) . None the less, 
with one exception, all these studies in normal human 
subjects are compatible with the normal range in the 
present series. 
The exception 1 case is that of Subject 'D' who 
was studied in Part I, Section I(a). This was an 
apparently "normal" post -menopausal woman to whom 40 mg. 
of progesterone was administered orally for twenty - 
two days. The first plateau of pregnanediol excret- 
ion corresponded to approximately 25 per cent. of the 
administered hormone and thus to about 22 per cent. 
of intra- muscularly administered progesterone. This 
value is outwith the suggested normal range, and it 
was of the greatest interest to recall that at the 
time of the experiment the patient was complaining of 
vague arthralgias and of "arthritis" of the right 
knee. No significance had been attached to these 
features at that time, but at a recent visit the 
patient volunteered the information that the "meno- 
pausal arthritis" had now resolved. 
As illustrated in Figs. 16 and 17, the duration 
of the excretion of pregnanediol following the 
administration 
-116- 
administration of progesterone to rheumatoid arthritics 
is more prolonged than that observed in normal subjects, 
as would be expected in view of the greater amount of 
the steroid excreted. In the present series the in- 
crease in the proportion of the administered hormone 
converted to urinary pregnanediol over that converted 
by normal subjects (mean value: 13.4 per cent.) varied 
from 40 per cent. to 160 per cent., and the results 
clearly indicate an abnormality of progesterone 
metabolism associated with rheumatoid arthritis. 
Some salicylates are known to be excreted in the 
urine in conjugation with glucuronic acid and the 
possibility had to be considered that salicylates 
might in some way influence the excretion of pregnane- 
diol by interfering with the formation of pregnanediol 
glucuronide. Accordingly, the precaution was taken 
of witholding all salicylates for one to eight weeks 
prior to the metabolic experiment. There remained, 
however, the theoretical possibility that previous 
prolonged therapy by salicylates might have affected 
the metabolism of progesterone. To investigate this 
possibility, the following experiment was carried out. 
Subject 'J': / 
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Subject 'J' : Man aged twenty -five. Admitted to 
hospital five weeks previously with 
acute rheumatic fever. The patient 
had received acetyl salicylic acid 
('Dysprin') 30 gr. daily during that 
time and the disease was now quiescent. 
The salicylate was continued through- 
out the metabolic experiment, which 
was carried out as described above. 
The proportion of administered pro- 
gesterone converted to urinary preg- 
nanediol by this convalescent patient 
was 10.2 per cent. 
This result clearly indicates that a normal pro- 
portion of administered progesterone can be excreted 
as urinary pregnanediol despite the concurrent 
administration of large doses of salicylates, and that 
the high recoveries observed in rheumatoid arthritics - 
some of whom had received no such therapy during the 
previous two months - cannot be attributable to such 
therapy. 
(b) Administration of progesterone (intra- muscular) 
to atyzical cases of rheumatoid arthritis 
The cases reported above exhibited the character- 
istic clinical features of active rheumatoid arthritis. 
Two further cases were investigated which do not fall 




Subject 'B': A man aged forty -one years, with 
rheumatoid arthritis of eight years' 
duration. The disease had an acute 
onset and a virulent course. It was 
now completely quiescent, however, 
with E.S.R. 2 mm. /hr (Westergren), 
leaving the patient with marked limi- 
tation of movement and gross damage to 
shoulder, elbow and hip joints. 
Progesterone (60 mg.) was administered 
by intra- muscular injection. 
Apparent pr egnanedi of recovery: 9.24 mg. 
Corrected for control "blank ": 8.32 mg. 
Recovery from administered progesterone.- 
15.87 per cent. 
Subject 'S': A post -menopausal woman, aged 48 years, 
with arthritis of twelve years' 
duration. A diagnosis of osteo- 
arthr it is had been made and arthro- 
plasty of both hip joints was advocated 
following a poor response to deep 
X -ray therapy. It was noted, however, 
that the E.S.R. was raised - 16 mm. /hr. 
at the time of the investigation and 
the possibility was considered that 
there might be latent or superimposed 
rheumatoid arthritis (there appeared 
to be no other cause for the elevated 
E.S.R.) 
Progesterone (60 mg. intra- muscular) was 
administered 
Apparent pr egnanedi of recovery: 12.14 mg. 
Corrected for control "blank ": 11.69 mg. 
Recovery from administered progesterone 
19.5 per cent. 
Conclusion 
The result in subject 'B' confirms the clinical 
impression of a case in which the disease - initially 
acute and destructive - had "burned itself out ". In 
subject 'S' the progesterone metabolism experiment 
appears to afford a criterion of the activity of the 
disease / 
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disease and a possible means of differentiating such 
complicated cases from authentic osteo -arthritis. 
(c) Repetition of progesterone metabolism experiment 
in rheumatoid arthritic subjects and attempt to 
correlate the clinical status with the abnormality of 
steroid metabolism 
The experimental procedure was repeated later in 
the course of the disease in seven of the rheilmatoid 
arthritic subjects investigated in the original series. 
The results of these progesterone metabolism experi- 
ments are shown in the following table. 
Repetition of Progesterone ILetab olism Experiment 
Progesterone, 60 mg. Intra -muso. 




(weeks) 1st Experiment 
'P' 21.7 24.4 5 
'Moil' 33.0 29.2 5 
'H' 31.0 24.9 5 
'C' 36.4 34.6 6 
'Z.:ci' 37.3 36.2 6 
'A' 25.7 25.2 12 




This series affords striking evidence that in the 
majority of cases the abnormality of steroid metabolism 
associated with rheumatoid arthritis remains remarkably 
unaffected by the fluctuations in clinical status which 
are so characteristic of the disease. The following 
paragraphs summarise changes in the clinical condition 
of the patients since the previous progesterone 
metabolism experiments. 
Subject 'F': No marked change in clinical condition 
during the intervening five weeks but 
E.S.R. has fallen from 48 mm. /hr. to 
10 mm. /hr. 
Sub ject 
c ' 
No marked change in clinical condition. 
Anaemia persists (Hb. 83 per cent.) 
E.S.R. 33 mm. /hr. 
Subject 'H': Definite improvement in general conditim 
Movements freer and much less painful. 
Patient now fully ambulatory. 
E.S.R. has fallen from 40 mm. /hr. to 
9 mm. /hr. 
Subject 'C': Moderate improvement in general condit- 
ion, but disease still active and 
patient complains of pain in the 
splinted joints. 
Sub j ec t 
Subject 'A' :/ 
Definite improvement in general condit- 
ion but disease still active and pain 
and stiffness have been increased 
following withdrawal of salicylates. 
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Subject 'A': No marked change in clinical status 
since the first experiment although 
there have been several transient 
exacerbations during the intervening 
three months. Disease is still very 
active. 
Subject 'D': During the intervening six months there 
was some clinical improvement but 
recently the patient complained in- 
creasingly of pain on weight -bearing. 
E.S.R. has not fallen (now 45 mm. /hr) 
and anaemia has increased (Hb. 70 per 
cent.) . 
It is obviously of some importance to determine 
whether the deviation from normal of the metabolism of 
progesterone in rheumatoid arthritics reflects their 
clinical condition. 
Attempts to find a correlation between clinical 
status and the metabolic abnormality studied in the 
present work are rendered difficult by the inadequacy 
of quantitative objective criteria in rheumatoid 
arthritis. The functional capacity of rheumatoid 
arthritics may be measured in various ways but active 
movement may be limited more by pain than by muscular 
stiffness or articular changes and thus the functional 
capacity is profoundly influenced by the psychological 
factors which determine the threshold for pain. 
Where tests are devised to afford a quantitative 
measurement of functional capacity skill increases 
with practice. Furthermore, a complicating factor in 
the present series was the necessity to withdraw 
salicylate therapy, thereby intensifying pain and 
1t:lffYAQQ_ / 
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stiffness in many cases. 
Similarly, it is difficult to derive a quantita- 
tive expression of the activity of the disease. The 
criteria employed have been listed in sub -section (a) 
and although these of themselves may be valid they are 
not readily converted into an "activity index ". 
Reviewing the cases studied, it is apparent that 
no correlation exists between the degree of steroid 
metabolic abnormality and the age of the patient, the 
duration of the disease, the height of the E.S.R. or 
the degree of anaemia. There is, however, a suggest- 
ion that in cases with minimal metabolic abnormality 
the disease is more "quiescent" and in cases with 
maximal metabolic abnormality the disease is more 
"active". Since this impression is not based upon 
elevation of E.S.R. or the degree of anaemia it must 
refer to the articular changes and to the general con 
dition of the patient. Accordingly, it seems to the 
author that a more detailed study of the local changes, 
in the joints of such patients may throw some light 
upon the basis of the abnormality of steroid metabolise. 
The "burned out" case (Subject 'B') is of especial 
interest. In such a case the gross joint lesions 
represent the ravaged aftermath of a disease process 
which is no longer active, and in this case the 
metabolism of administered progesterone was normal. 
The / 
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The fact that in the present study the severity of 
the metabolic abnormality was not proportional to the 
number of joints involved is not discouraging to this 
hypothesis since the number involved does not necess- 
arily reflect the intensity of the articular pathology. 
A. study of joint temperature changes or histological 
studies by biopsy might be of value in this connection, 
and it will be of interest to study the steroid metab- 
olism of patients suffering from forms of acute 
arthritis. 
figure 16. 
Apt+IM11TIkpTisN OF -RloGáSTERONE (120r.+g. INTtA_MuX). 
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TABLE 19 
PROGESTERONE (120 mg. INTRA- MUSC.) TO RHEUMATOID 
ARTHRITIC POST -MENOPAUSAL WOMEN 
Admin- 
istration 
Pregnanediol mg. 24 hr. 
Subject 'ï,. Subject 'L' Subject ' 
- 0.18 0.20 - 
0.15 C.18 
Progesterone 0.16 0.21 0.11 
60 mg. 0.19 0.19 0.13 
Progesterone 5.23 5.25 2.09 
60 mg. 5.13 5.18 2.07 
- 9.70 12.70 11.75 
9.83 12.63 11.93 
- 7.18 5.45 9.20 
7.00 5.53. 9.25 
- 2.96 1.73 4.35 
3.00 1.71 4.33 
1.70 0.59 2.50 
1.69 0.63 2.53 
0.59 0.23 1.43 




PROGESTERONE (120 mg. INTRA- NUSC.) TO RHEUJiATOID 
ARTHRITIC PEST- LENOPAUSAL WOMEN 
Admin- 
istration 
Prenanediol mg. /24 hr. 
Subject 'Y' Subject 'C' Subject 'DT 
- - 0.21 0.27 
0.26 0.24 0.25 
Progesterone 0.28 0.26 0.28 
60 mg. 0.23 0.25 0.26 
Progesterone 10.58 5.63 5.00 
60 mg. 10.45 5.70 4.90 
- - 11.55 15.85 
11.30 11.63 16.05 
- 4.98 4.60 5.40 
5.15 4.73 5.50 
- 3.88 1.69 3.95 
4.08 1.64 3.83 
- 0.57 0.34 2.13 




PROGESTERONE (120 mg. INTRA- LftrSC.) TO RHEUIv;ATOID 
ARTHRITIC POST -MF NOPAUSAL 'WOMEN 
Admin- 
istration 
Pregnanediol mg. 24 hr. 
Subject rCa' Subsject íH' Subject 'Mc' 
Progesterone 0.20 0.25 0.20 
60 mg. 0.18 0.24 0.18 
Progesterone 10.30 7.05 8.90 
60 mg. 10.38 7.15 9.05 
- 19.30 15.75 21.60 
19.65 15.85 21.75 
9.60 9.53 6.10 
9.63 9.65 6.08 
2.67 2.64 3.08 
2.70 2.69 3.00 
2.01 2.10 0.71 






PROGESTERONE (60 mg. INTRO- MUSC.) TO RHEUMÁTOID 
ARTHRITIC POST -MENOPAUSAL WOMEN 
dn.in. 
Pregnanediol mg. /24 hr. 
Subject 'S' Subject 'B' Subject 'W' Subject 'Bo' 
0.21 Proses- 0.13 0.22 0.19 
terone 
60 mg. 
0.14 0.18 0.18 0.20 
- 5.68 9.70 5.50 7.10 
5.60 9.50 5.75 7.25 
- 3.75 8.45 4.50 5.45 
3.80 8.35 4.65 5.60 
- 0.45 3.50 2.48 2.62 
0.48 3.55 2.60 - 
- 0.20 1.15 0.28 0.29 
0.17 1.16 0.32 0.30 
TABLE 24 
PROGESTERONE (60 mg. INTRA- MUSC.) 
TO RHEU2iATOID ARTHRITIC MEN 
Admin- 
istratißn 
Pregnanediol mg. 24 hr. 
'Subject T Ì Subject 'IcI Subject 'la' 
Progesterone 0.16 0.31 0.31 
60 mg. 0.21 0.33 0.31 
- 9.05 15.50 6.25 
9.10 15.10 6.38 
- 3.53 5.75 4.30 
3.45 5.50 4.13 
- 1.34 1.71 2.25 
1.31 1.68 2.30 
- - 1.05 0.35 
0.32 1.01 0.38 
- - 0.29 _ 
0.28 
TABLE 25 
PROGESTERONE (60 mg. INTRA- MUSC.) 
TO RHEUYATOID ARTHRITIC MEN 
Admin- 
istration 
Pregnanediol mg. 24 hr. 









- 8.40 7.75 8.70 
8.70 8.00 8.80 
- 4.50 9.90 2.00 
4.88 10.15 1.96 
- 0.95 2.48 0.35 
0.98 2.42 0.38 
- 0.20 0.28 0.18 
0.21 0.33 0.20 
TABLE 26 
PaOGESTERONE ADL.INISTRATION AND SALICYLATE THERAPY 
SUBJECT 'J' 
Administration Pregnanediol mg. /24 hr. 
Progesterone 60 mg. 
plus 
"Dysprin" (30 gr.) 
0.21 
0.24 
"Dysprin" (30 gr.) 
3.03 
3.13 




"Dysprin" (30 gr.) 0.88 
0.19 
"Dysprin" (30 gr.) 0,23 
TABLE 27 
PROGESTERONE (60 mg. INTRA- MUSC.) TO ATYPICAL CASES 
OF RHEUMATOID ARTHRITIS 
Administration Pregnanediol mg. /24 hr. 
Subject 'Stk' Subject 'Bin' 
Progesterone 0.15 0.24 
60 mg. 0.14 0.21 
- 8.75 5.00 
9.05 5.15 
- 3.00 3.05 
3.05 3.08 
- 0.18 0.85 
0.23 0.81 




PROPORTION OF ADMINISTERED PROGESTERONE 
EXCRETED AS URINARY PREGNANEDIOL BY SUBJECTS 
-.IITH DISEASES WHICu EXHIBIT ONE OR LORE OF THE 
L I; C EA Si r R1 
In the previous section, it has been shown that 
an abnormality of the intermediary metabolism of pro- 
gesterone is associated with rheumatoid arthritis. It 
was not claimed that the occurrence of this abnormality 
is limited to rheumatoid arthritis, to the rheumatic 
group of diseases or even to arthritic disease in 
general, and this section is concerned with an attempt 
to investigate the distribution of the phenomenon. 
The erythrocyte sedimentation rate (E.S.R.) is elevated 
in many conditions other than rheumatoid arthritis - 
for example, tuberculosis and neoplasm, and it seemed 
possible that the abnormality of progesterone metabol- 
ism might be no more specific. 
Seven subjects were investigated in this connect- 
ion and the experimental procedure was identical to 
that described in Section I. 
Subject 'C':/ 
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Subject 'C': Man, aged 26 years. 
Diagnosis: Tuberculosis of spine. 
Bilateral pulmonary tuberculosis, and 
tuberculosis of the third and fourth 
lumbar vertebrae. The patient has 
recently had a recurrence of a right 
psoas abscess. E.S.R. 44 mm. /hr. 
(Yestergren). 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 7.84 mg. 
Corrected for control "blank ": 7.18 mg. 
Recovery from administered progesterone - 
12.0 per cent. 
Subject 'H': Man, aged 58 years. 
Diagnosis: Unresolved lobar pneumonia - 
? neoplasm. 
Patient has an unresolved lobar pneumonia 
with opacity at the base of the right 
lung. Very high E.S.R. 110 mm./hr. 
Pneumonic signs are resolving slowly 
and the possibility that there is an 
underlying neoplasm is being investi- 
gated. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 7.41 mg. 
Corrected for control "blank ": 6.93 mg. 
Recovery from administered progesterone - 
11.6 per cent. 
Subject 'ü': Man, aged 51 years. 
Diagnosis: Osteoarthritis of spine. 
Duration of disease - 3 years. 
History of trauma. Unequivocal radiol- 
ogical evidence of hypertrophic osteo- 
arthritic changes. No elevation of 
E.S.R. (5 mm. /hr.). No anaemia (Hb. 
102 per cent.). 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 8.59 mg. 
Corrected for control "blank ": 8.11 mg. 
Recovery from administered progesterone - 
13.5 per cent. 
bject 'Ba':/ 
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Subject 'Bat: Man, aged 39 years. 
Diagnosis - Spondylitis Ankylopoietica. 
Duration of disease - 2 years. 
Early case of spondylitis with stiffness 
and limitation of movement of the 
sacro -iliac joints and lower lumbar 
region of spine. Radiological 
changes are diagnostic but minimal. 
(E.S.R. 20 mm. /hr.). 
Progesterone: 120 mg. intra- muscular. 
Apparent pregnanediol recovery: 15.66 mg. 
Corrected for control "blank ": 14.41 mg. 
Recovery from administered progesterone - 
12.0 per cent. 
Subject 'S': Girl, aged 9 years. 
Diagnosis - Still's disease. 
Duration of disease - 6 years. 
Characteristic multiple articular in- 
volvement. History of splenic en- 
largement. Anaemia (Hb. ea per cent.) 
E.S.A. has fallen from 50 mm. /hr. to 
23 mm. /hr. during past two months. 
Progesterone: 55 mg. intra- muscular. 
Apparent pregnanediol recovery: 5.03 mg. 
Corrected for control "blank ": 4.67 mg. 
Recovery from administered progesterone- 
8-.5 per cent. 
Sub j e c t 
'MoR': 
Boy, aged 15 years. 
Diagnosis - Rheumatic Carditis. 
Admitted for rest following the diagnosis 
of active carditis following acute 
rheumatic fever. E.S.R. 50 mm. /hr. 
Hb . 84 per cent. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 6.50 mg. 
Corrected for control "blank ": 6.06 mg. 
Recovery from administered progesterone - 
10.1 per cent. 
Subject 'Cut:/ 
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Subject 'Cu': han, aged 20 years. 
Diagnosis - Atypical Juvenile Rheumatism. 
Duration of disease - 31 years. 
Endocrine type of obesity and gynae- 
comastia. No involvement of small 
joints or spindling of fingers. 
Generalised joint stiffness and effus- 
ion in right knee. Cannot be classi- 
fied as Still's disease. E.S.R. - 
59 mm./hr. Hb . 84 per cent. 
Progesterone: 60 mg. intra- muscular. 
Apparent pregnanediol recovery: 10.08 mg. 
Corrected for control "blank ": 9.20 mg. 
Recovery from administered progesterone - 
-T5.3 per c en . 
Conclusion 
The proportions of administered progesterone ex- 
creted as urinary pregnanediol by these cases of 
Tuberculosis, Osteoarthritis, Spondylitis, Rheumatic 
Carditis and Still's Disease, fall within the range: 
8.5 per cent. to 15.3 per cent. A comparison of 
these values with those of normal subjects (9.3 per 
cent, to 16.0 per cent.) leaves no doubt as to the 
normality of progesterone metabolism in these cases, 
despite clinical features similar to those found in 
rheumatoid arthritis. The number of cases of any 
one type of disease is too small to permit the con- 
clusion that an abnormality of steroid metabolism 
does not occur in subjects affected by such a disease 
but the series as a whole strongly suggests that the 
abnormality of steroid metabolism may be strictly 
limited / 
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limited in its distribution, and affords ground for 
speculation that the abnormality is not merely assoc- 
iated with, but is intimately concerned in, the path- 
ology of rheumatoid arthritis. Spondylitis ankylo- 
poietica and Still's disease have been shown to 
respond to A.C.T.H. therapy (Elkinton, 1949; Boland, 
1950) and this apparent anomaly will be discussed. 
TABLE 28a 
PROGESTERONE ( 60 mg. INTRA-MUSC.) TO CASES WITH 
CLINICAL FEATURES IN CO-1,110N WITH 
R"riEUL:A T O I D ARTHRITIS 
Admin. Pregnanediol mg.j24 hr. 
Subect 'Ha' Subject 'Cu' Subject rGe' Subject 'Col 
Prog. 0.18 0.23 0.18 0.26 
60 mg. 0.15 0.21 0.14 0.29 
- 5.25 4.30 5.30 2.30 
5.00 4.25 5.50 2.13 
- 1.70 2.54 3.00 0.66 
1.90 2.65 2.90 0.71 
- 0.50 0.98 0.28 0.35 
0.46 0.94 0.20 0.39 
- 0.15 0.23 - 0.23 
0.14 0.24 0.24 
- - F 
TABLE 28c 
PROGESTERONE (120 mg. INTRA- LUSC.) TO CASE OF 
SPOitiDYLITIS i NL OP0IETICA 
Administration 
mg. /24 hr. 
Subject 'Box' 
Progesterone 0.25 
60 mg. 0.24 
Progesterone 4.08 











INVESTIGATION OF THE EFFECT OF THE 
ADRENOCOaTICOTiiOPHIC HORMONE (A.C.T.H.) 
UPON THE METABOLISM OF PROGESTERONE 
IN RHEUMATOID AiiTHRITIC SUBJECTS 
A relationship between the activity of the anter- 
ior pituitary gland and hypertrophy of the adrenal 
cortex was first observed by Evans (1924). This ob- 
servation was confirmed and extended by Smith (1926) 
and in 1933, Collip et al. obtained pituitary extracts 
with high adrenocorticotrophic activity. The isolat- 
ion of the pure protein hormone from swine pituitary 
was reported by Sayers, White and Long in 1943, and 
from sheep pituitary by Li, Evans and Simpson in the 
same year. 
The purified hormone preparations obtained by 
these two groups were closely similar in chemical, 
physical and biological properties. Thus elementary 
analysis revealed a similar content of carbon, 
hydrogen, sulphur, nitrogen and phosphorus, and elec- 
trophoretic studies indicated that the two proteins 
had almost identical isoelectric points. Li, Evans 
and Simpson found that sheep A.C.T.H. contained cystinej 
(7 per cent), tyrosine (4.5 per cent.) and methionine 
(2 per cent.). In 1943, these workers carried out 
partial (50 per cent.) hydrolysis of the hormone with 
crude / 
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crude pepsin and were able to demonstrate that the 
hormonal activity resides in the hydrolysed fragments 
(polypeptide residues) of the original protein molecule. 
From later studies Li hús concluded that these biolog- 
ically active peptide fragments have an average amino - 
acid content of eight, that the pure hormone has a 
molecular weight of about 20,000 whereas these peptides 
have a molecular weight of about 1,200, and that these 
partial peptide hydr olysat es are many times more active 
than the protein hormone (Li and Evans, 1948; Li, 1949; 
Li, 1950). These observations have been largely con- 
firmed by Henly, Morris and Morris (1949), and by 
Morris and Morris (1950), who have prepared a similar 
polypeptide fraction by ultra- filtration and chroma- 
tography of fractionated extracts of beef anterior 
pituitary. This polypeptide is approximately ten 
times more active than the protein hormone of Sayers, 
White and Long. 
Adrenocorticotrophic activity has also been 
detected in the urine of women (Blumenthal, 1940, 1945) 
and in the serum of pregnant mares (colla and Reiss, 
1942). 
In 1948, Thorn et al. described in detail the 
effect of the administration of A.C.T.H. on the level 
of circulating eosinophils and lymphocytes and upon 
electrolyte balance, and Conn et al. (1948) stressed 
the 
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the importance of the changes in carbohydrate metabol- 
ism which follow administration of the hormone. The 
interesting studies of Li and others upon the admin- 
istration of A.C.T.H. to animals, are outwith the 
scope of the present work, but in connection with the 
work of Conn et al. it may be mentioned that it has 
been clearly shown that the hormone enhances diabeto- 
genecity in alloxan- treated animals (Li and Evans, 
1947) and inhibits the insulin effect on gly_c ogenes is 
in isolated rat diaphragm (Li, 1949, 1950). 
Reference was made in the Introduction to the 
dramatic results which followed the clinical trial of 
A.C.T.H. in rheumatoid arthritis by Hench et al.(1949). 
Since that trial, it has been claimed that the hormone 
has beneficial results in a galaxy of conditions. At 
least sixty distinct clinical entities have been 
studied including rheumatic fever, Still's disease, 
disseminated lupus and rare diseases of the collagen 
group, nephrosis, ulcerative colitis, leukaemia, asthma, 
and other allergic disturbances. (Li, 1950; Davidson, 
1950; Boland, 1950). 
In addition, interesting studies have been made 
of the effect of the adrenocorticotrophic hormone 
(A.C.T.H.) or of its polypeptide components (A.C.T.P.) 
on the excretion of urinary steroids. From these 
studies it is clear that an administration of the 
hormone / 
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hormone results in a marked increase in the excretion 
of 17- ketosteroids and corticoids. Thus, Mason (1949, 
1950) administered A.C.T.H. (100 mg. daily) to a 
rheumatoid arthritic woman for twelve days and obser- 
ved a rise in the 17- ketosteroids from a control 
period level of 4.0 to 4.3 mg. per twenty -four hours 
to a level of 43.8 mg. per twenty -four hours on the 
twelfth day. The corticoid excretion rose from 
1 mg. per twenty -four hours to 17.5 mg. per twenty - 
four hours during this period. A sharp fall in the 
urinary level of these steroids occurred within 
twenty -four hours of withdrawal of the hormone. 
Mason estimated that 30 to 50 per cent. of the corti- 
coids chemically determined in these experiments con- 
sisted of 17- hydroxycorticosterone (Kendall's compound 
'F'). 
This recent work by Mason et al. confirms the ob/ 
servation of Mason and Sprague (1948) that 17- hydroxy- 
corticosterone was excreted in the urine of a case of 
Cushing's syndrome with severe diabetes mellitus. 
Unpublished work by Mason et al . , quoted by Boland 
(1950) appears to indicate that the urinary excretion 
of 17- ketosteroids falls during cortisone therapy. 
The immediate relevance of A.C.T.H. to the 
present work lies in the fact that its administration 
appears to offer a method of testing the validity 
of 




biochemical defect in rheumatoid arthritis consists of 
an abnormality in cortisone metabolism, rather than in 
a deficiency of cortisone secretion. If the former 
is true, then it might be anticipated that administra- 
tion of A.C.T.H. would not ameliorate the hypothetical' 
abnormality of cortisone metabolism and by analogy 
would not affect the demonstrated abnormality of pro- 
gesterone metabolism. Furthermore, it may be argued 
that if the administration of A.C.T.H. leads to correc- 
tion of the metabolic defect, then during prolonged 
administration of the hormone the metabolic abnormality 
should gradually resolve and the dose required to 
elicit the clinical response should diminish. There 
is no evidence to suggest that this is so. 
To investigate the effect of A.C.T.H. on the ab- 
normal progesterone metabolism of rheumatoid arthritics, 
the following procedure was adopted. 
Experimental Procedure 
(1) Control metabolic experiment in which proges- 
terone (60 mg. intra- muscular) was adminis- 
tered and the proportion excreted as urinary 
pr egnanedi of was determined as in Section I. 
(2) / 
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(2) A.C.T.H. plus Progesterone: (seven days later) 
(a) Intra- muscular injections as follows: - 
(i) Saline: 2 ml. daily for three days. 
(ii) A.C.T.H. (Organon) 75 mg. daily 
for five days in divided doses 
of 25 mg. 
(iii) Progesterone: 60 mg. along with 
the first A.C.T.H. injection on 
the third day of A.C.T.H. 
administration. 
(iv) Saline: 2 ml. daily for three 
days. 
The saline injections were employed in 
order to minimise psycho- somatic effects. 
(b) Determination of urinary pregnanediol 
carried out daily (in duplicate), 
throughout the experiment. 
(3) Repetition (ten days later) of the progesterone 
metabolic experiment as in (1) 
This procedure has so far been carried through in 
only two cases (subjects 'Ca' and 'McN') but the 
results are sufficiently clear -cut to permit a definite 
conclusion. In subject 'Ca' the post -A.C.T.H. proges- 
terone metabolic experiment was again repeated after a 
lapse of ten days. 
Results 
Improvement in the clinical condition of both 
patients was apparent by the second day of A.C.T.H. 
administration. 
Subject 'IAN' / 
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Subject 'L:cN' , who had been walking with great diffi- 
culty due to limitation of movement and much pain in 
the hip and knee joints experienced complete relief 
from pain and was able to walk freely. Movements, 
such as getting out of bed or rising from a chair, 
were changed overnight from penance to pleasure. 
Subject 'Ca' also experienced dramatic relief from 
pain and stiffness and awoke with the sensation that 
her joints had been miraculously "released". This 
patient had been confined to bed for many months but 
she was able to walk a few steps by the fifth day of 
the administration. The changes in electrolyte 
balance were similar to those previously reported and 
the excretion of urinary 17- ketosteroids which was 
determined in I1 C7Ç!' was markedly increased. These 
findings will not be described in more detail since 
neither the ancillary biochemical determinations nor 
the assessment of clinical improvement vrere carried 
out by the author. 
The results of the progesterone metabolism ex- 
periments are summarised in the following table in 
which the proportion of administered progesterone 
excreted as urinary- pregnanediol before, during, and 
after A.C.T.H. therapy, is expressed as a percentage 
of the dose. A marked diuresis followed withdrawal 
of the adreno- corticotrophic hormone in both cases. 
Percentage / 
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Percentage of Administered Progesterone 



















These results are illustrated in Fig. 17 (subject 
'McIi') and detailed in Tables 29a, 29b, 29c. 
Conclusion 
The results show clearly that no significant 
alteration in the abnormality of the intermediary 
metabolism of progesterone, associated with rheumatoid 
arthritis, resulted from concurrent administration of 
progesterone and of the adrenocorticotrophic hormone. 
It is doubtful if any significance should be attached 
to the slight fall in the percentage conversion which 
was detected ten days after cessation of A.C.T.H. 
therapy / 
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therapy in subject 'Ca' but this point will be eluci- 
dated by other identical experiments which are in 
progress. In fact the absence of a significant 
effect is especially convincing in this case in whom 
the proportion of administered progesterone excreted 
as urinary pr egnanedi of has gradually fallen from 
36.4 per cent. (Section I) to 31.0 per cent. over a 
period of five months. The orthodoxy of the changes 
induced in the clinical condition, electrolyte balance 
and 17- ketosteroid excretion indicate the potency of 
the preparation employed and the reversibility of the 
lesions. It seems probable, therefore, that these 
two cases represent a typical response to A.C.T.H. in 
rheumatoid arthritis and this enhances the value of 
the observations on progesterone metabolism. 
As was indicated in the introduction to this 
section,proof of the inability of A.C.T.H. to 
influence the abnormality of progesterone metabolism 
adds support to the original working hypothesis con- 
cerning the fundamental rSle of an abnormality of 
steroid metabolism in rheumatoid arthritis and 













A.C.T.H. AND THE ABNORLiAL PROGESTERONE METABOLISM 
OF RHEUMATOID ARTHRITICS 
Administration 
(Intra -musc.) 
Pregnanediol ./24 hr. 
ubb ject 'McN' Subject 'Car 
Saline 0.26 0.25 
(3rd inj.) 0.24 0.30 
A.C.T.H. 0.29 0.26 
75 mg. 0.25 0.28 
A.C.T.H. 0.28 0.38 
75 mg. 0.31 0.34 
A.C.T.H. 75 mg 
0.58 0.80 
plus 
Prog. 60 mg. 
0.61 0.73 
A.C.T.H. 12.75 15.25 
75 mg. 12.40 15.35 
A.C.T.H. 4.55 5.85 















A.C.T.H. AND THE ABNORMAL PROGESTERONE METABOLISM 
OR RHEUMATOID ARTHRITICS 
SUBJECT 'Ca' 
Administration 
Before .C.T.H. After k.C.T.H. 
(a) I (b) 
Pregnanediol mg. /24 hr. 
Progesterone 0.25 0.19 0.28 
60 mg. - 0.18 0.23 
- 5.89 6.30 9.60 
5.70 6.28 11.00 
- 8.50 6.75 5.50 
8.35 7.00 5.65 
- 4.10 3.35 3.35 
4.50 3.25 3.45 
- 2.50 1.01 0.31 
2.63 0.98 0.34 
- 0.56 0.20 
0.48 0.16 
TABLE 29c 
A.C.T.H. AND THE ABNORMAL PROGESTERONE METABOLISL 
OF RHEUMATOID ARTHRITICS 
SUBJECT 'McN' 
Administration Before A.C.T.H. After A.C.T.H. 
Pregnanediol mg. /24 hr. 
Progesterone 0.31 0.24 
60 mg. 0.33 0.23 
- 15.50 16.40 
15.10 16.60 
- 5.75 4.95 
5.50 5.13 
- 1.71 0.98 
1.68 0.80 






PRELILINARY ATTEMPT TO INFLUENCE 
THE ABNOiaAL PROGESTERONE METABOLISM 
OF RHEUMATOID ARTHRITIC SUBJECTS 
In the Introduction the possibility was considered 
that the intermediary metabolisms of progesterone and 
cortisone might be closely similar consisting mainly 
of a progressive metabolic reduction of their carbonyl 
substituents and it was suggested that the abnormality 
of progesterone metabolism is attributable to an ab- 
normality of the appropriate enzyme reducing system. 
In Part I, Section II, the possible róle of 
a- tocopherol as a participant in reversible oxidation - 
reduction systems was considered in some detail and it 
was now of considerable interest to investigate whether 
the abnormal metabolism of progesterone might be 
influenced by the administration of such a potential 
coenzyme. In the present work ascorbic acid was 
chosen for this purpose for the following reasons. 
(1) The róle of ascorbic acid in cell metabolism is 
obscure but its participation as a coenzyme 
in redox reactions is more plausible than is 
that of a-tocopherol. Its possibilities in 
this connection hinge upon the reversibility 
of the system ascorbic /dehydroascorbic acid 
and / 
--139- 
and upon the value of its potential. 
It has been claimed that certain enzymes 
are activated by ascorbic acid notably succinic 
dehydrogenase and cytochrome oxidase (Harrer 
and King, 1941). 
(2) Three aspects of the occurrence and physiolog- 
ical action of ascorbic acid appear to have 
especial relevance to the present work. 
(i) There is scattered evidence to suggest 
that the vitamin may be concerned in 
steroid biogenesis. Thus the corpora 
lutea and adrenal cortices are rich 
in ascorbic acid (its concentration 
in the pars intermedia of the 
pituitary is even higher) and it has 
been shown that the ascorbic acid 
concentration of the corpus luteum 
is directly proportional to its 
functional activity (Pincus and 
Berkman, 1937; Pincus and 'Nerthes en, 
1938; Biskind and Glick, 1936). 
Following the isolation of pure 
A.C.T.H., Sayers et al. observed 
that a marked fall in the ascorbic 
acid and cholesterol content of the 
adrenal 
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adrenal cortex follows administration 
of the hormone to rats (1943, 1944) 
and Sayers and Sayers (1946) obser- 
ved the same changes in hypophysec- 
tomised rats and developed a sensit- 
ive method for the bioassay of 
..C.T.H. 
(ii) It is well established that ascorbic 
acid participates in the formation 
of the colloidal intercellular sub- 
stances which comprise those of 
cartilage, the matrical of bone and 
the collagen of fibrous tissue 
(Jeney and Torö, 1936; Litchell, 
1945). 
(iii) It is recognised that ascorbic acid is 
implicated in the metabolism of 
amino -acids. For example, Levine 
et al. (1941) demonstrated an abnor- 
mality of 1- tyrosine metabolism in 
premature infants and showed that 
this could be resolved by the admin- 
istration of the vitamin. This ob- 
servation has been confirmed and ex- 
tended by Morris et al. (1950). It 
is of considerable interest, there- 
fore to learn that there is some 
evidence / 
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evidence for the existence of an ab- 
normality of amino -acid metabolism 
associated with rheumatoid arthritis. 
(Stephens et al., 1949) 
(3) In 1949, Lewin and Wassen reported dramatic alle- 
viation of signs and symptoms of rheumatoid arthritis 
occurring within one hour of a combined intra- muscular 
injection of 11- desoxycorticosterone and an intravenous 
injection of ascorbic acid. Attempts to repeat these 
results have led to very variable results and contro- 
versy rages between those for and those against the 
view that such therapy is indeed beneficial. At the 
time of writing the opinion of those in favour appears 
to be outweighed but the fact that the situation should 
have arisen provided another reason for the present 
investigation. Furthermore, Rinehart et al. (1938) 
claim that the fasting plasma- concentration of ascorbic 
acid is invariably and markedly low in rheumatoid 
arthritis, and that the administration of ascorbic 
acid to such cases produces at best a delayed increase, 
in the plasma ascorbic acid level, and in some cases 
no response. 
As a preliminary investigation it was decided to 
investigate the proportion of administered progesterone 
excreted as urinary pregnanediol by subjects saturated, 
with 
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with orally administered ascorbic acid. Three 




Control progesterone metabolism experiment in 
which 120 mg. of progesterone was adminis- 
tered by intra -muscular injection and the 
proportion excreted as urinary pregnanediol 
calculated as in Section I. 
(ii) Ascorbic acid: 2 gm. orally daily for four 
days. 
Progesterone: 60 mg. intra -muscularly on 
the second and third days. 
Pregnanediol determinations throughout the 
experiment. 
The results are shown in the following table 
and are detailed in Table 30. 
Proportion of Administered Progesterone 
Recovered as Urinary Pregnanediol 




'H' 31.0 28.0 
'Ca' 36.4 33.2 




It is clear that in this preliminary series the 
administration of large doses of ascorbic acid did not 
have a significant effect on the abnormality of Pro- 
gesterone metabolism in rheumatoid arthritics. It 
would not be anticipated,hawever, that the oral admin- 
istration of the vitamin would favour its participat- 
ion in a redo systeri. Accordingly, variations in thé 
ex erii ental procedure and especially parenteral admin- 
istration of the vitamin may yield a different result.. 
Wh .tever the result of such experiments there 
seems little doubt that the attractive nature of the 
a coenzyme is 
to an abnormality in the metabolic reduction of the 
steroid calls for the investigation of other potential 
participants in reversible oxidation- reduction systems. 
The results of experiments of this nature - which 
are in progress - suggest that the hope that the abnor- 
mality of steroid metabolism can be profoundly influen- 
ced is not ill- founded, arid this experimental attack 
is being pursued, not without a certain optimism. 
TABLE 30 
PROGESTERONE (120 mg. INTRA -MUSC.) AFTER 
ADMINISTRATION OF ASCORBIC ACID TO POST- MF,NOPAUSAL 
RHEUMATOID ARTHRITIC WOMEN 
Admin- 
istration 
Pregnanediol mg. /24 hr. 










Progesterone 7.60 6.25 6.80 
60 ng. 7.45 6.35 6.95 
- 13.25 14.85 17.40 
13.00 14.60 17.25 
- 11.65 9.23 7.00 
11.73 9.03 7.15 
L 
- 5.18 3.78 3.38 
5.33 3.83 3.35 
- 3.11 0.92 0.60 
3.12 0.94 0.62 
- 0.33 0.35 0.18 
0.38 0.25 0.21 
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DISCUSSION 
It has been necessary in presenting exploratory 
work of this nature to introduce the experiments by 
fairly detailed discussion. The conclusions which it 
seems reasonable to draw from these experiments have 
also been considered but the underlying biochemical 
mechanisms and the potential clinical implications re- 
main to be discussed. £t the present stage in this 
work, and in the absence of previous studies of a 
similar nature, such speculation will be brief. 
(1) The abnormality of steroid metabolism associated 
with rheumatoid arthritis 
The present results leave no doubt as to the ex- 
istence of an abnormality of progesterone metabolism 
in rheumatoid arthritic subjects. Furthermore, the 
failure to demonstrate this abnormality in subjects 
with other types of arthritis and with other causes of 
elevation of the E.S.R., and the suggestive correlat- 
ion between the degree of the abnormality and the 
clinical status of the patient indicate that the ab- 
normality may be intimately related to the pathology 
of the disease. It will be of the greatest interest, 
therefore, to study the intermediary metabolism 
of 
cortisone in rheumatoid arthritic subjects. 
The 
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The difficulties associated with such a study 
were discussed in the Introduction notably the unknown 
nature of cortisone metabolites and the possibility 
that, once recognised, their quantitative determinat- 
ion might prove difficult if not impossible. Thus 
the prospects of a quantitative study of cortisone 
metabolism are poor although the possibility should be 
considered that cortisone may be partly metabolised 
to some easily determinable 17- ketosteroid. 
The observation of large amounts of 17- hydroxy- 
corticosterone ('F') in the urine of subjects receiv- 
ing the adrenocorticotrophic hormone (Mason, 1948) 
suggests the possibility that this steroid may be 
derived from 17- hydroxy- 11- dehydrocorticosterone ('E) 
by reduction of the 11- carbonyl substituent but does 
not constitute proof, since 17- hydroxycorticosterone 
may be secreted independently of the 11- dehydro com- 
pound or may even be derived from the enigmatic 
biologically active amorphous fraction. 
In view of these difficulties it is of immediate 
interest to supplement the study of the metabolism of 
progesterone in rheumatoid arthritic subjects by a 
study of other steroid precursors of urinary pregnane- 
diol (Fig. 14). 
(a) 11- desoxycorticosterone 
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(a) 11- desoxycorticosterone 
This steroid is, of course, more closely related 
to cortisone than is progesterone and it has 
been shown by Cuyler et al. (1940) and by 
Horwitt et al. (1944) that the proportion of 
administered 11- desoxycorticosterone recovered 
in the urine as pregnanediol is similar to that 
which follows the administration of progester- 
one. 11- desoxycorticosterone would have been 
selected for the original study had it not been 
for the lack of accurate data concerning the 
proportion of administered steroid excreted as 
urinary pregnanediol by normal subjects and 
because it seemed doubtful if doses, large 
enough to permit accurate determination of the 
proportions so excreted, could be administered 
with safety in view of the salt- retaining 
properties of this mineralo- corticoid. Follow- 
ing the results obtained with progesterone, an 
attempt is being made to overcome these diffi- 
culties. 
(h) 
5 5 -pregnen- 3¡ -o1 -20 -one 
This steroid was administered to human subjects 
by Pearlman and Pincus (1942) and pregnane- 
3,20d -diol was isolated from the urine. 




1950) that beneficial results follow its admin- 
istration to cases of rheumatoid arthritis and 
spondylitis ankylopoietica. These observat- 
ions suggested that a study of the intermediary 
metabolism of this steroid in rheumatoid 
arthritic subjects might be of interest. The 
amounts of pregnane- 3ä,20a -diol isolated by 
Pearlman and Pincus were very small, however, 
and it will be recalled that small amounts of 
that steroid have been isolated from the urine 
of normal men and ovariectomised women (p. 7) . 
It was perhaps not surprising, therefore, to 
find in the course of the present work that 
after the oral administration of 120 mg. of 
pregnen -4 -o1 -20 -one to a normal man an insig- 
nificant increase over the control period 
"blank" value of apparent pregnanediol recovery 
was observed. It will be necessary to repeat 
this experiment in a rheumatoid arthritic 
subject but it seems unlikely that this steroid 
will prove useful for the present purpose. 
(c) Cholesterol 
Similarly, the demonstration by Bloch (1945) of 
the derivation of urinary pregnanediol from ad- 
ministered cholesterol is not directly applic- 
able to the present work since the quantitative 
relationship / 
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relationship is obscure. Bloch suggests that 
the direct conversion of cholesterol to prog- 
esterone is a normal process. Studying the 
isotope concentration of the urinary pregnane- 
diol and of the blood cholesterol he estimated 
that about one -half to one -third of the pregnane- 
diol excreted by a pregnant woman receiving 
deuterium- labelled cholesterol arose from that 
source. 
less direct approach to the problem 
would be afforded by a quantitative study of the 
metabolisms of administered testosterone or of 
oestradiol in rheumatoid arthritis. The 
former study would be complicated, however, by 
variations in the urinary level of 17 -keto- 
steroids of endogenous origin and the latter 
rendered difficult by the imperfections of 
current methods for the determinations of the 
urinary metabolites of the oestrogenic hormones. 
In view of the differing metabolic pathways in- 
volved, failure to demonstrate an abnormality 
of the intermediary metabolism of these steroids 
would in no way invalidate the working 
hypothesis that there is an abnormality of 
cortisone metabolisms in rheumatoid arthritis. 
It / 
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It has been suggested in the Introduction 
that this abnormality reflects an abnormality 
of the enzyme system - reductase - responsible 
for the metabolic reduction of progesterone and 
possibly of cortisone. On the other hand, it 
is conceivable that the abnormality is concerned 
with glucuronide synthesis or hydrolysis (p. 491 
It seems likely that these two possibilities 
could to a certain extent be differentiated by 
a comparison of the administration of proges- 
terone and of pregnane- 3a,20a -diol to rheumatoid 
arthritic subjects. Further speculation on 
this, the most fundamental aspect of the problem, 
may properly be reserved, however, until these 
results and the results of attempts to modify 
the metabolic abnormality (section Iv) have 
been obtained. 
(2) Clinical Implications 
Of immediate relevance is the possibility that a 
calculation of the proportion of administered pro- 
gesterone excreted as urinary pregnanediol may con- 
stitute a new and valuable objective criterion in 
rheumatoid arthritis. 
Further investigation should establish whether 
there is a significant correlation between the extent 
of / 
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of the metabolic abnormality and the "activity" or 
prognosis of the disease, and whether a progesterone 
metabolism experiment might reflect the potential re- 
sponsiveness of individual cases to adreno -cortical 
hormone therapy. It was perhaps not surprising that 
the metabolic abnormality was absent in spondylitis 
ankylopoietica but it is less easy to rationalise its 
absence in Still's disease. Until the mechanism of 
the metabolic abnormality is more clearly understood 
this can only be attributed to the characteristic 
pathology of that entity and extension of this aspect 
of the work on diseases related to rheumatoid arthritis 
may indicate a clinical value for a progesterone 
metabolism experiment in differential diagnosis. It 
will be important to stud;, the metabolism of proges- 
terone in non -arthritic diseases which have been shown 
to respond to adreno-cortical hormone therapy. 
Further discussion of the clinical and therapeutic 
implications of this work is highly speculative, at 
the present time, but the possibility cannot be over- 
looked that such abnormalities of steroid metabolism 
are of aetiological significance. During the past 
two decades evidence has accumulated indicating 
the 
validity of the ancient concept of psycho- somatic 
aetiology. Selye (1944, 1949) has crystallised 
his 




"adaptation" and Pincus (1947) may have elucidated 
part of the somatic pathway by the study of changes 
in the pattern of urinary steroid excretion during con- 
ditions of stress. ¡in essential feature of the psycho- 
somatic concept is the belief that prolongation of a 
physiological function leads to changes in the 
structure of the functioning tissue and thus to irre- 
versible disease. ks the physiological importance of 
the adreno -cortical horn ones is recognised, their par- 
ticipation in disease causation becomes an ever more 
disturbing possibility. It is just conceivable that 
under the prolonged action of these hormones the 
enzyme systems engaged in steroid hormone disposal 
become 'primed" in a similar manner to the progester- 
one "priming" effect on the uterus (Part I). 
Is it not possible that such a deviation of inter- 
mediary steroid metabolism is fundamental to the 
mechanism whereby the physiological responses to 
stress become fixed and pathological? If this is so, 
then the introduction of a method for the correction 





The nature of the quantitative relationship 
between progesterone secretion and urinary preg- 
nanediol excretion had been investigated by the 
quantitative determination of the metabolite 
after continued daily administration of proges- 
terone to normal post -menopausal women, normal 
men, hysterectomised- ovariectomised women and 
hysterectomised post -menopausal women. These 
experiments prove that when the human body is 
subjected to the influence of progesterone for 
more than a few days, a progressive change in the 
relationship of hormone to metabolite occurs so 
that an increasing proportion of the administered 
hormone is recovered from the urine as the 
metabolite. This progesterone "priming" 
phenomenon has been shown to be attributable to 
a role of the uterus in the metabolism of 
progesterone. Pregnane -3 í,20a -diol has been ad- 
ministered to post -menopausal women and the 
biochemical mechanism and clinical implications 
of these findings have been discussed. 
(2) The claim by de datteville et al. (1948) 
that pre- treatment with a- tocopherol augments the 





pregnanediol has been investigated. An identical 
experimental procedure has been adopted but normal 
human subjects have been studied in place of 
patients with carcinoma of the uterus or breast 
and the method of Sommerville, Gough and Marrian 
(1948) has been used instead of the modified 
method of Huber (1947). The results clearly in- 
dicate that a- tocopherol does not have the effect 
observed by de '.Iatt ev ille et al. when normal 
subjects are studied by the former method. Ex- 
planations are offered for these contradictory 
results. 
A synthetic orally active progestogen - 
ethinyltestosterone - has been administered to 
normal men and the urine investigated for the 
presence of pregnanediol. Significant amounts 
of pregnanediol were not recovered from the urine 
but large amounts of an unidentified crystalline 
precipitate were observed. Excretion of this 
substance - which may be metabolite of ethinyl- 
testosterone - as a glucuronide would account for 
the results obtained by Allen, Viergiver and 
Soule (1944) . The clinical implications of a 
progestogen which is not metabolised to preg- 





The excretion of urinary pregnanediol has 
been studied during normal pregnancy and the 
results have been compared with those obtained by 
less specific methods for the quantitative deter - 
mination of the steroid. The results emphasise 
the necessity to establish values of pregnanediol 
excretion in normal pregnancy. 
It has been shown that the method of 
Sommerville, Gough and Marrian (1948) is applic- 
able to the determination of small amounts of 
pregnanediol in rabbit urine. The accuracy of 
the method when used for this purpose has been 
assessed and it is concluded that as little as 
0.25 mg. of the steroid can be determined in one 
half of a twenty -four hour urine specimen. 
«n analogy has been drawn between the 
intermediary metabolisms of progesterone and 
cortisone (17- hydroxy- 11- dehydrocorticosterone) 
and it was anticipated on theoretical grounds that 
an abnormality of progesterone metabolism might be 
associated with rheumatoid arthritis. Such an 
abnormality was demonstrated in a large series of 
women and men with rheumatoid 
arthritis, a.nd consisted in the conversion of an 
abnormally high proportion of administered 
progesterone 
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progesterone to urinary pregnanediol. 
The abnormality was not observed in a series 
of patients suffering from diseases which 
resemble rheumatoid arthritis in one or more of 
their clinical features. 
The belief in the possibility that the path- 
ology of rheumatoid arthritis is associated with 
an abnormality of steroid metabolism rather than 
with a deficiency of endogenous steroid secretion 
was strengthened by the observation that the ab- 
normality is not affected by the administration 
of the adrenocorticotrophic hormone of the 
anterior pituitary gland. 
The biochemical mechanism and clinical im- 
plications of the abnormality of steroid 
metabolism have been considered and the rational 
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Various methods have been described for the quantitative determination of preg- 
nanediol in human urine. Of these the original procedure of Yenning [1937, 1938], in 
which sodium pregnanediol glucuronidate is extracted from the urine and weighed 
after purification, is still perhaps the most widely employed. This method, although 
somewhat time -consuming and laborious, gives satisfactory results when applied to 
urines containing more than c. 10-15 mg. of pregnanediol per 24 hr., but suffers from 
certain serious disadvantages where urines containing smaller amounts of the steroid 
are concerned. Thus, as pointed out by Astwood & Jones [1941], `when only small 
amounts of material are present in the urine, the identity of the final product is some- 
times questionable '. Furthermore, it may be necessary to use a full 24 hr. or even. 
a 48 hr. specimen of urine for a single determination in order to obtain sufficient of the 
glucuronidate to weigh accurately. 
Other methods of determining pregnanediol as its glucuronide have been described 
by Allen & Viergiver [1941], Jayle, Crépy & Wolf [1943], and Bisset, Brooksbank & 
Haslewood [1947]. These methods would seem to be somewhat less laborious and 
considerably more sensitive than the Venning method, but they are open to criticism 
on the grounds of lack of specificity. A further disadvantage of all methods in which 
pregnanediol is determined as its glucuronide arises from the fact that, unless very 
special precautions are taken, hydrolysis of the latter by bacterial action may occur 
during the collection of the urine and subsequently. 
A method of a different kind was developed by Astwood & Jones in 1941. In this 
method the urine is boiled with acid to hydrolyse the glucuronide and the free preg- 
nanediol thus liberated extracted with toluene, purified and weighed. The originality 
of this method lies in the procedure used for the purification of the pregnanediol in the 
crude toluene extract. It was shown that from the toluene- soluble fraction, after 
removal of acidic substances by treatment with sodium hydroxide, nearly pure 
pregnanediol in almost quantitative yield can be obtained by precipitation from 
ethanolic solution with four volumes of water or dilute sodium hydroxide solution. 
The sensitivity of this method was considerably increased subsequently by Talbot, 
Berman, MacLachlan & Wolfe [1941], who estimated the purified pregnanediol colori- 
metrically by means of the yellow colour which it yields with concentrated sulphuric 
acid. Both groups of workers reported reasonably satisfactory recoveries of about 
70 % in short series of experiments in which sodium pregnanediol glucuronidate was 
added to men's urine in varying amounts,* but the evidence that either procedure 
* It seems possible that the recoveries obtained by these authors may actually have been somewhat 
higher than they themselves reported, since Marrian & Gough [1946] have shown that sodium preg- 
nanediol glucuronidate prepared and purified in the usual way [yenning & Browne, 1936] contains only 
about 80% of that compound. 
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would be dependable when applied to urines containing less than c. 10 mg. of preg- 
nanediol per 24 hr. was not entirely satisfactory. 
A somewhat simplified version of the Astwood & Jones method as modified by 
Talbot et al. has recently been developed by Guterman [1944, 1945] for the detection 
of pregnanediol in urine as a rapid means of diagnosing pregnancy. 
What will for convenience be called the Astwood- Talbot' method has several 
advantages over other methods of determining urinary pregnanediol. The colour 
reaction which pregnanediol gives with concentrated sulphuric acid is extremely 
sensitive, thus permitting the accurate determination of small amounts of the sub- 
stance ; and although it is not a specific reaction for pregnanediol it was shown by 
Astwood & Jones and by Talbot et al. that many of the other urinary substances 
which give it are largely eliminated in the ethanol -water precipitation process of 
purification. Since the pregnanediol is determined in the free state, elaborate pre- 
cautions to avoid bacterial hydrolysis of the glucuronide in the urine are unnecessary. 
The objective of the work described in this paper was to develop an accurate, 
specific, convenient and rapid method for the determination of the pregnanediol 
(1 -10 mg. /24 hr.) in the urine of women during the luteal phase of the menstrual 
cycle. Furthermore, in order to permit duplicate determinations of pregnanediol and 
of other urinary constituents to be carried out it was necessary that the method 
developed should require not more than one -fifth or one -quarter of a 24 hr. specimen 
of urine. 
This objective has been nearly, but not quite, attained. A procedure based on the 
Astwood- Talbot method has been elaborated which permits of the reasonably accurate 
determination of more than c. 0.4 mg. of pregnanediol in one -fifth of a 24 hr. urine 
specimen. Six determinations can be completed in two 8 hr. working days, and the 
method is such that it could be satisfactorily employed by a trained and competent 
laboratory technician. 
APPARATUS AND MATERIALS 
Quickfit & Quartz glassware, with interchangeable standard glass joints, was used 
throughout in order to avoid contamination of the urinary extracts with coloured or 
chromogenic material that might be dissolved out of rubber or cork stoppers. 
The toluene used for the extractions was `sulphur -free' and was distilled before use. 
Ethanol was purified by refluxing over sodium hydroxide and distilling twice. 
Pregnane -3(a), 20a -diol was prepared from human pregnancy urine and purified 
via its diacetate. The sample used in the recovery experiments melted at 236- 
237° (corr.). 
Sodium pregnane -3(a), 20a -diol glucuronidate was prepared from human pregnancy 
urine by the method of Yenning & Browne [ 1936] and freed from ketonic glucuronides 
by the method of Sutherland & Marrian [1946, 1947]. The preparation used in the 
recovery experiments melted at 282 -283° (corr.) with decomposition and evolution of 
gas. Samples of the glucuronidate were weighed out after exposure to moist air. As 
shown by Sutherland & Marrian [1947] material so treated is the trihydrate having the 
composition 027H48O8Na.3H20. 
For certain of the recovery experiments the toluene -soluble neutral fraction of acid - 
hydrolysed men's urine was required. This was prepared in the following way: 24 hr. 
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urine specimens from a number of normal men were pooled and heated to boiling, 
together with some toluene, acidified with one -tenth of its volume of concentrated 
hydrochloric acid, and the boiling continued for 10 min. After cooling the mixture was 
extracted three times with one -fifth volumes of toluene, emulsions being broken by 
filtration through a Buchner funnel with gentle suction. The combined toluene 
extracts were washed twice with one -sixth volumes of N sodium hydroxide, three 
times with one -sixth volumes of water, evaporated to a small volume on a hot plate, 
and finally taken to dryness under reduced pressure in the water -bath. The brown 
gummy material so obtained will be referred to as `male urine neutral fraction'. 
MODIFICATIONS MADE IN THE PROCEDURES OF ASTWOOD AND TALBOT 
In consequence of a very large number of preliminary experiments, the details of all 
of which are not reported here, a number of modifications have been made in the 
original procedures as described by Astwood & Jones [1941] and by Talbot et al. 
[1941]. These modifications were designed to minimize the number of transferences 
from vessel to vessel during the procedure and to facilitate the rigid standardization of 
technique which experience has shown is essential if accurate and reproducible 
results are to be obtained with urines containing less than c. 10 mg. of pregnanediol 
per 24 hr. urine volume. 
Removal of acidic substances 
Astwood & Jones and Talbot et al. removed acidic and phenolic material from the 
toluene extract of the hydrolysed urine by boiling with methanolic sodium hydroxide 
and then filtering off the resulting precipitate of sodium salts. In the experience of 
the present authors it is equally effective and much simpler to remove acidic and 
phenolic material by washing the toluene extract in a separating funnel with aqueous 
sodium hydroxide. 
. Purification of pregnanediol from the neutral fraction by precipitation from ethanol 
The accuracy and specificity of the Astwood -Talbot method are very largely 
dependent upon the efficiency of the precipitation process in separating pure preg- 
nanediol quantitatively from the neutral toluene -soluble fraction of the hydrolysed 
urine. Accordingly, considerable attention has been paid in the present work to 
investigating the optimal conditions for carrying out the precipitation and for 
collecting the precipitated pregnanediol. 
Collection of the precipitated pregnanediol. In the Astwood & Talbot procedures and 
also in the method of Guterman [1944] the precipitated pregnanediol was collected by 
filtration. To facilitate the quantitative collection of the small amounts of precipitate 
and in order to avoid as far as possible transference of the material from vessel to 
vessel, the precipitation process in the present work has been carried out in centrifuge 
tubes and the precipitate collected by centrifugation. At first some difficulty was 
experienced in getting the relatively light pregnanediol crystals to pack sufficiently 
tightly in the tubes to permit the siphoning -off of the supernatant solution. This 
difficulty was, however, overcome by adding to the precipitation mixture before 
centrifugation a small amount of the filter -aid Hyflo -Super Cel', which effectively 
entrained the precipitated pregnanediol. 
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Number of precipitations and volume of precipitation mixture. Astwood & Jones 
[1941] purified the pregnanediol from the neutral fraction by one precipitation with 
four volumes of N /10 sodium hydroxide followed by one with four volumes of water. 
Talbot et al. [1941] and Guterman [1944] used a single precipitation with four volumes 
of N /10 sodium hydroxide. In the experience of the present authors, however, one 
precipitation with sodium hydroxide and two with water are required in order to 
obtain the pregnanediol in a satisfactory state of purity. This multiple precipitation 
technique lengthens the process somewhat, but the loss of time is more than com- 
pensated for by the resulting increase in specificity which results. 
Numerous preliminary experiments showed that the most satisfactory results were 
obtained when the neutral fraction from one -fifth of a 24 hr. specimen of urine was dis- 
solved in 4 ml. of ethanol and precipitated with 16 ml. of N/10 sodium hydroxide or water. 
Rate of cooling after precipitation in. hot solution. The efficiency of the precipitation 
process has been studied in many series of recovery experiments in which varying 
amounts of pure pregnane -3(a), 20a -diol were added to quantities of male urine 
neutral fraction ' each corresponding to one -fifth of a 24 hr. urine specimen. In the 
early experiments of this kind it was found that satisfactory recoveries (80 % or 
better) were obtained when more than about 4 mg. of pregnanediol were present 
(corresponding to 20 mg. /24 hr.), but that with smaller amounts of pregnanediol the 
recoveries were very much lower and very irregular. 
The great irregularity of the recoveries suggested that some important variable 
factor in the purification process was not being properly controlled. Since the rate of 
cooling of the mixture after precipitation in hot solution might be expected to de- 
termine the size of the pregnanediol crystals it seemed possible that this might be the 
uncontrolled factor. 
This possibility was investigated in two series of recovery experiments in which 
varying amounts of pure pregnane -3(a), 20a -diol were added to portions of male 
urine neutral fraction ', each of which was equivalent to one -fifth of a single 24 hr. 
specimen. The pregnanediol in these mixtures was purified by the triple precipitation 
procedure, which was as described below (p. 252) with the exception that the cooling 
conditions following each precipitation were varied. In one series of experiments the 
precipitation mixtures were cooled rapidly by immediate immersion in an ice -bath 
and were then left in the refrigerator overnight before centrifugation. In a second 
series, which were duplicates of the first, the mixtures were cooled slowly by trans- 
ferring them in beakers of water at 75° to an incubator at 37° where they were allowed to 
remain for 2 hr. They were then cooled in the refrigerator for 30 min. and centrifuged. 
The results *, which are shown in Table 1, are quite conclusive. It will be seen that 
rapid cooling of the precipitation mixtures gave lower and much more irregular 
recoveries of pregnanediol than were obtained by the slow- cooling technique. It will 
also be'seen that the difference in recovery due to the rate of cooling was most marked 
with amounts of pregnanediol corresponding to less than c. 20-25 mg. /24 hr. 
Later experiments, which are not reported here, have shown that the recoveries by 
the slow- cooling technique are unaffected by the omission of the short period of 
refrigeration before centrifugation. It has also been-found that a longer period at 37° 
* A preliminary paper dealing with these findings was read to the Society for Endocrinology on 29 May 
1947. 
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than 2 hr. does not lower the recoveries. In the method finally adopted (p. 252) the 
actual periods during which the precipitation mixtures are incubated have been 
adjusted to fit a working day of convenient length. 
Table 1. The effect of varying the rate of cooling after precipitation on the 
recovery of pregnanediol added to `male urine neutral fraction' 
Pregnanediol recovered 
corrected for 'male 
urine blank' ( 
`Male urine Pregnanediol Pregnanediol recovered (mg.) 
neutral added Rapid Slow 
fraction' (mg.) Rapid cooling Slow cooling cooling cooling 
A 0-00 
0-00 0-012 0031 0055 0050 - 
0-00 00 6 0.040 
B 0-00 0.017 0.040 
0-00 0015 0014 0042 0040 - - 
000 0010 0.037 
A 0.27 0.032 0.123 
0 27 0.012 
1 
0.023 0.092 0.096 
0.27 0.025 0.072 
B 0.40 0.016 0.33 
0-40 0-021 0017 0-38 034 
040 0015 0.31 
A 0-53 0.4 0.45 
0.53 04 
3 
041 046 049 
053 037 0.57 
B 0-80 0.631 0.86 
0-80 0 82 0-75 0.82 0.84 
0 80 0.80 0.83 
A 4-0 4.0 4.2 
4.0 3.9 
11 
r 3-5 4.1 4.1 






In view of these findings it is of some interest to consider the precipitation and 
cooling techniques of previous workers who have used the Astwood- Talbot method. 
Astwood & Jones [1941] do not appear to have controlled the temperature at which 
precipitation was carried out very exactly, but they did allow the precipitation 
mixtures to cool to room temperature before cooling in the refrigerator. Such a 
procedure in an American laboratory, where `room temperature' may be 25° or more 
might be said to provide `slow cooling'; in the average British laboratory in winter 
time, however, the procedure might very well give quite rapid cooling. Neither 
Talbot et al. [1941] nor Guterman [ 1944] controlled the temperature of precipitation, 
and since in both cases the precipitation mixtures were transferred directly to the 
refrigerator or into an ice -bath, their procedures must have undoubtedly involved 
rapid cooling. It can be concluded that the procedures used by all these workers would 
be liable to give low and erratic results with urines containing less than c. 20 mg. of 
pregnanediol per 24 hr. 
Sulphuric acid colour reaction 
The finally purified pregnanediol obtained by the precipitation process from the 
urine of pregnant and of non -pregnant women has occasionally been found to be 
contaminated with traces of a blue pigment. The nature of this pigment has not been 
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investigated, but it is suspected that it may be of dietary origin. The presence of this 
pigment seriously interferes with the sulphuric acid colour reaction and it is therefore 
necessary to remove it before carrying out the reaction. This can be effectively done 
without loss of pregnanediol by warming in ethanolic solution with charcoal. In 
order to maintain a rigid uniformity in procedure this treatment with charcoal has 
been adopted as a routine whether the pigment is present or not. 
Talbot et al. [1941] carried out the colour reaction by allowing the purified preg- 
nanediol to stand with 10 ml. of concentrated sulphuric acid at room temperature for 
20 min. In the present work, in order to standardize conditions as far as possible, the 
colour development has been carried out in a water -bath at 25° instead of at `room 
temperature'. 
METHOD FINALLY ADOPTED FOR THE DETERMINATION OF PREGNANEDIOL IN URINE 
A 24 hr. specimen of urine collected with 5 ml. of toluene as preservative is made up 
to 2500 ml. and duplicate 500 ml. samples removed. Each sample is treated as 
follows: It is placed in a 1000 ml. flask and after the addition of 100 ml. of toluene 
brought to boiling point under a reflux condenser. To the boiling mixture is added down 
the condenser 50 ml. of concentrated hydrochloric acid (A.R. ), and the boiling continued 
for exactly 10 min. The flask is then rapidly cooled in cold water and the contents 
transferred to a separating funnel of 750 ml. capacity. After shaking and allowing the 
urine layer to separate, the latter is run off into the original flask and the layer of 
toluene and emulsion filtered with gentle suction through a Whatman No. 1 paper on 
a Buchner filter funnel. The urine layer is then returned to the separating funnel and 
extracted twice more with 100 ml. portions of toluene, each toluene and emulsion 
layer being filtered in succession through the same filter funnel. The combined 
filtrates are then transferred to a clean separating funnel, and after running off the 
small urine layer that separates, the toluene extract is washed twice with 100 ml. 
portions of N sodium hydroxide and twice with 100 ml. portions of water. The 
washed toluene extract is run into a 500 ml. round -bottomed flask and is evaporated 
nearly to dryness on an electric hot plate and then taken completely to dryness under 
reduced pressure on a boiling -water bath. 
The dry residue is transferred quantitatively with warm ethanol to a 20 ml. 
conical centrifuge tube and the ethanolic solution evaporated to dryness in a water - 
bath under a stream of air. To the residue in the tube are added exactly 4.0 ml. of 
ethanol and the tube is placed in a beaker of water maintained at 75 °. After stirring 
with a glass rod for 1 min. to obtain complete solution, 16.0 ml. of N /10 sodium 
hydroxide are added drop -wise from a burette during 3 min. with stirring, the last 
1 ml. being used to wash down the stirring rod into the tube. After a further 1 min. at 
75 °, the beaker of'water containing the tube is transferred to an incubator at 37° and 
left overnight. Approximately 8-10 mg. of Hyflo -Super Cel' (Johns- Manville Co. 
Ltd.) are added and the mixture stirred with a glass rod. The rod is washed down into 
the tube with 1 ml. of a 1 : 4 (v /v) ethanol -water mixture and the tube is then centri- 
fuged for 1 hr. (1500 r.p.m.; radius of centrifuge head: 15 cm.). The supernatant 
solution is finally sucked from the precipitate with the aid of a fine glass tube attached 
to a slowly running water -pump. 
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The second and third precipitations are carried out as described above, except that 
water instead of sodium hydroxide solution is used, and the incubation periods are 
reduced for convenience to 2 hr. No additional filter -aid is added before the centri- 
fugations following the second and third precipitations. 
To the final precipitate are added 5 ml. of ethanol and the pregnanediol dissolved 
by warming with stirring at about 75°. Norite' charcoal (c. 1 -2 mg.) is then added and 
the warming continued for 2 min. The mixture is filtered through a small filter 
(Whatman No. 1 paper) into a test -tube of 1 in. diameter, the centrifuge tube and 
filter being washed three times with 2 ml. portions of warm ethanol. The filtrate and 
washings in the tube are evaporated in a water -bath under a stream of air and the 
residue finally dried by leaving the tube in a vacuum desiccator over calcium chloride 
for several hour's. 
The colour reaction is carried out with not more than c. 0.5 mg. of the finally 
purified product. If, therefore, the amount of the latter appears on inspection to be 
in excess of 0.5 mg. a suitable aliquot portion is removed after solution in a known 
volume of ethanol. To the dry pregnanediol 10.0 ml. of concentrated sulphuric acid 
(A.R.) are added from a burette, and the tube is left in a water -bath at 25° for 20 min. 
with occasional shaking. The intensity of the yellow colour produced is measured in 
a Spekker' photoelectric absorptiometer using a `spectrum violet' No. 601 light 
filter. 
The absorptiometer readings are interpreted by reference to a calibration curve 
made with known amounts of pure pregnane -3(a), 20a -diol varying from 0.1 to 0.5 mg. 
It is advisable to construct a fresh calibration curve for each batch of unknowns. 
RECOVERY EXPERIMENTS 
The accuracy of the finally adopted method was tested in a long series of recovery 
experiments in which pure sodium pregnanediol glucuronidate was added in varying 
amounts to men's urine. The validity of such tests of accuracy depends upon 
two assumptions : (a) that all the pregnanediol in human urine is present as the 
glucuronide, and (b) that women's urine contains no substances which are not present 
in men's urine which would interfere with the determination of pregnanediol. Further 
work will be necessary to see whether these assumptions are justifiable or not. 
Twelve 24 hr. specimens of urine were collected from four normal men. Each 
specimen was made up to 2500 ml. and four 500 ml. samples removed. To each of two 
of these samples was added an identical amount of sodium pregnanediol glucuronidate 
dissolved in 80 % ethanol, the other two samples being retained for working -up as 
`male urine blanks'. All four samples from each specimen were then treated as 
described in the preceding section (pp. 252, 253). The results in Table 2 show that a 
pregnanediol content of c. 2 mg. /24 hr. is a critical one, above which recoveries are 
excellent, but below which they are poor. 
That the loss of pregnanediol when less than c. 2 mg. /24 hr. is present in the urine 
occurs mainly during the precipitation process rather than during the hydrolysis or 
extraction seems to be clear from the results shown in Table 1. This loss must be 
largely due to an effect of other substances in the neutral fraction upon the solubility 
of pregnanediol in 20 % ethanol, since experiments in pure solution have shown that 
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80-95 % of pregnanediol can be removed after the triple precipitation process when it 
is present in amounts corresponding to as little as 0.5 mg. /24 hr. It is possible, there- 
fore, that the critical concentration of pregnanediol below which recoveries are un- 
satisfactory may vary somewhat with different urines. However, the results reported 
here with a number of different specimens of men's urine suggest that this critical 
concentration is probably not far from 2 mg. /24 hr. in the majority of cases. 
Table 2. Recovery of pregnanediol after the addition of sodium 
pregnanediol glucuronidate to men's urine 





glucuronidato Pregnanodiol recovered (mg.) Pregnanediol 
Men's 1 of 24 hr. to 1 of 24 hr. recovery 
Corrected 
N 
urine specimen (mg.) urine specimen (corrected) 
specimen (ay. of duplicates) (mg.) Apparent for blank (%) 
C4 0.016 0.2 0.017 0.001 0 
0.2 0.012 - 0 
A3 0.008 0.2 0.021 0-013 7 
0.2 0.047 0.039 20 
B2 0.024 0-2 0.060 0.036 18 
0.2 0.045 0.021 11 
D4 0.035 0-4 0.32 0-29 72 
0-4 0-33 0-29 74 
B3 0.015 0-4 0-28 0-27 67 
0-4 0.29 0-28 69 
A2 0-018 04 0.35 0-33 82 
04 0-35 0-33 82 
A4 0.044 1-0 0-99 0.95 95 
1.0 0.98 0-93 93 
C3 0-019 1-0 0.94 0-92 92 
1.0 0.96 0-94 94 
D2 0-077 1-0 1-0 0.92 92 
1.0 0.98 0.90 90 
B4 0-030 2.0 19 1.9 95 
2-0 2-0 2.0 100 
D3 0.017 2-0 2-0 2.0 100 
2-0 1-9 1.9 95 
C2 0.026 2.0 l9 1.9 95 
20 1.9 1-9 95 
SPECIFICITY OF THE METHOD 
The sulphuric acid colour reaction is not specific for pregnanediol; many other 
steroids give similar colours with varying intensities. The specificity of the method as 
a whole therefore depends upon the completeness with which other chromogenic 
steroids originally present in the urine are eliminated in the extraction and purification 
process. 
Some data relevant to this extremely important point have been presented by 
previous workers. Thus Astwood & Jones [1941] showed that cholesterol and andro- 
sterone were completely eliminated by their double precipitation process when 
present in amounts not exceeding 16 and 8 mg. per litre respectively, while Talbot 
et al. [1941] showed that dehydroisoandrosterone in amounts up to c. 10 mg. per litre 
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caused no interference. In the course of present work additional relevant data have 
been accumulated, but since these data are still incomplete they will be referred to at 
the present time only briefly. 
Androsterone, isoandrosterone, and pregnan- 30) -ol -20 -one are not completely 
eliminated by the triple precipitation process used, but providentially they are so 
much less powerfully chromogenic than pregnanediol in the sulphuric acid reaction 
that their presence in the final product, except in abnormally large amounts, does not 
introduce any serious error into the pregnanediol determination. Dehydroiso- 
androsterone and pregnane -3(x), 17, 20- triol,'on the other hand, are very powerful 
chromogens, but, providentially again, they seem to be very readily eliminated in the 
precipitation process. Any possible interference by the pregnanetriol is doubly safe- 
guarded against by the fact that this compound would be largely decomposed during 
the initial hydrolysis of the urine with acid. 
These preliminary findings provide hope that the method may be reasonably 
specific for pregnanediol when applied to normal urines, but before definitely con- 
cluding that it is indeed so it will be necessary to carry out further experiments with 
other steroids likely to be present. At the present time the method cannot be recom- 
mended for pathological urines containing abnormally high concentrations of neutral 
17- ketosteroids or of other neutral steroids of adrenal origin. In such cases the preg- 
nanediol present might be considerably overestimated. In passing, it may be re- 
marked that any of the methods in which pregnanediol is determined as its glucuronide 
are also likely to give fictitiously high results when applied to urines containing 
abnormally high concentrations of steroids of adrenal origin, since certain of the latter 
are probably excreted as glucuronides also. 
DISCIISSION 
The methods of urinary pregnanediol determination which have hitherto been 
described are either insufficiently sensitive or insufficiently specific to permit of 
strictly quantitative studies being carried out upon pregnanediol excretion during the 
menstrual cycle and during the early stages of pregnancy. The method described here 
should make such studies more nearly possible, and in particular should be of some 
value in the investigation of causes of female sterility. 
Although the method was not designed for use as a means of pregnancy diagnosis, it 
may be useful for this purpose, and because of its more quantitative nature it may 
prove to be less subject to both positive and negative errors than the more rapid 
Guterman [1944, 1945] method. In view of the widespread interest in the latter it 
would perhaps not be out of place to discuss in the light of the findings in the present 
work some of the possible sources of the negative and positive errors to which the 
method seems to be subject [cf. Reinhart & Barnes, 1946]. 
In his latest paper on the method Guterman [1945] has arbitrarily fixed on an 
intensity of colour in the sulphuric acid reaction corresponding to 6-8 mg. of preg- 
nanediol per 24 hr. as the lower limit for a positive reaction. It seems probable that at 
such levels of pregnanediol excretion the unsatisfactory cooling conditions in the 
precipitation process in Guterman's procedure might lead to low and variable yields of 
pregnanediol and thus to false negative results. It is likely that a controlled `slow 
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cooling ' technique in the precipitation process might eliminate some at least of these 
false negatives. 
The findings in the present work suggest that false positives might be caused by the 
presence of abnormally large amounts of the weakly chromogenic saturated neutral 
17- ketosteroids which are incompletely removed even by a triple precipitation 
procedure, or by the incomplete elimination in the single precipitation of the Guterman 
method of the strongly chromogenic dehydroisoandrosterone. In this connexion it is 
noteworthy that Morrow & Benua [1946] recorded false positives in a case of arrhenq- 
blastoma which was excreting 59 mg. of 17- ketosteroids per 24 hr. It is doubtful 
whether false positives caused by the presence of abnormally large amounts of 17- 
ketosteroids could be entirely eliminated by any simple modification in the pre- 
cipitation process, but it is likely that their number could be reduced if a double 
instead of a single precipitation procedure were to be adopted. 
In conclusion, one may perhaps question whether it is justifiable to accept as 
diagnostic of pregnancy any arbitrarily fixed low level of pregnanediol excretion 
associated with amenorrhea. It must be remembered that little is known at the present 
time about the metabolism of progesterone, and there are in fact few reasons to 
believe that pregnanediol is even the main metabolic end -product of the latter. The 
low yields of urinary pregnanediol obtained after the administration to human 
subjects of progesterone raise the possibility that the latter may be largely meta- 
bolized in the body by other routes. It is therefore questionable whether the level 
of pregnanediol excretion provides a reliable indication of the progesterone production 
in the body, as has been so widely assumed. 
As pointed out by Reinhart & Barnes [ 1946], it is possible that the greatest source of 
error in the Guterman test is the `individual variations in the metabolism of pro- 
gesterone, both in the pregnant and the non -pregnant woman'. 
SUMMARY 
A procedure based on the methods of Astwood & Jones [1941] and Talbot et al. [1941] 
has been elaborated which permits of the reasonably accurate determination of more 
than c. 0.4 mg. of pregnanediol in a fifth of a 24 hr. sample of human urine. 
This work was carried out at the request of the Committee on Human Fertility of 
the Medical Research Council. The authors are indebted to the Medical Research 
Council for a grant from which the expenses óf the work were defrayed and for personal 
grants to two of them (N.G. and I.F.S.). They are also indebted to their colleagues who 
co- operated in the collection of urine and to Miss E. Sutherland who prepared the 
sample of pure sodium pregnanediol glucuronidate. 
Part of this work was carried out by I.F.S. during the tenure of a Vans Dunlop 
Scholarship in the Department of Obstetrics and Gynaecology. 
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Urinary Excretion of Pregnanediol* in Human Subjects following the 
Administration of Progesterone and of Pregnane- 3a:20a -diol. 1 
BY I. F. SO 1MERVILLE Arm G. F. MARRIAN 
Department of Biochemistry, University of Edinburgh 
(Received 13 September 1949) 
Since the establishment by Yenning & Browne in 
1937 of the status of pregnane -3x:20« -diol as a 
metabolic reduction product of progesterone, many 
figures have been accumulated by different workers 
on the urinary excretion of pregnanediol in human 
subjects of both sexes after the injection of the 
hormone. A critical examination of these figures, 
however, reveals a somewhat unsatisfactory state of 
affairs. While there is some measure of agreement 
that in the majority of human subjects, excluding 
women during the luteal phase of the menstrual 
cycle and during pregnancy, the pregnanediol 
appearing in the urine after the injection of pro- 
gesterone amounts to approximately 10 % of the 
amount of the hormone administered, wide varia- 
tions from this rough average have also been re- 
ported, and in no one paper are there sufficient figures 
from any one type of human subject to enable con- 
clusions to be drawn concerning the normal varia- 
tions which may occur in the conversion of pro- 
gesterone into urinary pregnanediol. Furthermore, 
without exception, methods of determining urinary 
pregnanediol have had of necessity to be employed 
which are of doubtful accuracy at the low levels of 
pregnanediol excretion usually encountered in such 
progesterone metabolism experiments. 
These considerations, and the availability of a 
method for determining urinary pregnanediol, which 
was believed to be more accurate at pregnanediol 
excretion levels below about 10 mg. /24 hr. than any 
that had hitherto been described (Sommerville, 
et al. 1948), led the present authors to reinvestigate 
the conversion of administered progesterone into 
urinary pregnanediol in human subjects. 
In the course of the work described in the present 
paper the urinary pregnanediol excretion has been 
studied after the administration of progesterone on 
2 successive days to normal men, to normal post- 
menopausal women with and without pre -treatment 
with oestrogens, and to hysterectomized women; a 
comparison has been made in men and in post- 
* The term `pregnanediol' is used to denote the material 
in urine consisting largely, but not necessarily entirely, of 
pregnane-3cc:20a-diol, which is determined by any of the 
widely used quantitative procedures such as those of Venning 
(1937, 1938), Astwood & Jones (1941), Guterman (1944, 
1945), and Sommerville, Gough & Marrian (1948). 
menopausal women between the pregnanediol ex- 
creted after intramuscularly and orally administered 
progesterone ; and the pregnanediol excretion follow- 
ing the oral administration of pure pregnane- 
3a:20a -diol to normal men has been determined. 
The next paper in this series (Sommerville & 
Marrian, 1950) describes experiments in which 
progesterone and pregnane-3x :20z-diol were ad- 
ministered to human subjects over long periods. 
EXPERLMENTAL METHODS 
Progesterone dissolved in arachis oil (10 mg. /ml.) was 
administered on 2 successive days, either by intramuscular 
injection or in gelatin capsules by mouth. Pregnane- 
3a:20x -diol was administered in solution in arachis oil in 
capsules by mouth. Subjects for the experiments were 
selected with great care, particular attention being paid to 
their willingness to co- operate in the collection of accurate 
24 hr. specimens of urine. 
Urine specimens (24 hr.) were collected in containers con- 
taining 5 ml. of toluene from the subjects in their own 
homes during a control period of several days prior to the 
administration of the steroid, during the 2 days of the 
administration and for the following 5-7 days. Specimens, 
volumes of which were less than 2500 ml., were made up to 
that volume with water before withdrawing two 500 ml. 
samples for the determination in duplicate of the preg- 
nanediol content by the method of Sommerville et al. 
(1948). In the few instances where the 24 hr. volumes were 
greater than 2500 ml., determinations were carried out on 
two 500 ml. samples and the appropriate volume correction 
subsequently applied. 
The percentage of administered progesterone, or preg- 
nane- 3a:20a -diol excreted as urinary pregnanediol, was 
calculated after correction of the apparent pregnanediol 
excretion for the control period `blank' value. 
RESULTS 
Pregnanediol excretion by post -menopausal women, 
hysterectomized women and men injected with pro- 
gesterone 
Determinations of urinary pregnanediol excretion in 
healthy post -menopausal women injected with pro- 
gesterone do not seem to have been previously re- 
ported, but observations have been reported on 
other types of women with minimal endogenous pro- 
gesterone production. Thus Venning & Browne 
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(1938) recovered 12 % of the administered dose as 
pregnanediol in the urine of an ovariectomized 
woman. Cope (1940) found a 6 % recovery in a case 
of hypoplasia of the uterus and 9 % in a case of an- 
ovulatory menstruation, while Jones & TeLinde 
(1941) report a recovery of 11.5 % in the pre - 
ovulatory phase of the menstrual cycle. 
Yenning & Browne (1938) first reported that preg- 
nanediol (as the glucuronide) could not be recovered 
from the urine after progesterone administration to 
two hysterectomized women. Later, however, these 
workers (Yenning & Browne, 1940) recovered 9.6 % 
after administering a larger dose of progesterone to a 
woman in whom a supravaginal hysterectomy had 
been performed. Using the same scheme of dosage, 
30 mg. on 3 consecutive days, Buxton (1940) re- 
covered 4.1 and 5.4 t! from two hysterectomized 
women, but failed to recover any pregnanediol at all 
from two similar cases. Following the administration 
of 40 mg. of progesterone on 3 consecutive days, 
Jones & TeLinde (1941) reported recoveries of 15.6, 
1950 
2 consecutive clays to six healthy post -menopausal 
women, three young men and four hysterectomized 
women. The experiment was repeated on four 
occasions in one subject (P.). The results are shown in 
Table 1. 
In all these experiments the proportion of the 
administered progesterone recovered in the urine as 
pregnanediol ranged from 9.1 to 16.0 %. There was 
no clear cviclence that the percentage recovery was 
greater in tice normal post -menopausal women than 
in the hysterectomized women and men. It can 
therefore be concluded that under these particular 
experimental conditions the post -menopausal uterus 
plays no significant role in the conversion of ad- 
ministered progesterone into urinary pregnanediol 
glucuronide. As will be shown in the following paper 
(Sommerville & Marrian, 1950), however, the uterus 
of the post -menopausal woman does seem to take a 
prominent part in the process when subjects are 
treated daily with progesterone for periods of longer 
than about 5-8 days. 
Table 1. Urinary pregnanediol after the administration by intramuscular injection of progesterone 
to post -menopausal women, hysterectomized women and men 
(Progesterone (60 mg.) injected on each of 2 successive days.) 
Percentage of administered 
progesterone recovered as 
Subject Age Type urinary pregnanediol 
E. 65 Normal post -menopausal woman 15.6 
H. 70 Normal post -menopausal woman 12-1 
Me a. 55 Normal post -menopausal woman 13.7 
A. 70 Normal post -menopausal woman 15.6 
N. 71 Normal post -menopausal woman 16.0 
Mc. 60 Normal post -menopausal woman 152 
M. 68 Hysterectomized post -menopausal woman 13.3 
H. 50 Hysterectomized post -menopausal woman 14.1 
R. 52 Hysterectomized ovariectomized woman 14.9 
L. 42 Hysterectomized ovariectomized woman 9.1 




J.P. 23 Normal man 14.7 
R. 22 Normal man 9.3 
12.9 and 10.9 % of urinary pregnanediol from three 
hysterectomized women. 
The excretion of urinary pregnanediol after the 
administration of progesterone to men was first re- 
ported by Buxton & Westphal (1939) who recovered 
17 % from a normal male and very variable amounts 
from two men with Addison's disease. Hamblen, 
Cuyler & Hirst (1940) reported a variation in the pro- 
portion excreted as pregnanediol of from 0 to 42.5 %, 
and observed a marked variation in the proportion so 
excreted when the same subject was investigated on 
several occasions. 
In the present work 60 mg. of progesterone was 
administered by intramuscular injection on each of 
It should be noted that, contrary to the findings of 
Hamblen et al. (1940), repetitions of the experiment 
in the same subject (P.) gave almost identical 
results. 
Pregnanediol excretion by men and post -menopausal 
women after oral and intramuscular administration 
of progesterone 
Dorfman, Ross & Shipley (1948) reported the ex- 
cretion of urinary pregnanediol after the oral ad- 
ministration of progesterone to two men, one with 
diabetes and the other with Addison's disease. 
Further observations do not seem to have been re- 
ported on oral administration of progesterone, nor 
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has a comparison been made between the proportion 
of administered progesterone excreted as urinary 
pregnanediol after oral and intramuscular admin- 
istration. 
In the present work, progesterone (60 mg. on each 
of 2 successive days) was administered in capsules 
by mouth to the three men and to two of the post- 
menopausal women investigated in the previous 
Intramuscular Oral 
1 ' Time (days) 
Fig. 1. Urinary pregnanediol excretion after the ad- 
ministration of progesterone to a normal man (subject P.) 
by intramuscular and oral routes. Arrows indicate 
administration of 60 mg. progesterone. The values ob- 
tained in the duplicate determinations are indicated by 
the double lines at the tops of the columns. 
series. The recovery experiment was repeated on 
three occasions in one of the male subjects. 
In Figs. 1 and 2 the rate of excretion of preg- 
nanediol following the oral administration of pro- 
gesterone is compared with that following intra- 
muscular injection of the hormone in one male and 
in one post -menopausal female subject. It will be 
seen that in these cases, which were typical, oral 
administration resulted in an earlier and more rapid 
excretion of pregnanediol than that which followed 
intramuscular injection. This suggests that the 
absorption of progesterone in oily solution from the 
gastro- intestinal tract is more rapid than it is from 
the site of intramuscular injection. 
Intramuscular Oral 
t f Time (days) T T 
Fig. 2. Urinary pregnanediol excretion after the admistra- 
tion of progesterone to a post -menopausalwoman (subject 
H.) by intramuscular and oral routes. Arrows indicate 
administration of 60 mg. progesterone. The values ob- 
tained in the duplicate determinations are indicated by 
the double lines at the top of the columns. 
In Table 2 the pregnanediol recoveries following 
the oral administration of progesterone to the three 
male and two female subjects are summarized and 
compared with those obtained from the same subjects 
after intramuscular injection. Particular attention 
is drawn to the following two points: (i) the preg- 
nanediol recoveries following oral administration of 
Table 2. Urinary pregnanediol after the administration of progesterone to men and to post -menopausal women 
by oral and intramuscular routes 







Percentage of administered 
progesterone recovered as 
urinary pregnanediol 
Type 'Oral Intramuscular 
Normal man 12.8 10.4 
Normal man 11.5 9.3 
Normal man (three experiments) 18.6 14.7 
17.4 
19.6 
Post - menopausal woman 18.0 16.0 
Post -menopausal woman 14.5 12.1 
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progesterone on three separate occasions to the same 
subject (J.P.) were virtually the same; (ii) the re- 
coveries following oral administration were in each 
case slightly higher than the recoveries in the same 
subjects following intramuscular injection. This 
latter finding is of some importance in connexion 
with the use of urinary pregnanediol determinations 
for clinical diagnostic and prognostic purposes. In 
view of the well- established fact that the physio- 
logical activity of orally administered progesterone, 
as judged by the rabbit -uterus test, is very small in 
comparison with its activity by intramuscular in- 
jection, this new finding suggests that the amount of 
pregnanediol in the urine may have little or no 
quantitative relationship to the amount of endo- 
genous progesterone acting on the target organs. 
Pregnanediol excretion after the administration of 
progesterone to post -menopausal women pre -treated 
with oestrogen 
The evidence in the literature concerning the effect 
of oestrogen treatment on the urinary excretion of 
pregnanediol following the administration of pro- 
gesterone to women is conflicting. Venning & Browne 
(1940) reported that, in two cases of amenorrhoea 
with hypoplastic endometria, virtually no preg- 
nanediol could be recovered from the urine. How- 
ever, after pre -treatment with oestradiol benzoate for 
several days the same subjects were found to excrete 
12 and 18 % of the administered hormone as preg- 
nanediol. Yenning & Browne (1940) suggested that 
this effect upon the pregnanediol excretion was due 
to the `building up' of the endometrium by the 
oestrogen. Contrary results were reported shortly 
afterwards by Cope (1940). In experiments on a 
similar case he found that pre -treatment with oestra- 
diol benzoate resulted in a slight diminution (6-3 %) 
of the proportion of administered progesterone ex- 
creted in the urine as pregnanediol. Evidence of a 
different character has been advanced by Smith & 
Smith (1940) to suggest that oestrogen increases 
the proportion of administered progesterone con- 
verted into urinary pregnanediol. They claimed that 
in toxaemic and diabetic pregnant women pro- 
gesterone administered alone resulted in a smaller ex- 
cretion of pregnanediol additional to that arising from 
endogenous sources than occurred when progesterone 
was injected together with oestradiol benzoate. 
In the present work the problem has been studied 
in three post -menopausal women with prolapse of 
the uterus. In two of these (H. and B.) 60 mg. of 
progesterone was injected intramuscularly on each of 
2 successive days, while in the third (K.) the dose was 
120 mg. /day. The progesterone administration was 
preceded by the injection of 30 mg. of oestradiol 
benzoate /day for 6 successive days with subjects H. 
and B., and for 20 successive days with subject K. 
The experiment was followed by total hysterectomy 
in subjects H. and B. and by endometrial biopsy in 
subject K. Histological section revealed an atrophic 
endometrium in H., a proliferative endometrium 
with foci of secretory glands in B. and a proliferative 
endometrium in K. 
The proportions of administered progesterone ex- 
creted as pregnanediol were 16.1, 16.2, 15.1 % re- 
spectively in the three cases. These proportions do 
not appear to be significantly different from those 
obtained with post -menopausal women receiving no 
oestrogen pre -treatment (see Table 1). It may be 
concluded from these results that under the con- 
ditions of these experiments the administration of 
oestradiol benzoate did not significantly affect the 
conversion of the administered progesterone into 
urinary pregnanediol; furthermore, the results 
suggest that the state of the uterine endometriwn 
had little influence on the conversion. The present 
authors do not, however, regard the matter as being 
in any way settled, since it is not improbable that 
under different experimental conditions oestrogen 
may influence the conversion of administered pro- 
gesterone into urinary pregnanediol. It is clear that 
a final decision on this problem must await the 
results of further work. 
Urinary pregnanediol excretion in men following the 
oral administration of pregnane-3x:201-diol 
yenning & Browne (1938) were unable to recover 
pregnanediol glucuronide from the urine of two 
hysterectomized women after the injection either of 
progesterone or of pregnane- 3z:20x -diol. How- 
ever, when sodium pregnanediol glucuronidate was 
injected into the same subjects, 58 and 43 % was 
recovered in the urine. In view of these findings it is 
surprising that further studies on the urinary ex - 
cretion of pregnanediol following the administration 
of pregnane- 3z:20a -diol have not been attempted. 
To the present authors it seemed that such a study 
might be informative. 
Because of the low solubility of pregnane- 
3x:20a -diol in oil it was not practicable to ad- 
minister sufficient by injection to give an accurately 
measurable urinary excretion. Accordingly, ad- 
ministration in oil solution by mouth was adopted. 
Solutions containing 2.4 -3.0 mg. /ml. were obtained 
by dissolving weighed amounts in minimal volumes 
of boiling ethanol, adding arachis oil, boiling off the 
excess of ethanol in a water bath and then making up 
to volume with more arachis oil. Such solutions were 
administered in measured amounts by mouth in 
capsules on 2 successive days to three young male 
subjects whose pregnanediol excretions following the 
oral administration of progesterone had previously 
been determined. The results are shown in Table 3. 
For comparison, the pregnanediol recoveries follow- 
ing the oral administration of progesterone to these 
áubjects are also included in this table. 
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normal post -menopausal women and hysterecto- 
mized women, 9 -16 % of the amount injected is sub- 
sequently excreted in the urine as pregnanediol. 
There is no evidence from these experiments that the 
post -menopausal uterus plays any significant role in 
the conversion of progesterone into urinary preg- 
nanediol glucuronide. 
2. The urinary excretions of pregnanediol follow- 
ing oral administration of progesterone to normal 
men and normal post -menopausal women were 
slightly higher than those observed in the same sub- 
jects following intramuscular administration of 
progesterone. 
3. No evidence was obtained to support the view 
that oestrogen pre- treatment of women with atro- 
phic endometria increases the proportion of ad- 
ministered progesterone excreted in the urine as preg- 
nanediol. 
4. Following the oral administration of pregnane- 
3x:20x -diol to normal men the urinary excretions 
of pregnanediol were very similar to those observed 
in the same subjects following oral administration of 
progesterone. 
Table 3. Urinary excretion of pregnanediol following 
the oral administration of pregnane- 3a:20a -diol to 





following the Pregnane- following the 
oral admis- 32:20x -diol administration 
istration of administered of pregnane- 
progesterone orally 3x:20x -diol 
Subject ( %) (mg.) ( %) 
R. 12.8 2 r. 48 12.3 
P. 18.6 2 x 56 16.3 
J. P. 11.5 2 x 59 13.4 
It is seen that the recoveries of pregnanediol in the 
urine following the oral administration of pregnane- 
3x:20a -diol are very similar to those obtained in 
the same subjects following the oral administration 
of progesterone. So similar are the recoveries in the 
two sets of experiments that it is tempting to 
speculate that administered progesterone may be 
largely reduced to pregnanediol in the body, and 
that the low recoveries of urinary pregnanediol, 
following administration of the hormone, may be 
due to excretion of the reduction product by other 
routes or further metabolism into products so far 
unidentified or to a combination of both processes. 
SUMMARY 
1. Following the intramuscular injection on 2 
successive days of progesterone into normal men, 
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Urinary Excretion of Pregnanediol in Human Subjects following the 
Administration of Progesterone and of Pregnane- 3 «:20« -diol. 2* 
BY I. F. SOMMERVILLE AND G. F. 31ARRIAN 
Department of Biochemistry, University of Edinburgh 
(Received 10 October 1949) 
It has been established by the work of many authors 
that when progesterone is administered for periods 
of 1 -3 days to human subjects in whom endogenous 
progesterone production is minimal, the amount of 
pregnanediol subsequently excreted in the urine 
accounts for only a small proportion (usually < 
20 %) of the administered hormone. In the preceding 
paper (Sommerville & Marrian, 1950) previous work 
in this field was comprehensively reviewed and it was 
shown in an extensive series of experiments on 
normal men, post -menopausal and hysterectomized 
women that about 9 -16 % of intramuscularly in- 
jected progesterone is excreted as urinary preg- 
nanediol, and that a slightly higher proportion of the 
latter is excreted when progesterone is administered 
orally. 
Venning & Browne (1938, 1940) showed that the 
administration of progesterone during the luteal 
phase of the menstrual cycle and during pregnancy, 
at times when `the process of conversion of pro- 
gesterone to pregnanediol was already in action', 
resulted in the excretion of a much higher proportion 
of the administered hormone as pregnanediol addi- 
tional to that arising from endogenous sources. More 
recently, the greater efficiency of conversion of ad- 
ministered progesterone to urinary pregnanediol by 
the pregnant woman compared to that of women 
with minimal endogenous progesterone production 
has been confirmed by Davis & Fugo (1947), who 
reported that 30-35% of progesterone injected 
during early pregnancy was excreted as additional' 
pregnanediol. These authors came to the important 
conclusion that the 'activity of the corpus luteum 
must exert some effect on the metabolism of pro- 
gesterone so that a much greater percentage 
can be accounted for as the inert metabolite preg- 
nandiol'. 
In view of the possibility that the `activity of the 
corpus luteum' responsible, according to Davis & 
Fugo (1947) for this phenomenon, might be the 
* A preliminary account of certain parts of this work was 
communicated to the Society for Endocrinology on 21 
October 1948 and to the first International Congress of 
Biochemistry, August 1949 (Sommerville & Marrian, 1949). 
secretion and physiological action of endogenous 
progesterone, we felt that some light might be 
thrown on the problem by studying the urinary preg- 
nanediol excretion of human subjects with minimal 
endogenous progesterone secretion during periods of 
prolonged daily administration of progesterone. The 
only earlier workers who appear to have studied 
urinary pregnanediol excretion during periods of 
progesterone administration longer than 3 days are 
Venning & Browne (1940) and Copo (1940). The 
former workers administered doses of progesterone 
of about 10 rug.!day for 4-8 days, but the preg- 
nanediol recoveries were irregular and showed no 
definite daily trend. The findings of Cope, on the 
other hand, were more definite. 
Cope injected a case of secondary amenorrhoea 
with 10, 5, 5, 5 and 5 mg. of progesterone on 5 con- 
secutive days respectively. Only doubtful traces of 
pregnanediol were recovered from the urine during 
the first 5 days, but 2.5 mg. was found on the sixth 
day. In a second experiment 10 mg. of progesterone 
was injected daily for 5 consecutive days into a case 
of unoo ular ni tt,tru,ttion. No pregnanediol at all 
was detected in the urine during the first 3 days, but 
a total of 4.5 mg. was found in the urine on the fourth 
and fifth days. Cope suggested that these findings 
might be explained on the basis of `a kind of satura- 
tion phenomenon comparable to that which is now 
well known to occur in the excretion of ascorbic acid 
taken by mouth', and he furthermore predicted that 
more prolonged daily treatment with progesterone 
should result in even higher proportions of the 
administered hormone appearing in the urine as 
pregnanediol. 
In view of the small closes of progesterone in- 
jected by Cope and the relative insensitivity of the 
method of determining urinary pregnanediol which 
he employed (yenning, 1937, 1938), it seemed doubt- 
ful whether very much quantitative significance 
should be attached to his results. Nevertheless, his 
work provided an indication that prolonged ad- 
ministration of progesterone might in some way 
cause a progressive enhancement of the power of the 
body to convert progesterone into urinary preg- 
- nanediol. 
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EXPERIMENTAL METHODS 
Che selection of subjects for these experiments, the collec- 
ion of urine specimens and the determination of the preg- 
)anediol in the latter were, except where stated otherwise, 
is described in the preceding paper (Sommerville & Marrian, 
.950). 
Progesterone solutions in arachis oil and in ethyl oleate 
10-25 mg. /ml.) were administered either by intramuscular 
njection or in gelatin capsules by mouth. Pregnane- 
lx:20a -diol was administered in solution in arachis oil in 
:apsules by mouth. 
RESULTS 
Urinary excretion of additional' pregnanediol follow- 
ing the administration of progesterone during 
pregnancy 
[n the first instance confirmation was sought of the 
findings of Venning & Browne (1940) and of Davis & 
Fugo (1947) that the percentage conversion of ad- 
ninistered progesterone into urinary pregnanediol 
s higher in pregnant women than in human subjects 
with minimal endogenous progesterone production. 
Chis was considered to be necessary, since neither of 
these groups of workers had provided convincing 
widence to show that the endogenous pregnanediol 
xcretion during the control periods in their experi- 
ments had been sufficiently constant to justify the 
!alculation of the `additional' urinary pregnanediol 
'ormed from the administered progesterone. 
The subject was a woman at the twenty- seventh 
week of her eighth normal pregnancy who was 
;offering from mitral stenosis. Since the patient was 
:onfined in a busy antenatal hospital ward, reliance 
:ould not be placed on the completeness of the 
:ollection of 24 hr. urine samples. Accordingly, the 
: reatinine content of the urine collected each day was 
letermined by the method of Folin (1914) and the 
) regnanediol values corrected to the average creati- 
)ine value. In calculating the average creatinine 
xcretion, determinations on the few urine specimens 
which were obviously incomplete were ignored. 
The experiment was carried out over five con - 
ecutive 5 -day periods as detailed below: 
Period 1. Control period for the determination of 
laily endogenous pregnanediol excretion: total pre - 
)anediol excretion = 94.2 mg. 
Period 2. Experimental period: 60 mg. progester- 
me injected on first and second days: total preg- 
ianediol excretion (endogenous + `additional') = 
L38.2 mg. 
Period 3. Control period as period 1: total preg- 
sanediol excretion = 98.4 mg. 
Period 4. Experimental period: 60 mg. pro - 
;esterone injected on first and second days: total 
) regnanediol excretion (endogenous + `additional') 
= 158.2 mg. 
Period 5. Control period as periods 1 and 3: total 
) regnanediol excretion= 112.4 mg. 
Biochem. 1950, 46 
The results are shown graphically in Fig. 1. It will 
be seen that the daily endogenous pregnanediol 
excretions during each of the three control periods 
were remarkably constant. It was therefore felt to 
be justifiable to assume for the purpose of calculating 
the `additional' pregnanediol excreted during the 
two experimental periods that the endogenous preg- 
















Fig. 1. Effect of progesterone on the excretion 
of pregnanediol during pregnancy. 
20 
represented by the average of those during periods 
1 and 3, while that during period 4 would be the 
average of those during periods 3 and 5. Thus the 
`additional' pregnanediol excreted during period 2 
is equal to 
138 2 
(94.2+98.4) 
= 41.9 mg. 
= 34.9 % of the administered progresterone, 
and the `additional' pregnanediol excreted during 
period 4 is equal to 
158 2 (98.4+ 
2 
= 52.8 mg. 
= 44.0 % of the administered progesterone. 
These results clearly confirm the earlier findings of 
Venning & Browne (1940) and of Davis & Fugo 
(1947). Provided, therefore, that the administration 
of progesterone does not stimulate the secretion of 
endogenous progesterone, it can be concluded that 
a much higher percentage of administered progester- 
one is converted into urinary pregnanediol by the 
pregnant woman than by human subjects in whom 
the endogenous secretion of progesterone is minimal. 
19 
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considerably enhanced after about 6-8 days of the 
treatment. 
In order to confirm this interesting finding and to 
see whether a second `plateau' of pregnanediol ex- 
cretion would ultimately be obtained four further 
experiments of longer duration were carried out 
upon three more post -menopausal women. The 
details of these experiments and the results obtained 
are shown in Table 1 and Fig. 3. 
It will be seen from Fig. 3 that in every experi- 
ment the daily pregnanediol excretion rose consider- 
ably after reaching a temporary initial ' plateau' 
level and ultimately attained a second ' plateau'. The 
results of the two preliminary experiments were thus 
18- amply confirmed and extended. This rise in preg- 
nanediol excretion from the initial 'plateau' level 
16- - will hereafter be referred to as a 'priming' effect. 
It will be seen from Table 1 that the 'priming' 
effect, expressed as the percentage increase of the 
final ' plateau' level above the initial ' plateau' level, 
was greatest in the experiment in which the pro- 
gesterone was administered intramuscularly. It may 
also be pointed out that in the three experiments in 
which oral administration was employed, a dose of 
60 mg. /day produced a greater 'priming' than was 
0 obtained with 40 mg. /day. As will be seen later, 
these observations may be of some significance. 
Urinary pregnanediol excretion during continued 
daily administration of progesterone to normal 
men 
Urinary pregnanediol excretion during continued 
daily administration of progesterone to normal post- 
menopausal women 
Preliminary experiments on pregnanediol ex- 
cretion during continued daily administration of 
progesterone were carried out upon two post- 
menopausal women. One (F.) received 60 mg. pro- 
gesterone per day intramuscularly for 10 days, while 
the other (N.) received the same daily dose admin- 
istered orally for 15 days. The results are shown 
Subject F. Subject N. 
Progesterone 
(60 mg. daily 
,intramuscular) 
Progesterone 







0 5 10 0 5 10 15 
Time (days) 
Fig. 2. Pregnanediol excretion during prolonged administra- 
tion of progesterone to normal post -menopausal women. 
graphically in Fig. 2. It will be seen that in subject F. 
the daily pregnanediol excretion was maintained at 
an almost constant 'plateau' level, corresponding to 
about 10 % of the daily dose of progesterone, between 
the third and eighth days. The pregnanediol excretion 
then rose sharply, and by the tenth day, when the 
experiment was discontinued, it had reached a 
value corresponding to 17 % of the daily dose of pro- 
gesterone. It will also be seen that a similar pheno- 
menon occurred in subject N. who received the pro- 
gesterone orally. In this experiment the preg- 
nanediol excretion was somewhat irregular, but it 
will be clear that after reaching a rather ill- defined 
plateau level corresponding to about 17 % of the 
daily dose of progesterone (second to sixth day), the 
pregnanediol excretion rose to 25 % of the daily dose 
of progesterone by the fifteenth day. These pre- 
liminary results indicated that in post -menopausal 
women treated with progesterone, either by in- 
jection or orally, the power to convert the admin- 
istered hormone into urinary pregnanediol becomes 
The fact that marked ' priming ' was observed in 
post -menopausal women receiving progesterone 
orally suggested at first that the effect was probably 
not associated in any way with the physiological 
action upon the uterus, since it is generally recog- 
nized that orally administered progesterone shows 
only a small fraction of the physiological activity, as 
judged by the rabbit uterus test, of that shown by the 
injected hormone. Furthermore, previously re- 
ported experiments (Sommerville & Marrian, 1950) 
in which progesterone was administered by injection 
on 2 successive days to post -menopausal and to 
hysterectomized women had suggested that the post- 
menopausal uterus might have no significant role in 
the conversion of administered progesterone into 
urinary pregnanediol. It was confidently expected, 
therefore, that a 'priming' effect, quantitatively 
similar to that observed in post -menopausal women, 
would be obtained in men. 
Experiments were therefore carried out on three 
normal men as follows : 
Subject M., aged 30; 40 mg. progesterone per day 
orally for 18 days. 
Subject R., aged 82; 60 mg. progesterone per day 
orally for 18 days. 
Subject P., aged 22; 60 mg. progesterone per day 
orally for 18 days. 
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15.0 20.0 33 
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(second experiment) 
Progesterone (60 mg. daily 
by mouth) 
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Fig. 3. Pregnanediol excretion during prolonged administration of progesterone to normal post -menopausal women. 
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The results, which are shown graphically in Fig. 4, 
clearly show that no `priming' whatsoever occurred 
in these three men. 
Subjett M. 
Progesterone 




menopausal uterus may have no role in the conver- 
sion of administered progesterone to urinary preg- 
nanediol in experiments of only a few days' duration, 
Subject R. 
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Fig. 4. Pregnanediol excretion during prolonged administration of progesterone to normal men. 
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Fig. 5. Pregnanediol excretion during prolonged administration of progesterone to hysterectomized -ovariectomized 
and hysterectomized post -menopausal women. 
Urinary pregnanediol excretion during continued daily 
administration of progesterone to hysterectomized 
(ovariectomized or post- menopausal) women 
The unexpected lack of any `priming' effect in 
men suggested the possibility that although the post- 
it might nevertheless be responsible for the `priming' 
observed in post- menopausal women after admin- 
istration of progesterone for longer periods. 
Accordingly, experiments as detailed below were 
carried out upon three women who had been hyster- 
ectomized not less than 2 months previously. 
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Subject R., aged 42; hysterectomized, ovariecto- 
mized; 40 mg. progesterone per day orally for 18 
days. 
Subject K., aged 45; hysterectomized, ovariecto- 
mized; 60 mg. progesterone per day orally for 18 
days. 
Subject H., aged 50; hysterectomized, post -meno- 
pausal; 60 mg. progesterone per day orally for 22 
days. 
The results shown in Fig. 5 indicate quite defi- 
nitely the complete lack of any `priming' in these 
three cases. There can be little doubt therefore that 
the uterus is necessary for the progesterone `priming' 






The results, shown in Fig. 6, indicate clearly that 
no `priming' occurred as the result of continued 
daily administration of pregnane- 3a:20a -diol. 
DISCUSSION 
It is clear from the previous work of others and of the 
present authors that the uterus is not essential for 
the conversion of administered progesterone into 
urinary pregnanediol; nor does it seem that the 
normal post -menopausal uterus plays any signifi- 
cant role in the conversion process when progester- 
one is administered over periods of only a few days 
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Fig. 6. Pregnanediol excretion during prolonged administration of pregnane- 3z:20a -diol 
to normal post -menopausal women. 
Urinary pregnanediol excretion during continued daily 
administration of pregnane-3a:20x-diol to normal 
post -menopausal women 
In view of the possibility, which is discussed later 
in this paper, that the priming' phenomenon in post- 
menopausal women may be associated with the 
action of progesterone in causing structural changes 
in the uterus, it seemed of importance to test for 
`priming' activity related steroids which are known 
or suspected to be progesterone metabolites, but 
which lack the physiological activity of the hormone. 
Unfortunately, owing to the lack of sufficient 
quantities of other possible progesterone meta- 
bolites, pregnane- 3a:20a -diol is the only one of 
these steroids which could be tested. 
Experiments, as detailed below, were carried out 
on two normal post -menopausal women, one of 
whom (H.) had previously shown definite `priming' 
with progesterone. 
Subject H., 40 mg. pregnane- 3a:20a -diol per day 
orally for 17 days. 
Subject S., 40 mg. pregnane-3a:20x-diol per day 
orally for 18 days. 
work, however, it has been clearly demonstrated 
that the enhanced power of the normal post -meno- 
pausal woman to excrete urinary pregnanediol after 
prolonged daily administration of progesterone de- 
pends upon the uterus. Accordingly, the conclusion 
can hardly be avoided that the post -menopausal 
uterus after prolonged exposure to the action of pro- 
gesterone or of one of its metabolic products is able 
to effect the conversion of progesterone into urinary 
pregnanediol, or at least some part of that con- 
version. 
At the present time there is no definite evidence to 
show whether this `priming' effect of progesterone 
is, or is not, associated with its physiological action 
in inducing structural changes in the uterine endo- 
metrium and myometrium. The observation that the 
`priming' was greater with intramuscularly than 
with orally administered progesterone, and the 
observation that in the three oral administration 
experiments the higher dose gave the greatest 
`priming', suggest that perhaps this may be the 
case. However, the figures at present available are 
obviously too few to constitute clear -cut evidence 
in favour of this view. Furthermore, it may be 
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doubted whether 40 mg. of progesterone per day 
administered orally without oestrogen would induce 
any structural changes in the uterine endometrium 
or myometriuun. 
The observation that the oral administration of 
pregnane- 3z:20z -diol gave no 'priming' in post- 
menopausal women is compatible with the theory 
that the effect may be due to progesterone per se. The 
possibility must be borne in mind, however, that 
'priming' might result from other progesterone 
metabolites which have not vet been tested. 
It is possible, but by no means certain, that the 
increased excretion of pregnanediol observed by 
Cope (1940) after 5-6 days administration of pro- 
gesterone may have been due to the same 'priming' 
phenomenon which is reported here. The possibility 
that the 'priming' effect might be due to a 'satura- 
tion phenomenon', such as was suggested by Cope 
(1940), must therefore be briefly considered. 
The fact that in men and in hysterectomized 
women a steady `plateau' of pregnanediol ex- 
cretion is established within 2 -3 days after the 
commencement of progesterone administration and 
is maintained for periods up to 22 days indicates 
that there can certainly be no 'saturation pheno- 
menon in the absence of the uterus. It is, further- 
more, unlikely for two reasons that the 'priming' in 
normal post -menopausal women could be due to a 
saturation of the uterine tissue with progesterone 
and/or its metabolites. First, if such a saturation 
were to occur, then in experiments of short duration 
the pregnanediol excretion should be relatively lower 
in normal post -menopausal women than in hyster- 
ectomized women. As has been previously shown, 
however, the presence or absence of the uterus seems 
to have little effect on the excretion of pregnanediol 
in experiments in which progesterone is administered 
for 2 days only (Sommerville & Marrian, 1950). 
Secondly, if the 'priming' effect were due to satura- 
tion of the uterine tissue with progesterone and /or 
its metabolites, one would expect that the clearance 
of pregnanediol, as judged by its rate of disappear- 
ance from the urine after stopping the administration 
of progesterone, would be delayed in the experiments 
of long duration in comparison with those of short 
duration. No such delay in pregnanediol clearance 
in experiments of long duration was in fact observed 
(see Fig. 3, Subject H., second experiment). 
It is not unlikely that the relatively high percent- 
age conversion of administered progesterone into 
`additional' urinary pregnanediol which occurs 
during pregnancy and also possibly during the 
luteal phase of the menstrual cycle may be due to a 
`priming' of the uterus with endogenous progester- 
one. At the present time, however, it would be pre- 
mature to assume that the two phenomena are 
necessarily due to the same cause. 
SU\LMAR 
1. Previous findings by Venning & Browne (1940) 
and Davis & Fugo (19.4 7) that the pregnant woman 
can convert a higher proportion of administered pro- 
gesterone into urinary pregnanediol than can human 
subjects in whom endogenous progesterone pro- 
duction is minimal have been confirmed. 
2. It has been shown that when progesterone is 
administered daily (intramuscularly or orally) to 
normal post -menopausal women for periods up to 
27 days, the daily urinary pregnanediol excretion 
reaches on the second or third day a preliminary 
plateau level which is maintained until the fifth to 
eighth day. The daily pregnanediol excretion then 
rises and at about the twelfth to sixteenth day 
reaches a second plateau which is then maintained. 
This phenomenon has been termed a 'progesterone 
"priming" effect'. 
3. No 'priming' effect was observed when pro- 
gesterone was administered daily to normal men, 
hysterectomized- ovariectomized and hysterecto- 
mized post- menopausal women. It has been con- 
cluded, therefore, that the uterus is necessary for the 
manifestation of progesterone 'priming'. 
4. No 'priming' effect was observed when preg- 
nane- 3x:20x -diol was administered daily (orally) 
to normal post- menopausal women. 
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From the University Department of Biochemistry and the 
Rheumatic Unit, Northern General Hospital, Edinburgh 
IT has recentl y been shown by Hench et al. (1949) that 
rheumatoid arthritics respond dramatically to treatment 
with 11- dehydro- 17- hydroxycorticosterone (` Cortisone') 
in the form of its acetate, at a dose -level of about 100 mg. 
per day. The high dosage required for the relief of the 
symptoms coupled with the fact that rheumatoid 
arthritics, as far as is known, do not exhibit any of the 
generally recognised symptoms of adrenal insufficiency, 
suggested to us that the condition might be associated 
with an abnormality in the metabolism of cortisone in 
the affected tissues, rather than with a deficient secretion 
of this hormone by the adrenal cortex. 
Since the large quantities of cortisone necessary for 
a direct test of this hypothesis were unavailable to us, 
we considered that it might be profitable to study 
quantitatively in rheumatoid -arthritic subjects the 
metabolism of some more readily obtainable steroid 
closely related structurally to cortisone. We felt that 
although the discovery of an abnormality in the meta- 
bolism of such a steroid in rheumatoid arthritis would 
not prove the original working hypothesis, it would at 
least indicate the desirability of attempting a direct 
experimental investigation as soon as the supply of 
cortisone improves. 
Progesterone was selected for this investigation in 
preference to the more closely related 11- deoxycorti- 
costerone for two reasons : (1) at the high dosages which 
have to be employed in such steroid metabolism experi- 
ments the sodium- retaining action of the latter might 
have constituted a serious danger, whereas at these 
dosages progesterone produces no undesirable physio- 
logical or pharmacological effect s apart from mild 
sedation in some instances : and (_'i as a result of previous 
investigations by two of us (Sommerville and \iarriau 
1950) a considerable amount of information was already 
available concerning the conversion of administered 
progesterone into urinary prep tanealiol in normal people. 
EXPERIMENTAL PHaaf 1:UCKE 
Progesterone dissolved in arachis oil was administered 
to the subjects by intramuscular injection in two succes- 
sive daily doses of 60 tug. Twenty- four -hour urine 
specimens (preserved with toluene) were collected from 
each subject during a preliminary control period of two 
days, during tite two days when the hormone was being 
administered, and for the following four days. Each 
specimen was made up to a volume of 2500 mill. with 
water, and pregnanediol determinations in duplicate 
were carried out on 500 ml. samples by the method of 
Sommerville, Gough, and 3Iarrian (1948). The total 
pregnanediol excreted as a result of the administration 
of the progesterone was calculated after correction of the 
daily apparent pregnanediol excretion for the average 
control- period " blank." 
Experiments were carried out on 9 postmenopausal 
women and 4 men suffering front rheumatoid arthritis. 
and on 6 normal postmenopausal women and 4 normal 
men.* Since some salicylates are known to be excreted 
in the urine in conjugation with glueuronic acid, the 
possibility had to be considered that these might in some 
way influence the excretion of pregnanediol by inter- 
fering with the formation of pregnanediol glucuronide. 
Accordingly salicylate therapy was withheld from all 
the arthritic subjects for from one to eight weeks before 
the experiments. 
RESULTS 
The results indicate quite clearly that rheumatoid 
arthritics of both sexes excrete in the urine as preg- 
nanediol an abnormally high proportion of intramuscu- 
larly administered progesterone. The values given are 
calculated front the mean of the duplicate determinations. 
In every case satisfactory agreement between the 
duplicate determinations was obtained. The percentage 
of administered progesterone recovered as urinary 
pregnanediol was as follows. 
All but one of the figures for the excretion of pregnanediol by 
normal postmenopausal women and nice following the intra- 
muscular injection of progesterone are taken from a previou, 
paper by two of us (Sommerville and Mercian 1950). 
elfen : 
Postmenopausal uomcn : 
3 
Normal Rheunudoid arthritic- 
9-3 .. 21.7 
10.0 .. 23.8 
12.2 .. 26.1 
147 27.4 
12.1 .. 19.0 
13.7 .. 20.7 
15.2 .. 22.0 
15.6 .. 25.1 
15.6 .. 25.7 




Careful assessment of all clinical data revealed no clear - 
cut correlation between the severity of the disease and 
the percentage of administered progesterone excreted as. 
urinary pregnanediol. 
DISCUSSION 
Until quantitative studies on the conversion of adminis- 
tered progesterone into urinary pregnanediol have been 
carried out in a wide variety of other clinical conditions,. 
the importance of the present observations must remain 
in some doubt, since the abnormality in progesterone- 
metabolism reported Here may be more common than we- 
now suppose. Furthermore, even though this abnormality 
should prove to be specific to rheumatoid arthritis and 
related conditions, it may be quite unrelated to the 
response of these conditions to cortisone therapy. 
Nevertheless, the discovery of an abnormality in the 
metabolism of progesterone in a clinical condition which 
yields to treatment with a closely related steroid hormone 
is not without interest ; and it now seems clear that our 
hypothesis that rheumatoid arthritis may be associated 
with an analogous abnormality in the metabolism of the 
adrenocorticaf steroid hormones deserves serious con- 
sideration and must be investigated experimentally as 
soon as circumstances permit. 
Further speculations about the possible significance of 
the present results would be unwise at the moment 
since little is known about the metabolism of cortisone 
in the body, while the exact physiological significance of 
pregnanediol as a metabolite of progesterone is still very 
obscure. 
Although there was no evidence of a correlation 
between the abnormality of progesterone metabolism 
and the activity of the disease process as assessed by the 
criteria available, further work may possibly reveal a 
relation between this metabolic abnormality and the 
fundamental pathogenesis of rheumatoid arthritis. 
4 
In the hope that others may wish to attempt the 
confirmation and further extension of our results, we 
wish to take this opportunity of pointing out that for 
quantitative studies of the urinary pregnanediol excretion 
following the administration of progesterone in doses of 
less than about 100 mg. per day, a method of pregnanediol 
determination at least as sensitive and accurate as that 
used in the present work must be employed. The differ- 
ence in the pregnanediol excretions between normal and 
arthritic subjects reported here are quite definite, but it 
is doubtful whether they would have been observed if a 
less accurate and sensitive quant it a t ive method had been 
used. In our opinion, older methods such as the original 
one of Velining (1937, 1938), or newer methods designed 
primarily for semi- quantitative routine diagnostic work, 
such as those of Guterman (1944, 1945) and of Sommer- 
ville, Marrian, and Kellar (1948), would be entirely unsuit- 
able for quantitative studies on progesterone metabolism. 
We wish to express our gratitude to the Medical Research 
Council for a personal grant to one of us (I. F. S.), and for a 
grant (to G. F. M.), from which the expenses of this work were 
largely defrayed. We owe much to the skilful technical 
assistance of Mr. D. W. Davidson. 
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